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ABSTRACT 
The concept of the bioartificial pancreas has developed substantially in the 
last decade, after the first successful islet transplantation in 2000. Islets are 
clusters of endocrine cells found in the pancreas. Amongst these cells, the 
insulin secreting beta cells are targeted by the immune system in Type 1 
Diabetes. One of the major challenges islet transplantation has faced is the 
rapid loss of islets, post-transplantation. To mitigate this, a bioartificial 
pancreas that provides support and immuno-isolation for islets before 
transplantation has been investigated.  
Polyhydroxyalkanoates (PHAs) are intracellular energy storage polymers 
synthesized by Gram-positive and Gram-negative bacteria. Because of their 
high degree of biocompatibility and structural properties, PHAs have been 
chosen as the scaffold material for the bioartificial pancreas. Alginate is a 
naturally occurring polysaccharide made up of mannuoronate and 
guluronate units. Because of its ability to mimic the extracellular matrix, it 
has been widely investigated for its use as a hydrogel and is being 
investigated for its use in islet transplantation.  
This project aimed to produce a bioartificial pancreas that contains 
pancreatic cells encapsulated in an alginate hydrogel environment 
(mimicking islets) and a PHA scaffold providing support and an additional 
layer of immuno-isolation.  
To identify a scaffold material, two PHAs were produced- P(3HB), a stiff, 
brittle polymer by Bacillus subtilis OK2 fermentation and a novel 
vi 
 
elastomeric P(3HO-co-HD) by Pseudomonas mendocina CH50. Several 
studies were performed on these produced polymers. Initially, they were 
characterised chemically, structurally, mechanically and thermally and 
compared to PLLA, a FDA approved polymer. It was observed that when 
these polymers were compared in terms of viability and insulin release, cells 
seeded in P(3HO-co-HD) performed best. Porosity was introduced into the 
P(3HO-co-HD) scaffold to mimic the mechanical properties of the native 
pancreas and facilitate exchange of nutrients and waste. The effect of the 
type of porogen, porogen size and concentration was also investigated. It 
was observed that the scaffold obtained using 100µm NaCl, at a 
concentration of 15% w/v was the best scaffold for the BRIN BD11cells. 
Next, the polymers were fabricated into 2D & 3D structures and evaluated 
for function. No statistical difference was observed when the mechanical 
properties of both 2D & 3D structures were compared. The same trend was 
observed for the viabilities and insulin release of BRIN BD11 cells seeded 
in these structures.  
In addition, three P(3HO-co-HD) dominated P(3HO-co-HD)/P(3HB) 
blends: 95:5, 90:10 & 80:20 were made in order to improve the handling of 
P(3HO-co-HD). When the handling of the scaffolds, the viability and 
insulin release of BRIN BD11 cells seeded in these blends were considered, 
the 95:5 P(3HO-co-HD)/P(3HB) blend was selected as the best 
combination. Further, the 95:5 P(3HO-co-HD)/P(3HB) blend was 
processed into 2D & 3D structures, evaluated and compared to 2D & 3D 
P(3HO-co-HD) structures. No significant difference was observed when the 
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95:5 P(3HO-co-HD)/P(3HB) blend and P(3HO-co-HD) structures were 
compared based on cell viability and insulin release.  
Finally, two kinds of alginate hydrogel structures were made- alginate 
microbeads and 3D printed block hydrogels. The effect of cell densities 
(1X105cells/ml & 5X105cells/ml) and alginate concentration (2%, 4% & 5% 
w/v) on cell viability was evaluated. The two structures were then compared 
based on cell viability and insulin release. Of all the conditions, 5% w/v 
alginate 3D printed block hydrogels containing 5x105cells/ml performed 
best based on cell viability and insulin release of BRIN BD11 cells seeded.  
In conclusion, in this work, two PHAs including a novel PHA have been 
successfully produced. In addition, the best blend structure for scaffold 
creation has been identified and evaluated. Further, alginate hydrogels with 
optimum cell densities and structures have been selected and used for the 
creation of the inner hydrogel environment. These represent the framework 
for the successful development of bioartificial pancreas in the future.   
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1. INTRODUCTION 
1.1 INCIDENCE OF DIABETES 
Globally, diabetes has become a major concern, hence the World Health Organisation 
commissioned a special global report on Diabetes in 2016. The last three decades have 
seen a dramatic rise in the amount of people living with diabetes. In 1980, the number 
of people living with diabetes was estimated to be 108 million; by 2014, this number had 
risen to 422 million. This number represents approximately 9% of the world population. 
Currently, diabetes and its complications is one of the leading causes of death in  people 
aged 20-79 (World Health Organisation, 2016).  
Projections show that there will be a marked increase in the percentage of the population 
living with diabetes between 2018 and 2045. The total population of diabetes sufferers 
is expected to increase from 422 million to 628.6 million (approximately 8.8% to 9.9% 
of total adults). The total expenditure on management and care of patients with diabetes 
will increase from $727 billion to $776 billion (World Health Organisation, 2016).  
1,106,500 of young people between the ages of 0-19 were living with Type 1 diabetes 
as at 2017 with 132,600 new cases being diagnosed every year (Ogurtsova et al., 2017).  
In 2016, about 4.5 million people in the United Kingdom suffered from diabetes and that 
number is predicted to rise to about 5 million by 2025. In 2013, the treatment and 
maintenance of people with diabetes cost the UK about £10-13.75 billion (Diabetes UK, 
2017). Type 1 Diabetes Mellitus (T1DM) is the most common chronic disease in 
children (Atkinson, Eisenbarth and Michels, 2014). About 500,000 children have been 
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diagnosed with the disease worldwide with about 32,000 of them in the UK (Diabetes 
UK 2015). 
1.2 DIABETES MELLITUS 
Diabetes refers to a group of metabolic disorders in which there is an inability to 
maintain blood glucose levels, resulting in hyperglycaemia. They significantly affect the 
quality of life of sufferers and if left untreated, can lead to retinopathy, neuropathy and 
nephropathy (Nathan, 1993; Zimmet, Alberti and Shaw, 2001; Bluestone, Herold and 
Eisenbarth, 2010; Lukic, Pejnovic and Lukic, 2014). There are two well-known types of 
diabetes, Type 1 - T1DM (insulin dependent) and Type 2.  
Diagnosis of diabetes has been described as fasting plasma glucose value greater than 
7mmol/L and random blood glucose level value greater than 11mmol/L. Diagnosis 
criteria also includes glycated haemoglobin (HbA1C) greater than 6.5% and 2-hour 
postprandial glucose level greater than 11mmol/L (American Diabetes Association, 
2012). In addition to hyperglycaemia, diabetes is also associated with three main 
symptoms- polyuria (excessive urination), polyphagia (excessive appetite) and 
polydipsia (increased thirst) (Atkinson, Eisenbarth and Michels, 2014). These usually 
present as primary symptoms. Diabetes also leads to weight loss and in long term has 
effects such as vision loss, kidney failure and neuropathy leading to foot ulcers. In severe 
cases, ketoacidosis can occur leading to coma and eventually death. It has also shown 
comorbidity with cardiovascular diseases, obesity, declined cognitive function and 
hypertension (Alberti and Zimmet, 1998; Hassing et al., 2004).  
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1.2.1 Type 1 Diabetes (T1DM) 
T1DM is a genetically inherited irreparable autoimmune disease in which the 
insulin producing β-cells of the pancreas are destroyed, leading to serious insulin 
dependence. Individuals with T1DM resort to supplementary insulin and dietary 
regulation to prevent further complications of the disease like retinopathy, 
neuropathy and nephropathy (Nathan, 1993; Alberti and Zimmet, 1998; Daneman, 
2006; Clery et al., 2017).  
1.2.2 Type 2 Diabetes 
Type 2 diabetes on the other hand, results from irregularities in insulin action and 
secretion. It is caused by a mix of genetics and lifestyle choices and can be managed 
through changes in diet, physical activity and medication (Vijan, 2010; Chatterjee, 
Khunti and Davies, 2017). It is the more common and better studied of the two types.  
1.3 THE PANCREAS 
The pancreas is an organ measuring about 14-18 cm long, 2-9cm wide, 2-3cm thick 
and weighing- about 70-150g. (Slack, 1995; Dolenšek, Rupnik and Stožer, 2015; 
Tortora and Derrickson, 2017). The pancreas is viscoelastic, more viscous than the 
spleen, kidney and liver, with a Young’s modulus between 1.4-2.1KPa and a 
dynamic modulus of 120-180Pa (Sugimoto et al., 2014). 
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Figure 1.1: The anatomy of the pancreas (taken from Staff, 2014). 
The pancreas has four parts as shown in Figure 1.1. The head is found in the concave 
groove of the duodenum, surrounding the mesenteric artery and vein. The neck is 
found between the head and the body of the pancreas covering the blood vessels. The 
body is the largest part containing the bulk of the cells and the tail acts as the 
boundary between the pancreas and the spleen (Ionescu-Tirgoviste et al., 2015). 
The pancreas has two types of cells that perform two different actions: the exocrine 
cells responsible for enzyme secretion and the endocrine cells in charge of hormone 
secretion. The enzyme secreting exocrine cells form most of the cells in the pancreas. 
These cells are easily visualised and are arranged in clusters called acini found 
around interconnected lobes which drain the secretory products into the pancreatic 
duct from where it proceeds to the duodenum (Dolenšek, Rupnik and Stožer, 2015; 
Ionescu-Tirgoviste et al., 2015). 
6 
 
1.3.1 Islets of Langerhans 
The endocrine cells of the pancreas are found in spherical clusters called islets of 
Langerhans, named after Paul Langerhans who identified them in the late 19th 
century. There are about 3million islets in the average pancreas arranged in density 
routes (Kulkarni, 2004). There are four kinds of endocrine cells– α, β, δ and 
Pancreatic Polypeptide producing (PP) cells that secrete glucagon, insulin, 
somatostatin and pancreatic polypeptides respectively (Figure 1.2). Of these cells, 
the β cells are the most abundant making up about 70-80% of islets, α-cells account 
for 17%, δ for 7% and PP for 6-7%. Islets also include ghrelin-secreting cells that 
are part of the appetite regulation system of the body. Insulin and glucagon are 
particularly involved in the essential glucose regulation system of the body (Wills, 
Thomas and Gillham, 2006; Naish et al., 2009; Ahmed, 2011). 
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Figure 1.2: The anatomy of the pancreas showing the exocrine and endocrine cells 
(taken from Staff, 2014). 
1.3.2 Insulin  
Insulin is a protein made of polypeptides linked by three covalent disulphide bonds 
with a molecular weight of 6,000 Daltons. It is derived by the cleavage of proinsulin 
a prohormone. Insulin is dimer of two chains, the A chain with 21 amino acids 
residues and the B chain with 30 amino acid residues (Humbel, 1965; Wills, Thomas 
and Gillham, 2006). 
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1.3.3 Insulin Synthesis  
The synthesis of insulin begins with the translation of insulin mRNA to produce 
preproinsulin, a single chain peptide. It is then transported into the endoplasmic 
reticulum in which the signal peptide is cleaved and proinsulin is formed. Proinsulin 
as a peptide has three chains- the B chain (carboxy terminal), C-chain (central chain) 
and the A chain- (the amino terminal) (Steiner and Oyer, 1967; Wills, Thomas and 
Gillham, 2006).  
The endoplasmic reticulum contains many enzymes, including the endopeptidases 
(prohormone convertases) and carboxypeptidases. These enzymes cleave the C-
peptide chain leaving the A and B chains which form insulin. Insulin is then stored 
in granules of the Golgi apparatus (Steiner and Oyer, 1967; Wills, Thomas and 
Gillham, 2006). 
1.3.4 Insulin Secretion  
1.3.4.1 Glucose stimulated insulin secretion (GSIS) 
Primarily, insulin secretion in the islets of Langerhans occurs in a biphasic manner. 
Initially, increase in blood glucose triggers an insulin secretion within 5-10 minutes. 
The second is a glucose independent secretion over 2-3 hours. (Gerich, 2002; 
Lorenzo et al., 2010) 
Figure 1.3 shows the insulin secretion process in the β-cell.  
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1. Initially, glucose is transported into the cells through the glucose transporter 
(GLUT2). It ensures that the rate of entry is proportional to the blood glucose 
levels. 
2. After transporting, the glucose in the cell is phosphorylated to glucose-6-
phosphate through the action of glucokinase. 
3. Glucose-6-phosphate enters the glycolytic pathway and the Kreb’s cycle. 
4. Acetyl-coA oxidation produces ATP molecules leading to a rise in the 
ATP:ADP ratio in the cell.  
5. This increased ATP:ADP ratio closes the ATP sensitive potassium channel 
leading to a build-up of potassium ions intracellularly. This leads to a 
depolarisation of the cell membrane. 
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Figure 1.3: Insulin secretion in pancreatic β-cells. When plasma glucose is low, the decreased ratio of ATP/ADP will increase 
K+ channel opening. Consequently, the cell membrane is hyperpolarized, preventing voltage-gated calcium channel opening, 
Ca2+ influx and insulin secretion. At high blood glucose levels, glucose is transported into the cell through GLUT2. Glucose 
metabolism leads to an increased ATP/ADP ratio resulting in closing of the K+ channel and depolarisation of the membrane. 
This leads to an opening of the calcium channel, influx of Ca2+ and insulin secretion (Lang and Light, 2010). 
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6. Depolarisation triggers the opening of the voltage dependent calcium 
channels (VDCC) and an influx of calcium ions. 
7. The increase in intracellular calcium ions leads to the release of insulin from 
intracellular secretory vesicles (Schuit et al., 1997, 1999; Gerich, 2002; Lang 
and Light, 2010; Lorenzo et al., 2010; Santulli et al., 2015). 
1.3.4.2 Other factors involved in insulin secretion 
Elevated levels of amino acids like L-glutamine, L-arginine, alanine and leucine lead 
to an increase in insulin secretion in β-cells. This effect can be observed individually 
as in the case of arginine and also in combination like leucine and glutamine (Van 
Loon et al., 2003; Newsholme et al., 2007; Henquin and Nenquin, 2016). 
Glucagon triggers insulin secretion through lipolysis. In insulin deficiency, lipolysis 
induction through glucagon action leads to the creation of glucose and induction of 
insulin secretion (Liljenquist et al., 1974). 
Incretins like glucagon like peptide (GLP-1) and glucose dependent insulinotropic 
peptide (GIP) lead to the rapid secretion of insulin. They also induce insulin gene 
transcription and islet generation (Macdonald et al., 2002; Pederson and McIntosh, 
2016).  
1.4 TREATMENT OF TYPE 1 DIABETES  
1.4.1 Insulin Supplementation 
Traditional treatment for T1DM is insulin replacement. This usually takes the form 
of daily injections of insulin to prevent hyperglycaemia. Apart from the obvious 
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problem of daily insulin injections, this method still faces the challenge of the insulin 
being exogenous and not being as sensitive as endogenous insulin produced by the 
body (Godfrey et al., 2012; Klein and Klein, 2015). Continuous subcutaneous insulin 
infusion (CSII) via the insulin pump has been shown to be safer and more effective 
at reducing blood glucose levels without increasing the risk of hypo- or 
hyperglycaemia (Misso et al., 2010). Combining continuous glucose monitoring 
(CGM) with CSII leads to stabilisation of blood glucose levels (Bergenstal et al., 
2010; Varanasi et al., 2011). 
1.4.2 Whole Pancreas Transplantation 
Whole pancreas transplants represent the holy grail of type 1 diabetes treatment. 
Between 1966, when the first successful pancreas transplant was performed, and 
2014, over 40,000 pancreases have been transplanted with treatments showing 
insulin independence up to 2 years after the transplant (Godfrey et al., 2012; Ramesh, 
Chhabra and Brayman, 2013; Gruessner and Gruessner, 2014). Because of some of 
the complications associated with this method including morbidity, a 1-3% rate of 
morbidity has been reported, immune rejection, lifelong immunosuppression for 
organ recipients and a shortage of suitable donors, transplantation is only 
recommended to patients who do not respond to insulin replacement therapies and 
are at a high risk of nephropathy (White, Shaw and Sutherland, 2009; Godfrey et al., 
2012).  
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1.4.3 Islet Transplantation 
The Edmonton procedure has led to the recognition of islet transplantation as an 
emerging treatment option for patients with recurrent and refractory hypoglycaemia. 
This procedure led to the successful transplantation of the islet cells, leading to 
insulin independence in seven patients as described in 2000 and then repeated in 36 
subjects in 2006 (Shapiro et al., 2000, 2006). In 2012, the Shapiro group observed 
that 79% of the patients that received islet transplants regained glucose regulation 
function. 96% survival rates and insulin independence rates of 50-60% were 
observed after 4 years (Barton et al., 2012). Globally, over 750 patients have 
received islet transplants with similar success rates (Barton et al., 2012; McCall and 
Shapiro, 2012).  
Several factors have been identified which determine to a large extent, the success 
of an islet transplant procedure. Some of these include donor age, cause of death and 
plasma glucose levels of donor, recipient age, success of islet isolation procedure, 
co-morbidities, cold ischemia time and the kind of immunosuppressors/vasopressors 
used (Zeng et al., 1994; Robertson, 2000; Matsumoto et al., 2004; Nano et al., 2005). 
Table 1.1 is a summary of the treatment options for type 1 diabetes with their 
limitations.  
Table 1.1: Treatment options for type 1 diabetes 
 Treatment Limitations Reference 
1. Insulin 
supplementation 
Long term effects- renal 
failure, nephropathy, 
frequent episodes of 
hypoglycaemia 
Stevens et al. 
2001 
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2. Pancreas 
transplantation 
Lack of donors, 
Immuno-suppression 
Robertson 2000 
3. Islet 
transplantation 
Lack of donors, 
Low survival of Islets 
Shapiro et al. 
2006 
4. Islet 
encapsulation/ 
seeding and 
transplantation 
Lack of donors, 
Biocompatibility/ 
biodegradability of 
encapsulating/ seeding 
materials 
Low survival of Islets 
Bromberg & 
LeRoith 2006 
Robertson 2000 
1.4.4 Challenges of Islet Transplantation 
Even though islet transplantation has been found to be successful experimentally, it 
has not yet gained wide clinical acceptance and usage. This is due to different factors 
including loss of islet cells upon transplantation (up to 60% are lost in the first few 
days), reduced function of the transplanted islet cells with time, risks associated with 
extended exposure to immunosuppression, increased risks of developing T1DM in 
donors and a resultant distinct dearth of donor islet cells (McCall & Shapiro 2012, 
Martin et al., 2015). Of all sixty-five patients who underwent an islet transplantation 
in 2004 under the Edmonton protocol, sixty- three of the patients received multiple 
transplants indicating that one transplantation was not sufficient (Ryan et al. 2005). 
One of the major factors preventing islet transplantation from being converted into 
mainstream clinical practice is the poor graft function in the long term. This is due 
to a lower number of islet cells surviving than the number that were transplanted. 
Islets also have a high specificity (high oxygen demand and vascularisation needs) 
and are susceptible to the immune response.  
To circumnavigate some of the issues associated with transplanting islets, different 
strategies have been suggested. These include the immunoisolation of islet cells 
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through the design of multifunctional scaffolds, encapsulating islet cells (mimicking 
their natural environment) and better immunosuppression strategies (Hatziavramidis 
et al., 2013).  
Encapsulation of islets before transplantation is a field that has been developed in 
response to the Edmonton protocol in which there was a loss of islets post 
transplantation and the potential for the elimination of immune suppressive drugs in 
transplantation. Encapsulating systems can be divided into two types,  hydrogel 
systems and macroencapsulation systems (An et al., 2018). Encapsulating islets is 
an area that has been researched and discussed extensively. Encapsulation provides 
a means for immunoisolation and protection of the islets. The ideal material for islet 
encapsulation should be biocompatible, inert, porous, allowing for exchange of 
oxygen, nutrients, glucose and insulin but also protective of the islet cells, protecting 
them from response molecules of the immune system  (Lim and Sun, 1980; Weir, 
2013; Kepsutlu et al., 2014). Due to their highly hydrophilic nature and their ability 
to mimic the extracellular matrix, hydrogels are favoured in the field of Tissue 
Engineering as encapsulation materials. More recently, these hydrogels are being 
investigated with addition of varying factors like vascular endothelial growth factor 
(VEGF), a promoter of angiogenesis to further mimic the extracellular matrix -ECM 
(Phelps et al. 2009).  
Different polymeric materials have been suggested and tested as scaffolds for islet 
transplantation. These materials range from synthetic to natural polymers with 
varying physical, mechanical and thermal properties (described later). These 
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scaffolds offer support and protection for the islets; potentially shielding them from 
the instant blood mediated inflammatory response (IBMIR). 
1.5 THE BIOARTIFICIAL PANCREAS 
A bioartificial pancreas is a biomimetic device that substitutes for the endocrine 
portion of the pancreas while also avoiding the need for immunosuppressive drugs. 
The bioartificial pancreas combines encapsulation and the concept of a scaffold to 
create 3D macro and micro environments that mimic the native pancreas. It provides 
immunoisolation for the cells while also providing a semipermeable membrane for 
exchange of oxygen and nutrients (Kizilel, Garfinkel and Opara, 2005; Hwang et al., 
2016).  
1.5.1 Biomaterial for Bioartificial Pancreas 
Biomaterials for bioartificial pancreas have the typical material requirements for 
Tissue Engineering (TE). Typical materials for tissue engineering must: 
• Support growth, attachment and proliferation of cells 
• Mimic native environment of the tissue 
• Provide mechanical support for the cells 
• Be non-immunogenic, non-toxic, biodegradable and biocompatible 
• Support blood supply to the cells (vascularisation) 
• Promote rapidity in response to stimulus  (Gunatillake and Adhikari, 2003; 
Kim et al., 2008; Iacovacci et al., 2016). 
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A variety of different materials have and can be considered for the development 
of Bioartificial Pancreas. These are described below: 
1.5.1.1 Poly (ethylene) glycol 
Poly(ethylene) glycol (PEG) has been widely investigated for use in islet 
encapsulation in the form of hydrogels because of its highly adjustable material 
characteristics. PEG has been shown to trigger a minimal immune response and 
promote cell adhesion, making it a good candidate for islet transplantation. Reported 
ways in which it’s been used in islet transplantation include cell encapsulation in the 
form of hydrogels and in the modification of islet surfaces to reduce the instant blood 
mediated inflammatory reaction (IBMIR) pre-transplant (Lim and Sun, 1980; Kizilel 
et al., 2010; Lin and Anseth, 2011). 
Cruise et al. observed 90% encapsulation efficiency and islet viability after 
encapsulation of islets in photopolymerised PEG. This could be attributed to the fact 
that photopolymerised PEG forms an immune barrier on the surface of porcine islets. 
These findings are corroborated by studies showing that encapsulating islets cells in 
photopolymerised PEG is more efficient; with no loss of functionality to the cells 
(Cruise et al., 1998; Teramura and Iwata, 2011). Polyethylene glycol conjugated 
with maleimide (PEG-MAL) is a derivative of PEG that has been used for 
encapsulation of β-cells. These encapsulated structures did not impair insulin release 
and showed physical stability up to 30 days, post-transplantation. Since 
vascularisation is an important factor for survival of islets, vascular endothelial 
growth factor was bound to the PEG-MAL structures which led to vascularisation 
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within 4 weeks of transplantation in diabetic rats (Phelps et al., 2013; Teramura et 
al., 2013).  
Binding islets to PEG and its derivatives is a viable method of protecting islets post-
transplantation. Treating islets with isocyanate, monosuccinimide and disuccinimide 
derivatives of PEG provided significant cyto-protective functions to the cells (Panza 
et al., 2000; Xie et al., 2005). When PEG was used as an immobiliser for 
microencapsulation of islets, increased encapsulation efficiency and insulin response 
were observed (Teramura and Iwata, 2011). 
Further, PEG has also been used to coat microspheres of other materials used for 
islet transplantation. For example, coating the surface of alginate-polylysine islet 
microspheres with charged derivatives of  PEG has been shown to further increase 
their biocompatibility (Chen et al., 1998).  
Using PEG hydrogels requires increased cell densities of up to 107 cells/ml. This is 
not always viable in situations where islets are limited. Cell adhesion rates vary with 
molecular weights of PEG structures. Because of this, other strategies like 
functionalisation of the surface of the PEG with proteins and ligands responsible for 
cell adhesion or insulin secretion in cells must be applied to make them more 
cytocompatible. PEG hydrogels have been functionalised with proteins like 
glucagon-like peptide-1 (GLP-1) and ligands like thiolated ephrin A5-Fc to foster 
the cell-cell interactions that are important for the survival and function of islets post 
transplantation (Kizilel et al., 2010; Lin and Anseth, 2011). 
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1.5.1.2 Polyvinyl alcohol (PVA) 
Polyvinyl alcohol (PVA) has been explored as a hydrogel material for many different 
biomedical applications. Due to its highly hydrophilic nature, it forms hydrogels 
easily and can be easily manipulated. It has also been shown to have selective 
permeabilities to different substances (Inoue et al., 1992). Several studies have been 
performed in which islets encapsulated in PVA hydrogels have been transplanted 
into rats and they have all reported success in decreasing non-fasting blood glucose 
levels (Qi et al., 2004, 2012). Although it possesses high hydrophilicity, it has a low 
mechanical strength. This can be circumnavigated through addition of substances 
like glutaraldehyde or by using specific methods for preparation of the hydrogel such 
as the addition of structural support like a mesh. (Young et al., 2002). 
1.5.1.3 Gamma Polyglutamic acid (γ-PGA) 
Gamma Polyglutamic acid (γ-PGA) is a natural, hydrophilic, biodegradable and 
biocompatible homopolymer of D- and L-glutamic acid. Because of its high 
biocompatibility, hydrophilicity and low mechanical strength, it has been 
investigated widely as a carrier system in drug delivery, cell therapy and for the 
encapsulation of cells for soft tissue engineering (Shih and Van, 2001; Bajaj and 
Singhal, 2011; Ozdil and Aydin, 2014). Glutamic acid is an important part of the 
insulin release/production pathway indicating that polyglutamic acid could 
potentially play a part in both encapsulating islet cells and stimulating insulin 
secretion.  
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In combination with other polymers, γ -PGA hydrogels have been designed for 
different medical applications like drug and cell delivery (Yang et al., 2002; Sonaje 
et al., 2010). 
1.5.1.4 Agarose 
Agarose is another polysaccharide derived from seaweed. Because of its cytotoxicity 
and non-immunogenicity, it has been applied for use in transplanting islets. After 
diabetic mice were implanted with agarose cell encapsulated islet cells, they could 
achieve normoglycaemia for up to 100days. They also showed high degrees of 
immunoisolation. Another study showed that agarose encapsulated islets 
transplanted into mice demonstrated normoglycaemia indefinitely (Iwata et al., 
1992; Hwang et al., 2016). It has also been shown to protect islets from the immune 
response via mononuclear infiltration (Kobayashi et al., 2003).  
1.5.1.5 Poly(Glycolic Acid)-PGA, Poly(Lactic Acid)-PLA, Poly(L-lactic Acid)- PLLA and 
Poly(Lactic-co-Glycolic Acid)-PLGA  
These are synthetic polymers that have been investigated for their use in different 
tissue engineering as scaffolds for seeding cells and in making microspheres for 
encapsulation of cells and drug delivery. They are biodegradable, biocompatible 
polymers that are good candidates for islet transplantation. Islets encapsulated in 
PLGA microspheres and transplanted into rats led to decreased glucose levels and 
greater insulin yields (Abalovich et al., 2001; Anderson and Shive, 2012). Thin 
PLGA-collagen meshes have also been shown to stimulate insulin release in rat 
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pancreatic cells (Kawazoe et al., 2009). Islet-like cells derived from stem cells when 
seeded in PLGA scaffolds could reverse hyperglycaemia (Mao et al., 2009). 
Studies have shown that diabetic rats that had been injected with islets co-cultured 
with PGA had a better morphology of cells, cell viability, lower blood glucose levels 
and higher insulin content and remained hyperglycaemic up to 3 months post-
transplantation (Juang et al., 1996; Chun et al., 2008; Hou et al., 2009). Although 
these materials pose a good option, their bulk degradation need to be resolved for 
them to be perfect candidates for islet transplantation. 
1.5.1.6 Polycaprolactone (PCL)  
PCL is an FDA approved polymer that is used in a wide range of biomedical 
applications. For islet transplantation, PCL is favourable due to its adjustable 
degradation rates. It has been more commonly applied in combination with other 
polymers in islet transplantation. Islets seeded in PCL and alginate scaffolds have 
been shown to have similar insulin response to free floating islet cells in chicken 
membrane models. The scaffolds were however able to induce vascularisation 
(Marchioli, Luca, et al., 2016). MIN6 cells were encapsulated in PCL/PEG 
nanoporous structures in allogenic mouse models. These systems did not induce an 
immune response but contributed to rapid vascularisation around the scaffold 
(Nyitray et al., 2015). PCL/ polyethylene oxide micelles have shown the ability to 
load and deliver the SP600125 (a c-Jun NH2-terminal kinase inhibitor) cell signalling 
modulator that prevents the death of human islets. This is an indication that the 
addition of these micelles to the scaffolds could improve the chances of islet survival 
post-transplantation (Savić et al., 2009). Even though PCL scaffolds have 
22 
 
mechanical properties that make them suitable for soft tissue engineering, they have 
a slow degradation rate of about 2-3 years which is less than ideal for most Tissue 
Engineering applications (Chen, Liang and Thouas, 2013).  
1.5.1.7 Collagen  
Collagen is another biopolymer that has been widely explored for tissue engineering 
purposes. This is largely because it is a protein found in the extracellular matrix so 
it provides cells with a more native environment than matrices without the ECM 
proteins (Riopel and Wang, 2014). For islet transplantation, when mice islets were 
suspended in a collagen gel matrix and transplanted into diabetic C57BL/6 mice, 
both the viability and insulin release function of these cells was maintained. (Jalili et 
al., 2011). Although its biocompatibility has been established, due to the availability 
of a wide variety of collagens, it faces an issue of variability in mechanical and 
physical properties (Sai K and Babu, 2000; Chen, Liang and Thouas, 2013).  
Blended with alginate, collagen has also been shown to improve islet function both 
in vitro and in vivo with a reduction in glucose levels to 200mg/dl 60 minutes after 
transplantation into mice (Lee et al., 2012). Collagen has also been shown to promote 
the aggregation of different endocrine cells in islets showing it as a potential polymer 
for bioartificial pancreas (Montesano et al., 1983). 
Based on the advantages and drawbacks of materials discussed earlier, alginate was 
determined to be a material of interest in the creation of bioartificial pancreas. 
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1.6 ALGINATE 
Alginate is an anionic highly hydrophilic polysaccharide with low cost, high 
biocompatibility, low toxicity and ease of customisation (Kuo and Ma, 2001; Lee 
and Mooney, 2012). It is a natural occurring polymer produced by brown seaweed 
species including Laminaria digitata, Laminaria japonica, Laminaria hyperborea. 
It is also produced by bacteria, especially the Azotobacter and Pseudomonas sp. (Lee 
and Mooney, 2012). Bacteria derived alginate is favoured because it has more well 
defined chemical and physical structures and properties.  
1.6.1 Structure of Alginate 
Alginate is a family of block copolymers containing β-D-mannuronic (M) and α-L-
guluronic (G) acids linked a the (1, 4) positions respectively (Kuo and Ma, 2001; 
Remminghorst, 2007). The chemical structure is shown in Figure 1.4. The ratios of 
mannuronic acid to guluronic acid in the structure depends on the source and 
synthesis of alginate. They can contain consecutive or alternating M and G residues. 
Due to the different arrangements and combinations possible, a huge variety of 
alginate polymers exist (Kuo and Ma, 2001; Remminghorst, 2007; Lee and Mooney, 
2012).  
To form hydrogels, metal salts of alginate (typically sodium or potassium) are 
crosslinked with ions such as Ca2+ derived from CaCl2, CaCO3 and CaSO4. 
Typically, the Ca2+ ions bind to the guluronate residues of each polymer and join up 
with another polymer chain. Many factors influence the mechanical and physical 
properties of the hydrogel formed including the M/G ratio, G-block chain and 
24 
 
molecular weight, making it an easily modifiable polymer (Kuo and Ma, 2001; Lee 
and Mooney, 2012).  
 
Figure 1.4: Chemical structure of alginate. 
 
1.6.2 Microbial Production of Alginate 
Although seaweed are the primary sources of alginate, microbial production of 
alginate is another area of interest due to its potential environmentally friendly 
applications. 
Microbial production is carried out via fermentation of a range of carbon sources 
ranging from sugars, glycerol and acetate. Alginate is produced under nitrogen 
limiting conditions, especially nitrogen and phosphate. Alginate offer protection 
from adverse conditions like high temperature to bacteria (Mian, Jarman and 
Righelato, 1978; Clementi, 1997).  
Two major species of bacteria have been indicated in the production of alginate, 
including Pseudomonas and Azotobacter. Alginate is produced in Pseudomonads in 
microaerophilic conditions and the yield of alginate increases in nutrient limiting 
conditions (Sabra and Zeng, 2009; Franklin et al., 2011; Hay et al., 2014). The 
polymer plays a role in cell adhesion and quorum sensing activities of Pseudomonas 
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aeruginosa in opportunistic infections present in conditions like cystic fibrosis. The 
alginate produced also enhances survival in adverse conditions. Azotobacter spp. are 
Gram-negative bacteria that participate in nitrogen fixation. Alginate is produced 
extracellularly as part of their life cycle under conditions of nutrient limitation 
(Clementi, 1997). Azotobacter vinelandii is the most widely studied producer of 
alginate. It produces alginate with more gulucoronic acid residues than alginate 
produced by Pseudomonads. This directly affects the strength of the crosslinking in 
hydrogel formation as crosslinking efficiency is directly related to proportion of 
gulucoronic acid residues (Bonartseva et al., 2017). Additionally, due to the safety 
issues associated with Pseudomonas aeruginosa, alginate from Azotobacter 
vinelandii is preferred. The drawback is that the yield of alginate produced from 
Azotobacter vinelandii is very low (Bai et al., 2017). 
1.6.3 Biomedical Applications of Alginate 
1.6.3.1 Drug Delivery 
Alginate has been extensively studied for its use in drug delivery systems. Because 
of the ease of modification of alginate hydrogel systems, hydrogels with different 
properties can be developed. These include controlled drug delivery systems, pH and 
temperature sensitive hydrogels. They can be applied in different forms including 
capsules, micro and macro spheres and beads (Jain and Bar-Shalom, 2014). Some of 
these drugs include gentamycin sulphate, pindolol, nitrofurantoin, timolol maleate, 
diclofenac, lidocaine HCl, sodium salicylate, acebutulol and indomethacin 
(Filipović-Grćić et al., 1995; Fernández-Hervás et al., 1998; Park et al., 1998; Sezer, 
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1999; Takka, 1999; Kulkarni et al., 2000; Coppi et al., 2001; Tønnesen and Karlsen, 
2002). 
1.6.3.2 Wound Dressings 
Due to its ability to form hydrogels easily, alginate has been widely investigated for 
its use in wound healing. One of the areas that have been studied is in diabetic ulcers. 
Alginate in combination with other materials is mainly used in hydrogel form for 
wound healing. 
Silver alginate dressings have shown long-term anti-microbial effect and efficacy 
over a 21-day test period (Percival and McCarty, 2015). In combination with DNA, 
alginate gels have been trialled for their use in diabetic ulcers. These tests showed a 
high degree of biocompatibility for the hydrogels, proving its potential for use in 
diabetic ulcers (Tellechea et al., 2015). Chitosan-alginate wound dressings have been 
proven to promote production of collagen and fibrous tissue, hence speeding up 
wound healing (Caetano et al., 2015). In combination with curcumin and chitosan 
nanoparticles, alginate has been shown to accelerate shrinkage, complete 
epithelialization and formation of collagen (Karri et al., 2016).  
1.6.3.3 Islet Cell Encapsulation 
Many studies have evaluated alginate hydrogels as materials for cell encapsulation. 
Most recently, beta cells derived from human embryonic stem cells were 
encapsulated in alginate derivatives and transplanted into mice. The cells could 
retain function up to 174 days after transplantation. The alginate derivatives provided 
support from the IBMIR (Vegas et al., 2016). Sustained function and reversal of 
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diabetes has been reported after pig islets were encapsulated in alginate and then 
transplanted into animal models and one human model (Dufrane, Goebbels and 
Gianello, 2010; Jacobs-Tulleneers-Thevissen et al., 2013). Islets encapsulated in 
biocompatible capsules formed by crosslinking alginate with barium chloride 
maintained their levels in non-obese diabetic (NOD) mice up to 350 days post-
transplantation (Duvivier-Kali et al., 2001). More frequently, alginate has been used 
in conjunction with other polymers for encapsulation of islet cells. Combining 
alginate with other biopolymers like collagen and PEG for encapsulation of islets 
has helped improve the biocompatibility of the constructs and given the islets a better 
chance of survival in vivo (Montesano et al., no date). Alginate hydrogels embedded 
in polytetrafluorethylene membranes showed positive graft function in a 60-year-old 
patient up to 10 months post-transplantation. Sustained insulin response was also 
observed (Lee et al., 2012). When coated with poly-lysine, implanted alginate 
hydrogel capsules influenced better insulin response than crude alginate capsules 
(Vos et al., 1997). Embedding peptides in alginate hydrogels has been shown to 
increase cell accessibility and adhesion (Vériter et al., 2010; Sun and Tan, 2013). 
Alginate has been combined with argynyl-glycyl-aspartic acid (RGD peptide) with 
no immune/ inflammatory reaction up to 60 days after transplantation into rats (Lee 
et al., 2012).  
1.7 POLYHYDROXYALKANOATES (PHAS) 
Polyhydroxyalkanoates (PHAs) are polymers of hydroxyalkanoic acids with high 
molecular weight. The monomer units have hydroxyl groups attached at the 3, 4, 5 
or 6-positions (Figure 1.5). Because of this variability in the structures of different 
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PHAs, they have varying physical properties and hence can be used in  many 
different applications (Lee, 1996a; Khanna and Srivastava, 2005; Keshavarz and 
Roy, 2010). These fields range from hard tissue engineering like bone to soft tissue 
applications like cardiac, nerve and skin tissue engineering and delivery systems for 
drug and cells (Chen and Wu, 2005; Philip, Keshavarz and Roy, 2007; Pooja Basnett, 
K Y Ching, et al., 2013; Lizarraga‐Valderrama et al., 2015). PHAs also exhibit better 
biocompatibility than other commonly used materials for TE like PLA, PCL and 
PLGA. This has led to them being applied widely in the biomedical field. 
Applications that have been investigated include wound patches, cardiac patches, 
bone tissue engineering, drug delivery, urological stents, artificial oesophagus, nerve 
tissue engineering and coronary artery stents (Valappil et al., 2007; Akaraonye, 
Keshavarz and Roy, 2010; Ranjana Rai et al., 2011; Pooja Basnett, K Y Ching, et 
al., 2013). PHAs have been shown to support the growth of a wide range of cells 
including murine islet cells, cardiac, nerve, bone and mesenchymal stem cells (Yang 
et al., 2010; Mouriño et al., 2013; Nigmatullin et al., 2015). They have also been 
explored for other uses like drug delivery systems, suture materials and cell delivery 
systems (Ranjana Rai et al., 2011; Garg, Singh and Goyal, 2013) 
 
Figure 1.5: The general structure of polyhydroxyalkanoates (x = number of 
methylene groups in the backbone; n = 1000-10000; R = alkyl groups, C1-C13) 
29 
 
 
1.7.1 Classes of PHAs 
PHAs are classified into two types based on their monomer chain length. 
1.1.1.1.Short-Chain Length PHAs (Scl-PHAs) 
Short chain length PHAs have 3-5 carbon atoms in their monomers usually 
accumulated by bacteria of the Bacillus, Cupriavidus and Azotobacter spp. They are 
stiff, brittle polymers with high crystallinity, melting temperatures between 160-
180oC and glass transition temperatures between -5-+20oC (Basnett and Roy, 2010). 
They also have high tensile strength, low elongation at break. An example is poly(3-
hydroxybutyrate)-P(3HB) (Zinn, Witholt and Egli, 2001; Reddy et al., 2003; Ojumu, 
Yu and Solomon, 2004; Keshavarz and Roy, 2010).  
The brittleness of P(3HB) is a challenge to its processibilty, so blending with mcl-
PHAs is preferred for biomedical applications. 
1.1.1.2.Medium-Chain Length PHAs (mcl-PHAs) 
Mcl-PHAs contain 6-14 carbon atoms in their monomer units. They are accumulated 
by fluorescent Pseudomonas spp. in harsh growth conditions. They exhibit low 
melting temperatures between 40-60oC, glass transition temperatures between -50-
25oC. They also show low tensile strength and high elongation at break, typical of 
elastic polymers They typically consist of 1,000 monomer units (Sun et al., 2007; 
Keshavarz and Roy, 2010; R. Rai et al., 2011).  
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Due to their low thermal characteristics and tensile strength, blending with scl-PHAs 
is an attractive option for creating blends with optimal properties for biomedical 
applications (Witholt and Kessler, 1999; P. Basnett et al., 2013). 
PHAs can also be classified as homo or heteropolymers. Examples of homopolymers 
include P(3HO) and P(3HB). Examples of heteropolymers include poly(3-
hydroxyhexanoate-co-3-hydroxyoctanoate) P(3HHx-co-3HO) (Keshavarz and Roy, 
2010). Blending two classes of PHAs creates polymers with different properties to 
the individual component polymers. For example, blending P(3HB) and P(3HV) 
forms a polymer blend that is more malleable than the stiff P(3HB) (R. Rai et al., 
2011). 
1.7.2 Properties of PHAs 
There are a few general properties exhibited by all the classes and types of PHAs. 
These include: 
• Solubility in chlorinated solvents and insolubility in water. 
• Wide range of melting temperatures (40-180oC). 
• Degradation dependent on the side chains and monomeric units present. 
• Biocompatibility. 
• Biodegradability. 
• Non-toxicity. 
• Slow degradation rates. 
• Resistant to hydrolytic degradation (Ali Raza, Riaz and Banat, 2017; Basnett 
et al., 2017; Raza, Abid and Banat, 2018a). 
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The properties of PHAs can be varied through genetic or physiological strategies. 
Including a co-monomer or a different hydroxyalkanoic acid monomer into the 
polymer backbone can alter polymer properties like flexibility, toughness and 
stiffness (Valappil et al., 2007).   
1.7.3 Synthesis of PHAs 
PHAs are accumulated in inclusions (granules) in the cytoplasm of cells under 
nutrient limiting conditions. These inclusions are between 0.25-0.5µm and can be 
viewed by contrast light microscopes. They are lipid-like molecules and can be 
stained by Sudan black (Sudesh, Abe and Doi, 2000). Figure 1.6 summarises the 
pathways involved in the synthesis of PHAs. 
1.7.3.1 P(3HB) Synthesis 
P(3HB) synthesis takes place on the surface of the granule. It is a three-step process 
catalysed by important enzymes. 2 Acetyl-CoA molecules from the tricarboxylic 
acid cycle (TCA) are condensed by β-ketothiolase (PhaA) to form acetoacetyl-CoA. 
This is then reduced through the NADH-dependent acetoacetyl-CoA reductase 
(PhaB) at the C3-position to form 3-hydroxybutyryl-CoA. P(3HB) synthase then 
esterifies 3-hydroxybutyryl-CoA to P(3HB), releasing the CoA molecules (Zinn, 
Witholt and Egli, 2001; Verlinden et al., 2007a).  
1.7.3.2 Mcl-PHA Synthesis 
There are three different metabolic pathways that are involved in supplying mcl-
PHA precursors for the final conversion to mcl-PHAs: 
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• de novo fatty acid biosynthesis in which (R)-3-hydroxyacyl-CoA is formed 
using unrelated carbon sources like sugars. 
• Fatty acid degradation by β-oxidation, which is the main metabolic route for 
fatty acids.  
• Chain elongation of acyl-CoA to acetyl-CoA.  
These pathways all generate mcl-PHA precursors: (R)-3-hydroxyacylacyl-CoA, 3-
ketoacyl-CoA and 2-trans-enoyl-CoA. These are then converted to (R)-3-
hydroxyacyl-ACP by the actions of 3-hydroxyacyl-CoA epimerase, 3-ketoacyl-
ACP-reductase and (R)-specific enoyl-CoA hydratase (PhaJ). 
These (R)-3-hydroxyacyl-ACP molecules are then converted to  
(R)-3-hydroxyacyl-CoA in a reaction catalysed by (R)-3-hydroxyacyl-ACP-CoA 
transferase (PhaG).  
Finally, mcl-PHA synthases (PhaC) modulate the conversion of  
(R)-3-hydroxyacyl-coA to the respective mcl-PHA with a release of CoA (Witholt 
and Kessler, 1999; Zinn, Witholt and Egli, 2001; Kim et al., 2007; Chen et al., 2015; 
Wang, Chung and Chen, 2017). 
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Figure 1.6: Pathways for synthesis of polyhydroxyalkanoates
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1.7.4 Microbial Production of PHAs 
Ever since granules containing P(3HB) were discovered in cells of Bacillus 
megaterium in 1926, PHAs have been discovered in a wide range of bacteria 
(Lemoigne, 1926; Lee, 1996b). These bacteria are predominantly of the Bacillus, 
Pseudomonas, Azotobacter and Cupriavidus sp. (Anjum et al., 2016; Raza, Abid and 
Banat, 2018b). Most PHAs are synthesized from structurally similar substrates, so 
types and quantities of carbon source for fermentation determine the final PHA 
produced (Lee, 1996a; Ojumu, Yu and Solomon, 2004). Bacteria have PHA synthase 
enzymes that determine the PHA production pathway undertaken and hence, the 
particular class of PHAs produced (Anjum et al., 2016). 
Bacillus sp. are a class of Gram-positive bacteria in which P(3HB) was first 
discovered. They have been shown to produce scl-PHAs including P(3HB), P(4HB) 
and their copolymers using sugars as the carbon source (Aslim, Yüksekdağ and 
Beyatli, 2002; Valappil et al., 2006; Halami, 2008a).  
B. licheniformis, B. megaterium, B. cereus and B.subtilis OK2 have all been shown 
to produce P(3HB) when glucose was used as a carbon source (Chen, König and 
Lafferty, 1991; Singh, Patel and Kalia, 2009; Sukan, Roy and Keshavarz, 2017; 
Lukasiewicz et al., 2018). 
Organisms belonging to the rRNA class of Pseudomonas sp. including  
P. putida, P. oleovorans, P.aeruginosa, P.mendocina have been shown to produce 
mcl-PHAs through the fatty acid β-oxidation pathway. This occurs when alkanoic 
acids or fatty acids are used as the carbon source (Suriyamongkol et al., 2007). Some 
Pseudomonas sp.  have been shown to use other substrates as carbon sources. These 
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include sugars (Wang et al., 2016), biodiesel waste (Chanasit et al., 2016) and 
glycerol (Poblete-Castro et al., 2014).   
Cupriavidus necator has been shown to produce P(3HB) from simple sugars 
(Khanna and Srivastava, 2005) and plant oils (Fukui and Doi, 1998; Kahar et al., 
2004). 
1.7.5 Biomedical Applications of PHAs 
1.7.5.1 Drug Delivery 
Because of the high levels of biodegradability and biocompatibility, PHAs are 
promising candidates for drug delivery. PHA micro and nanospheres have been 
widely investigated for their use in varying drug delivery applications (Zinn, Witholt 
and Egli, 2001). P(3HB) is the PHA of choice for drug delivery because of its ready 
availability, ease of production and application in controlled release of drug. Another 
advantage of using PHAs as drug delivery systems is that they degrade slower than 
other commonly investigated biopolymers (Park, Choi and Lee, 2005; Nigmatullin 
et al., 2015). 
PHAs have also been used in drug delivery systems in the form of drug loaded rods 
and drug eluting scaffolds. Antibiotic loaded PHA rods were transplanted into 
rabbits with infected tibias. These rods showed both burst and sustained release up 
to 2 months post-transplantation. Successful antibiotic leaching also resulted in 
elimination of infection up to six weeks post transplantation (Gursel et al., 2002). 
Incorporating aspirin into PHA blend films led to uniform distribution and constant 
aspirin release over 20-30 days (Pooja Basnett, Kuan Yong Ching, et al., 2013) 
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1.7.5.2 Hard Tissue Engineering 
The most prevalent use of PHAs in hard tissue engineering is in bone tissue 
engineering with P(3HB) as the PHA of choice due to its mechanical strength. Due 
to its brittleness though, co-polymers or composites of PHAs are commonly used. In 
comparison to P(3HB), poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-
hydroxyhexanoate)- P(3HB-co-HV-co-HHx) has shown higher levels of human 
marrow mesenchymal stem cell adhesion  (Hayati et al., 2012). 
Blending PHAs with hydroxyapatite (HA) has been shown to increase their 
compressive modulus and maximum stress. Additionally, osteoblasts grown on 
P(3HB)/HA structures showed increased cell growth and alkaline phosphatase 
activity (Wang et al., 2005). In rats, formation of connective tissue was observed 45 
days after P(3HB)/HA composite structures were implanted. These implants also 
showed complete repair of bone defects in rats post transplantation. By day 30, the 
bone was completely healed (Shishatskaya et al., 2016). 
PHA scaffolds containing BioglassTM have been shown to have increased bioactivity, 
protein adsorption and bactericidal effects (Misra et al., 2010). Including zirconium 
dioxide in PHA scaffolds improved the mechanical properties, making them similar 
to that of native bone (Meischel et al., 2016). 
1.7.5.3 Soft Tissue Engineering 
In Cardiac Tissue Engineering, PHAs have been a primary focus. When P(3HO) is 
blended with P(3HB) in a cardiac stent to provide mechanical support, the structure 
exhibits significantly high cell viability and protein adsorption (Basnett and Roy, 
37 
 
2010). When mcl-PHA based trileaflet heart valves were incubated with ovine 
vascular cells, extensive cell attachment and confluence were observed. The 
structure also exhibits flexibility better than other commonly used polymers (Sodian 
et al., 2000).  
The creation of cardiac patches is another area where PHAs have proven to be 
important biomaterials. Tepha Inc. have produced a trileaflet scaffold made up of 
P(4HB) and P(3HOHHx). This scaffold can be used without the need for sutures due 
to its adhesive properties.  (Dubey, 2017). P(3HO) neat patches also showed high 
cell viabilities, proliferation and adhesion with neonatal ventricular rat myocytes and 
cardiomyocytes seeded on them (Bagdadi et al., 2018). 
Due to their elastomeric properties that can mimic those of the nerves, mcl-PHAs 
are favoured in nerve tissue engineering. P(3HO) and P(3HB) blend  
films seeded with NG 108-15 neuronal cells exhibited appropriate mechanical 
properties for nerve tissue engineering. They also showed better cell growth and 
differentiation (Lizarraga‐Valderrama et al., 2015). When Schwann cells and 
neuronal growth factors were included in the P(3HB) scaffolds, the scaffolds showed 
an increased ability to enhance regeneration (Armstrong et al., 2007). P(3HB) 
scaffolds with glial growth factor and transplanted into rabbits with 2-4cm gaps in 
nerves showed nerve regeneration within 63 days post-transplantation (Mohanna et 
al., 2003). 
P(3HB-co-3HHx) nerve conduits implanted in rats exhibited stable mechanical 
properties, selective permeability and integrity of structure even after >20% loss in 
molecular weight due to degradation. After 3 months, these factors showed excellent 
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nerve regeneration, hence confirming their potential as nerve conduits (Bian et al., 
2009). P(3HB-co-3HHx) scaffolds exhibited more extensive differentiation of 
human bone marrow mesenchymal stem cells into nerve cells (Zhang et al., 2018). 
P(3HB-co-3HHx) nanofibre scaffolds have been shown to promote nerve stem cell 
differentiation to neurons (Xu et al., 2010).  
1.7.5.4 Pancreatic Tissue Engineering 
Even though PHAs have been extensively researched for their use in biomedical 
applications, not a lot of research has been carried out involving PHAs in Islet 
transplantation. Chaturvedi et al. investigated the use of PHA nanoparticles for the 
oral delivery of insulin and demonstrated that these nanoparticles sustained insulin 
release (Chaturvedi et al., 2015). Yang et al. compared the growth of NIT-1 cells 
(murine beta cell line) on poly-lactic acid and two different PHAs - poly(3-
hydroxybutyrate-co-3-hydroxyhexanoate) and poly(3-hydroxybutyrate-co-4-
hydroxybutyrate). Their study showed that the PHAs promoted cell interaction of 
the NIT-1 cells and increased insulin secretion in comparison to PLA (Yang et al., 
2010).  
Table 1.2 shows a summary of some of the most popularly used polymers for islet 
transplantation with their drawbacks. 
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Table 1.2: Polymers Used in islet transplantation 
Polymer Natural/ 
Synthetic 
Uses Drawbacks 
Poly(ethylene) glycol Synthetic • Photo-polymerised hydrogel 
• Surface coating of microspheres increasing 
biocompatibility 
• Surface modification of islets providing 
immunoprotection.  
Non- uniform 
porosity, non-
biodegradability 
Polyvinyl alcohol Synthetic Hydrogel encapsulating islets Low mechanical 
properties 
Alginate  Natural • Encapsulating islets 
• Increases biocompatibility of other polymers 
• Reduces IBMIR when modified with peptides 
Huge variability in 
types 
PLGA, PGA, PLLA, PGA Synthetic • Microspheres stimulating insulin release from islets 
• Scaffold for cells 
Bulk degradation 
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Polycaprolactone Synthetic • Easily tunable 
• Scaffolds for cells 
• FDA- approved 
Low mechanical 
strength 
Polyhydroxyalkanoates Natural • Scaffolds for islets 
• Wide variety of properties in class of polymers 
Expensive to produce 
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1.8 MULTI-POLYMERIC DEVICES FOR PANCREATIC TISSUE 
ENGINEERING 
To overcome some of the issues associated with islet transplantations, current research has 
been geared towards the creation of 3D multipolymer scaffolds, otherwise known as 
bioartificial pancreas. These devices are multifunctional devices created to mimic the native 
pancreas and give the islets a greater chance of survival. They aim to resolve some of the 
challenges associated with islet transplantation by targeting multiple issues at the same time. 
The basic design for most of these devices is to have encapsulated islets and then to surround 
them with a polymeric scaffold. Several combinations of biopolymers have been exploited 
for creating this ideal bioartificial pancreas. Table 1.3 summarises some of these devices. 
The TRAFFIC device consisting of an alginate hydrogel layer spun around a polymer 
scaffold was investigated (Figure 1.7). In diabetic mice that received the device, 
normoglycaemia was observed up to 4 months post-transplantation. When scaled up to 
beagle dogs, the same effect was observed up to 1 month with the device remaining intact 
enough to be retrieved (An et al., 2018).  
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Figure 1.7: Schematic design and fabrication of the TRAFFIC device (An et al., 
2018). 
Maki and his colleagues at the New England Deaconess Hospital in Boston tested a 
bioartificial pancreas designed using a porous copolymer membrane in dogs. In dogs given 
a dose of aspirin after transplantation, 30% did not require exogenous insulin for 
normoglycaemia (Maki et al., 1991).  
Marchioli et al. described a 3D device in which a heparin immobilised alginate core 
functionalised with VEGF is surrounded by a PCL scaffold.  This device attempted to 
provide cytoprotection, immune isolation and vasularisation. Islets encapsulated in this 
device were shown to be effective in insulin response. The device was also shown to promote 
vascularisation (Marchioli, Luca, et al., 2016). 
Ludwig et al. explored the use of alginate and Teflon to create a multifunctional device that 
provided both immune protection and oxygen supply (Figure 1.8). The device was made of 
2 islet modules with polytetrafluorethylene (PTFE) membranes impregnated with alginate. 
The device contained two islet modules separated by an oxygen module with a port for 
supplementation (Ludwig et al., 2012, 2013; Neufeld et al., 2013). 
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Figure 1.8: Islet transplantation device consisting of PTFE membrane impregnated 
with alginate and islet modules (Neufeld et al., 2013) 
This device was transplanted into a 63-year-old gentleman. The transplanted islets continued 
to show structural integrity and glucose responsiveness up to 10 months post-transplantation 
when the device was removed. This technology was scaled up by Beta-O2 funded by the 
Juvenile Diabetes Research Foundation (JDRF) who in conjunction with the Uppsala 
University Hospital have taken it to Phase I clinical trials.   
Viacyte, a company that is an offshoot of the Edmonton group have designed the Encaptra 
drug delivery system which contains embryonic stem cells embedded in a polymeric 
scaffold. The device contains stem cell precursors of islets. The company received a $16.6-
million-dollar grant from the California Institute of Regenerative Medicine and $20 million 
from a Johnson & Johnson Venture arm. The device is in clinical trials (Dolgin, 2014, 2016; 
Lou, 2014).  Living Cell technologies in New Zealand developed Diabecell, a xenograft of 
pig islet cells encapsulated in an undisclosed hydrogel. The company received NZ$ 4 million 
to scale up the technology. Diatranz-Otsuka bought the product licence and have now taken 
the product to Phase II/III clinical trials (Garkavenko et al., 2011).  
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Table 1.3: Summary of bioartificial pancreas models available 
Source Structure  Cells Site of 
Transplant 
Progress 
New England 
Deaconess 
Hospital  
Co-polymer membrane Canine pancreatic cells Iliac artery  
Marchioli et al. Heparin immobilised 
alginate core 
Embedded in PCL scaffold 
Human islets Hepatic portal 
vein 
 
Beta-O2  
(β-air) 
Alginate hydrogel 
Polytetrafluorethylene 
(PTFE) membrane 
Human islets Abdomen Phase I clinic 
trials 
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Viacyte 
(Encaptra) 
Undisclosed polymeric 
scaffold 
Embryonic stem cell 
precursors of islets 
(PEC-01) 
 Phase I/IIa 
clinical trials 
Living Cells 
Technologies 
(Diabecell) 
Undisclosed hydrogel Porcine Islets  Phase II/III 
clinical trials 
TRAFFIC device Alginate hydrogel layer 
around wettable 
undisclosed polymer 
thread 
Human islets Kidney  
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AIMS AND OBJECTIVES 
The major aim of this project is to create a novel 3D functional bioartificial 
pancreas for the treatment of insulin deficiency in Type 1 diabetes. This 
structure will be made up of an outer biodegradable 3D PHA scaffold to 
provide immuno-protection and structural support. This outer layer will 
surround an inner hydrogel layer made up of alginate encapsulated 
pancreatic cells. This inner layer will also provide additional immune-
isolation and mimic the morphology of the natural environment of the Islets 
of Langerhans. Figure 1.9 is a summary of the final outcome 3D printed 
structure planned from this work. 
To achieve this aim, the following objectives were set and achieved: 
1. Production and characterisation of polyhydroxyalkanaoates: two kinds of 
PHAs- P(3HB) and an mcl-PHA, Poly(3-hydroxyoctanoate-co-3-
hydroxydecanoate), P(3HO-co-3HD), were produced by fermentation using 
Bacillus subtilisOK2 and Pseudomonas mendocina CH50. They were then 
characterised chemically, mechanically and thermally. Their production 
was also monitored and profiled with respect to optical density, biomass and 
usage of nutrients.  
2. Fabrication of PHA scaffolds: Both P(3HB) and mcl-PHA, P(3HO-co-
3HD), were fabricated into 2D neat films, 2D porous films and 3D porous 
scaffolds. These structures were characterised mechanically, thermally and 
physically. Cell viability and insulin release studies were then carried out 
on pancreatic cells seeded within or on these scaffolds.  
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3. Mcl-PHA/(P3HB) blends were generated in an attempt to optimise the 
mechanical and thermal properties of scaffolds to those of the native 
pancreas. A variety of blends were made and these blends were tested for 
cell viability and insulin release. 
4. Alginate hydrogels were created using two different methods- droplet 
method for microspheres and 3D- printing. Pancreatic cells were seeded in 
these and they were then tested for cell viability and insulin release effects.  
 
 
Figure 1.9: The final 3D scaffold planned to be constructed in future using 
the knowledge developed using the work described in this thesis.  
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CHAPTER TWO: 
MATERIALS AND 
METHODS 
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2. MATERIALS AND METHODS 
2.1. BACTERIAL STRAINS, CELL LINES AND CHEMICALS 
All chemicals were purchased from Sigma-Aldrich and VWR except 
otherwise stated. Pseudomonas mendocina CH50 and Bacillus subtilis OK2 
were derived from the University of Westminster’s culture collection with 
B. subtilis OK2 kindly supplied by Professor Fujio Kawamura from the 
Department of Life Sciences, Rukkyo University, Tokyo Japan. Cell culture 
studies were carried out using BRIN-BD11, rat pancreatic beta cell line 
purchased from European Collection of Cell Cultures (ECACC) (Dorset, 
UK). Cell culture studies were carried out using cell culture grade reagents 
from Sigma-Aldrich or Gibco. Insulin estimation was carried out using 
Mouse Insulin ELISA kit from Merck-Millipore.  
2.2.PRODUCTION OF THE POLYMERS 
2.2.1. Production of P(3HB)  
P(3HB) was produced using Bacillus subtilis OK2 by fermentation in 10L 
fermenters (Fermac 310/60, Electrolab, Texas USA) with glucose as carbon 
source. The production was carried out in two stages and at each stage the 
inoculum used was 10% of the working volume. Nutrient Broth Number 1 
was used to produce the seed culture. The constituents of nutrient broth are 
shown in Table 2.1.  
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The production medium was a modified Kannan and Rehacek. Components 
of the media are as shown in Table 2.2. The media was maintained at pH 
6.8.   
Table 2.1: Constituents of Nutrient Broth 1 used in P(3HB) Production 
from B. subtilis OK2 
Constituent Composition (g/L) 
Glucose 1 
Peptone 15 
Sodium chloride 6 
Yeast extract 3 
 
The growth in nutrient broth was carried out at 30°C with orbital shaking at 
140 rpm (C25KC incubator shaker, Edison, NJ, USA). The production stage 
was inoculated and grown (30°C, pH 6.8 and stirrer speed 200 revs/minute) 
in 10L glass bench top fermenters (Fermac 310/60, Electrolab, Texas USA). 
The fermentation was carried out for 48 hours and then harvested.  
Table 2.2: Modified Kanan-Rehacek for the production of P(3HB) from B. 
subtilis OK2 
Media Component 
Composition (g/L) 
Yeast extract 2.5 
(NH4)2SO4 11 
Glucose 35 
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2.2.2. Production of P(3HO-co-3HD):  
P(3HO-co-3HD) was produced using Pseudomonas mendocina CH50 by 
fermentation in 20L glass bench top fermenters with e-Z control (Applikon) 
with glucose as the carbon source. The production process (Figure 2.1) was 
carried out in three stages and at each stage the inoculum measured 10% of 
the working volume. 
Nutrient Broth Number 2 was used to produce the seed culture. The 
constituents are shown in Table 2.3. 
Table 2.3: Constituents of Nutrient Broth 2 used for P(3HO-co-3HD) 
Production from P. mendocina CH50 
Constituent Composition (g/L) 
Meat peptone 4.3 
Casein peptone 4.3 
Sodium chloride 6.4 
 
Second stage medium and Production Stage medium were slightly modified 
versions of Mineral Salt Medium (Table 2.4). The media was maintained at 
pH 7.00.  The second stage was inoculated using a 16-hour seed culture and 
grown at 30°C with orbital shaking at 140 rpm (C25KC incubator shaker, 
Edison, NJ, USA). Production stage inoculation was carried out when the 
absorbance of the second stage medium measured 1.6 at  
450 nm. Production stage was incubated and grown (30°C, pH 7 and stirrer 
speed 200 revs/minute) in fermenters 20L glass bench top fermenters with 
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e-Z control (Applikon). The fermentation was run for 48 hours and then 
harvested.  
Table 2.4: Media Constituents for Second and Production Stages of 
P(3HO-co-3HD) Production 
 Amount (g/L) 
Substance Second Stage 
Medium 
Production Stage 
Medium 
(NH4)2SO4 0.4  0.5 
Na2HPO4 3.4 3.8 
KH2PO4 2.3 2.65 
MgSO4.7H2O 0.4 0.4 
Glucose 20 20 
Trace elements 1 ml 1 ml 
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Figure 2.1: P(3HO-co-3HD) Production and Characterisation 
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2.3. DOWNSTREAM PROCESSING OF POLYMER 
PRODUCTION 
The fermentation broth containing cells and polymer was centrifuged at 
4,600 rpm for 30 minutes (Sorvall ST 40R, Thermo Scientific, LED GmbH, 
Germany). The harvested cells were washed by suspending in 10% ethanol 
and centrifuged again at 4,600 rpm for 30 minutes to remove extraneous 
media components and extracellular lipids and proteins from the cells. The 
cells were then placed in a deep freeze refrigerator at – 20°C for 24 hours 
and then in a freeze drier for 48 hours.  
After drying, cells were lyophilised and the polymer was extracted using a 
modified Soxhlet extraction method as described by Ramsay et al. (Ramsay 
et al., 1994). Briefly, dried cells were set up in a reflux system containing 
methanol to remove the impurities in the cells. This process was run at 60oC 
twice for 24 hours and the methanol was discarded. After obtaining a clear 
methanol solution, the solvent was then changed to chloroform and then the 
reflux was run for 24 hours at 45oC. 
 After this, the chloroform solution was concentrated using a rotary 
evaporator (R210, Buchi, Postfach, Switzerland). The polymers were then 
precipitated using ice cold methanol. The precipitated polymers were then 
purified by re-dissolving in chloroform and re-precipitating. This process 
was repeated twice to ensure complete elimination of impurities.  
 53 
 
2.4.TEMPORAL PROFILING 
Temporal profiling of the fermentation was carried out to monitor and 
control the parameters of fermentation. This was done by taking samples 
every 3 hours. Optical density, pH, nitrogen concentration, glucose 
concentration and biomass were measured for every sample. The profile was 
then drawn using SYSTAT Software Incorporation’s SigmaPlot v12.5. 
2.4.1. Fermentation Parameters 
2.4.1.1. Optical Density 
The optical density of the fermentation broth was measured throughout the 
fermentation to give an indication of the growth of the bacteria during 
fermentation. The optical densities of samples taken were measured at 450 
and 600nm for P(3HO-co-3HD) and P(3HB) production respectively using 
a UV-spectrophotometer (Jenway 6320D, Bibby Scientific, Essex UK).  
2.4.1.2.Biomass 
Biomass estimation was carried out to monitor the dry cell weight of 
bacterial cells throughout the fermentation. 1ml of culture was centrifuged 
in Eppendorf tubes at 12,000g for 10mins. The supernatant was then 
discarded. The pellets were freeze dried and weighed. Biomass was 
calculated as: 
Biomass (g) = 𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡𝑢𝑏𝑒 𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑖𝑛𝑔 𝑑𝑟𝑦 𝑐𝑒𝑙𝑙𝑠 −
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡𝑢𝑏𝑒 
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2.4.1.3.Glucose Estimation 
Since glucose was the carbon source for both fermentations, it was 
important to measure the usage of glucose throughout the fermentation. 
Hence, glucose estimation was carried out. 
Glucose estimation was carried out using the phenol sulphuric acid assay 
(Rai et al., 2011). The culture was centrifuged at 12,000 g for 10 minutes 
and the supernatant was diluted 100-fold. 5% phenol in sulphuric acid was 
then added to the sample. This was then left standing for 10 minutes. It was 
then vigorously mixed and left standing for a further 30 minutes at room 
temperature. After this, the absorbance was read at 520nm and values 
extrapolated from the standard curve. 
2.4.1.4.Nitrogen Estimation 
Since nitrogen was the limiting nutrient in the fermentations, it was also 
important to monitor its usage in the process.  
Nitrogen estimation (ammonium ion estimation) was carried out using the 
phenol hypochlorite reaction method. (Rai et al., 2011) Culture samples 
taken were centrifuged at 12,000g for 10 minutes. The supernatant was 
diluted 100-fold and the reaction was carried out. Briefly, 1ml of phenol 
nitroprusside buffer was added in 2.5ml of the sample and mixed. 1.5ml of 
hypochlorite reagent was then added and the samples were mixed by 
vortexing with IKA Vortex 3 shaker (IKA, Staufen Germany). After this, 
the samples were isolated from light and incubated for 45 minutes. The 
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absorbance at 635nm was then read and values were extrapolated from the 
standard curve. 
Phenol nitroprusside buffer: 
The making of the phenol nitroprusside involves two steps 
• 3 g each of sodium phosphate tribasic and sodium citrate with 0.3g 
ethylene tetraacetic acid (EDTA) were dissolved in distilled water. 
The pH was then adjusted to 12.  
• To this solution, 6g of phenol and 20mg of sodium nitroprusside 
was added. This solution was kept away from light by covering with 
aluminium foil and keeping in a dark cupboard. 
Alkaline hypochlorite solution 
40ml of the 1M of sodium hydroxide was mixed with 2.5ml of sodium 
hypochlorite solution (4% chlorine).  
2.5.CHARACTERISATION OF POLYMERS, BLENDS AND 
SCAFFOLDS  
2.5.1. Chemical Characterisation 
2.5.1.1.Attenuated Total Reflection Fourier-Transform Infrared Spectroscopy 
(ATR-FTIR)  
ATR-FTIR was carried out in order to identify the polymer by analysing the 
bonds and functional groups present. Characterisation of the polymer was 
carried out using the Spectrum Two Spectrometer (PerkinElmer, 
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Massachusetts USA). 2mg of the polymer was used for these analyses. 10 
scans were measured under the following conditions:  
4000 - 450 cm-1 spectral range, window material CsI, and 4 cm-1 spectral 
resolution, with a temperature stabilised FR-DTGS detector. 
2.5.1.2.Gas Chromatography-Mass Spectroscopy (GC-MS) 
To identify the monomer content of the polymer GC-MS was carried out. 
The polymer was made to undergo methanolysis to volatilise it in in the 
ester form (Huijberts et al., 1994). 30 mg of the polymer were dissolved in 
3 ml of chloroform, before adding 20 µl of methyl benzoate and 3 ml of 
15% sulphuric acid. Anti-bumping granules, were added and the mixture 
was placed in reflux and run for 4 or 16 hours for P(3HB) and P(3HO-co-
3HD) respectively. This resulted in the separation of phases. The organic 
phase, which contained the polymer, was collected and mixed with 10 mg 
of sodium bicarbonate and 10 mg of sodium sulphate. This was then filtered 
using Whatmann filter paper and placed into the GC vial and frozen at 20°C. 
GC-MS analysis was carried out using Chrompack CP-3800 (Varian Inc, 
California, USA) and a Saturn 2000 MS/MS workstation.  The CP-3800 gas 
chromatograph was equipped with Elite-5MS capillary column 
(PerkinElmer, Massachusetts, USA). The dimensions of the column were 
30m length, 0.25mm internal diameter and 0.25µm film thickness. 1 µl of 
the sample in chloroform was injected along with Helium (1ml/min) as the 
carrier gas. The column temperature was raised from 40°C to 240°C at 
18°C/min and held at the highest temperature for 10 minutes (Akaraonye et 
al., 2012)  
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2.5.1.3.Nuclear Magnetic Resonance (NMR) 
13C and 1H NMR were carried out to confirm the chemical structure of the 
polymer.  
20 mg of the polymer was dissolved in 1 ml of deuterated chloroform 
(CDCl3) and transferred into NMR tubes. Prepared samples of PHAs were 
sent to the Department of Chemistry, University College London (UK) for 
analysis using Bruker AV400 (400 MHz) (Bruker, Coventry UK). The 
resulting spectra were analysed using MestRec analytical software suite 
(Mestrelab, Coruna Spain).   
2.5.2. Mechanical Characterisation 
Mechanical testing was carried out using Instron 5942 MicroTester 
(Buckinghamshire, UK) on the PHA structures produced. The films were 
cut into 23 mm long and 5 mm wide strips. The initial load range was set at 
1-6000 mN, at a rate of 200 mN min-1. The set up is shown in Figure 2.2. 
The results generated were analysed using Bluehill 3 (Instron, 
Buckinghamshire UK) software to calculate the Young’s modulus, tensile 
strength and elongation at break (%) from the stress-strain curve (Ranjana 
Rai et al., 2011). The values were calculated as follows: 
(a) Young' s Modulus (E) = Stress/Strain  
(b) Tensile strength =  (load at break) / (original width x original thickness)  
(c) Elongation at break = elongation at rupture x 100/initial gauge length  
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Figure 2.2: Tensile testing showing the PHA film a. during elongation b. 
at break 
2.5.3. Thermal Characterisation 
The thermal properties such as glass transition temperature (Tg), melting 
temperature (Tm) and enthalpy of fusion (∆Hf) of the polymer were studied 
by Differential Scanning Calorimetry (DSC). DSC measurements were 
carried out on samples weighing 3-5 mg using DSC 214 Polyma (Netzsch, 
Selb, Germany). The samples were placed in pre-weighed aluminium pans 
and then placed in a nitrogen environment for testing. Heating-cooling-
heating cycles were carried out at 20˚Cmin-1, between 50˚C and 200˚C 
(Misra et al., 2008; Ranjana Rai et al., 2011). Glass transition temperature 
(Tg), melting temperature (Tm) and enthalpy of fusion (∆Hm) values were 
measured from the DSC curve obtained. Tg indicates the temperature at 
which the amorphous part of the polymer transitions from glass to rubber 
state and Tm indicates the melting point of the crystalline part of the 
polymer. 
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2.5.4. Surface Properties 
2.5.4.1.Scanning Electron Microscopy (SEM) 
Surface topography of the PHA scaffolds generated was studied using a Jeol 
JSM- 5410LV SEM (Jeol, Welwyn UK). The samples were placed on 8 mm 
diameter aluminium stubs and coated with gold-palladium for 2 minutes 
using gold K 550X sputter coater (Quorum Technologies, Kent UK). 
Operating pressure of 7 x 10-2 bar and deposition current of 20 mA was used 
(Misra et al., 2008; P. Basnett et al., 2013).  
For samples containing cells, the cells were fixed to the samples after cell 
culture using 3% paraformaldehyde. The samples were then dehydrated 
using serial dehydration in increasing concentrations of ethanol (50% to 
absolute). The analysis was carried out at the Department of Biomaterials 
and Tissue Engineering, Eastman Dental Institute, University College 
London, UK. 
2.5.4.2.Water Contact Angle 
Static contact angle testing was performed on the PHA scaffolds to measure 
the hydrophobicity/hydrophilicity of the samples. This was performed using 
a KSV Cam 200 goniometer (Biolin Scientific, Vastra Folundra Sweden). 
About 200 μL- 400 μL of deionized water was dropped onto the surface of 
the films using a gas-tight micro-syringe. Immediately the water droplet 
dropped on the sample, 10 images were captured (frame interval= 1s). 
Images were analysed using the modular KSV Cam 200 software (Biolin 
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Scientific, Vastra Folundra Sweden). This analysis was carried out in the 
UCL Eastman Dental Institute of University College London. 
2.5.4.3.Protein Adsorption 
Protein adsorption was analysed. To do this, samples with areas of 1cm2 
were incubated in 400uL of foetal bovine serum (FBS). This was incubated 
at 370C for 24 hours. After 24 hours, the samples were washed thrice in 
PBS. The washed samples are then placed in 1ml of 2% sodium dodecyl 
sulphate (SDS) in PBS to dissolve the proteins attached to the surface of the 
samples. These samples were then incubated at a temperature 37oC and 
shaking of 150rpm for a further 24 hours. After this, the protein adsorption 
was measured using the Bicinchonic acid assay (Walker, 2002).  
2.6.FABRICATION OF PHA SCAFFOLDS 
Polymers were processed into three different structures- 2D non-porous 
films, 2D porous films, 3D structures and porous 3D- structures.  
2.6.1. Non-Porous 2D Films (Neat Films) 
Neat films were made by the solvent casting method described by Basnett 
et al. 2013. PHAs were dissolved in chloroform (10%w/v) and left stirring 
overnight to ensure complete dissolution. After this, the solution was 
vortexed and cast in glass petri dishes. They were then left to air dry for one 
week before characterisation tests were carried out. 
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2.6.2. Porous 2D Films 
2.6.2.1.Porous Films with Different Sizes of Porogen (NaCl) 
Porous films were prepared using the salt leaching method. Sodium chloride 
(NaCl) was sieved using sieves with 100 and 300 µm particle size 
(Endecotts, London UK) to obtain particles of sizes <100 µm and <300 µm 
respectively. Then, 5% w/v and 15% w/v of each porogen size was mixed 
with the polymer-chloroform solution and left to dissolve for 24 hours 
(Marchioli, Hertsig, et al., 2016). After complete stirring, films were cast in 
glass petri dishes and left to dry. After drying, the samples were thoroughly 
washed in HPLC grade water three times.  The porous samples created are 
recorded in the Table 2.5. 
Table 2.5: Concentrations and sizes of NaCl used to create porous films 
Porogen Size- Diameter 
(μm) 
Porogen Concentration 
(%w/v) 
5 15 
100 A B 
300 C D 
2.6.2.2.Comparison of Porous Films with (NaCl & Sucrose) 
Porous films were made with two different porogens (NaCl & sucrose). As 
described earlier, porogens of sizes <100 µm and <300 µm were used to 
create porous films by salt leaching. Samples were cast in petri dishes and 
left to dry. After drying, they were washed with 5 times with 20ml HPLC 
grade water.  
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2.6.3. 3D-Structures  
PHAs were printed using the Inkredible+ bioprinter (Cellink, Goteborg 
Sweden). Figure 2.3 shows the printer set up. The method of printing was 
extrusion printing from a solution. For PHAs, 50% PHA solution in 
chloroform was prepared. The solution was then poured into an aluminium 
syringe with nozzle size 20G (outer diameter 0.9081mm, inner diameter 
0.603mm). 
A pre-programmed model from the Slic3r software was used. The tissue 
culture model was loaded on an SD card and transferred to the printer. The 
printer settings are shown in Table 2.6. The structure was then printed at 
pressures between 180-220KPa into 24 well tissue culture plates (Apelgren 
et al., 2017).  
Table 2.6: 3D printer settings 
Parameter Value 
Model size 13.5x13.5x13.5mm 
Layer height 0.30mm 
Layer count 45 printed, 94 visited 
Extruder speed 10.00mm/s 
Move speed 80.00mm/s 
Retract speed 40.00mm/s 
Print time per layer 20.6 seconds 
Total print time 23.44 minutes 
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Temperature 30oC 
 
After drying, the structures were washed with ethanol and incubated at 37°C 
in a 5% CO2 atmosphere ready for cell culture.  
 
Figure 2.3: a. Cellink Inkredible+ 3D Bioprinter b. Close up of the 
syringe system. 
2.6.4. Porous 3D-Structures 
Porous 3D-structures were made by the solvent casting and salt leaching 
method using NaCl as the porogen (pore size ≤100µm). 5g of porogen and 
0.27g of PHA was dissolved in 6ml chloroform. After complete stirring, the 
solution was poured into Teflon moulds and left to dry. After drying, 
scaffolds were removed and washed in HPLC water for 48 hours, changing 
the water every 3 hours. 
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2.7.FABRICATION OF ALGINATE STRUCTURES 
2.7.1. Alginate Microencapsulated Cells. 
Alginate encapsulated BRIN BD11 cells were prepared using a modified 
method described by Fritschy et al. and Hamid et al. (Fritschy et al., 1991; 
Hamid et al., 2001). After BRIN BD11 cells reached 70% confluence, they 
were harvested and suspended in 1.2% sodium alginate solution at a density 
of 1-5 X 105/ml. Microbeads were formed by dropping the cell solution 
through a 22-gauge needle into 0.12M CaCl2 solution. The beads were left 
in the solution for 10 minutes for gelation. After 10 minutes, the beads were 
re-suspended in 0.06M CaCl2 and 0.03M CaCl2 solutions and left to gel for 
10 minutes in each solution. The beads were then placed in 1mM egtazic 
acid (EGTA) solution for 10 minutes. Following complete washing with 
Kreb’s Ringer Bicarbonate Buffer Solution (KRB), the beads were 
equilibrated in RPMI 1640 media overnight before cell culture and insulin 
release analyses.   
2.7.2. 3D-printed Alginate Hydrogels 
2.7.2.1.Preparation of Alginate Solution 
2, 4, 5% w/v alginate in water solutions were prepared. This produced 
viscous solutions that were manually mixed to ensure complete dissolution. 
The solutions were then transferred into plastic syringes with 25G needles 
attached (precision conical bioprinting nozzles- Cellink, Gutenberg 
Sweden). 
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2.7.2.2.Preparation of Gelatin Slurry 
A slurry of gelatin in CaCl2 for the crosslinking of alginate was prepared. 
150ml of 4.5% gelatin solution was prepared in 11mM CaCl2. The solution 
was stored at 4oC overnight to ensure complete gelation. This solution was 
then mixed with an additional 350ml of 11mM CaCl2 and blended at pulse 
setting.  
This pulsed solution was then centrifuged at 4,200rpm for 5 minutes. The 
supernatant was discarded and replaced with ice cold 11mM CaCl2. The 
centrifugation process was repeated until the supernatant contained no more 
bubbles. The slurry was then transferred into glass petri dishes and stored at 
4oC until needed for printing (Hinton et al., 2015; Webb and Doyle, 2017). 
2.7.2.3.Printing of Alginate Hydrogels 
A 3D model of the hydrogel to be printed including the shape, dimensions, 
printing temperature and speed was generated using AutoCAD (AutoDesk, 
London UK). Figure 2.4 is a summary of the 3D printing process for 
fabricating 3D printed alginate hydrogel.  
The model generated in AutoCAD was then loaded in a Repetier-Host 
software (Hot-World GmbH, Willich Germany) and edited to match the 
printer’s specifications. The edited model was then converted into G-code 
(Figure 2.5) using Slic3r open source software to generate a G-code that was 
then loaded on to an SD card. The SD card was then placed into the printer 
and the code was printed with the Cell Ink Inkredible+.  
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Figure 2.4.: 3D printing of alginate hydrogel. 
Before printing, the printer was sterilised with 70% ethanol and a high efficiency 
particulate air (HEPA) filter-0.3μm was attached to the printer to prevent 
contamination. The alginate solution was then transferred in a plastic syringe with a 
plastic nozzle plastic (nozzle size 25G, pressure- 45-60KPa). The hydrogel was 
printed into a glass dish filled with the gelatin slurry containg CaCl2. After printing, 
the hydrogel was allowed to set in the gelatin slurry for 20 minutes and then used for 
cell culture to allow for crosslinking to occur.  
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Figure 2.5: G-code generated 2D and 3D models of structures printed showing printer path
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2.8.CELL CULTURE 
2.8.1. Culturing of Pancreatic Beta Cell (BRIN-BD11) 
Clonal pancreatic BRIN-BD11 cells were routinely cultured in Roswell 
Park Memorial Institute medium (RPMI) 1640 (passage numbers 20–30) 
containing 11.1 mM glucose, 0.3 g/L L-glutamine supplemented with 10% 
(v/v) foetal bovine serum, penicillin 100 IU/ml and streptomycin 0.1 g/L in 
sterile vented 75 cm2 tissue culture flasks (Thermo Scientific, Hvidovre 
Denmark) at 37°C with 5% CO2 and 95% air using a Binder GmbH cell 
culture incubator (Tuttlingen, Germany), as described previously 
(McClenaghan, Barnett, Ah-Sing, et al., 1996). BRIN BD11 cells were 
passaged when cells reached 70 % confluence. Prior to detachment, cells 
were washed twice with 10 ml Phosphate Buffered Solution (PBS) followed 
by treatment with 0.025 % trypsin (w/v), 1 mM EDTA in PBS (w/v) at 37oC. 
Detachment of cells from flasks was confirmed by viewing the flasks under 
100X magnification using an Olympus CX41 phase contrast microscope 
(Olympus, Southend-on-Sea, UK).  
2.8.2. Seeding Cells 
After the cells had reached 70% confluence in the 75 cm2 tissue culture 
flasks, they were detached using trypsin-EDTA solution as described above. 
After treatment with trypsin-EDTA, the mixture was centrifuged at 1,000 
rev/min for 5minutes. The cell pellets were recovered and resuspended in 
media. They were then counted using a haemocytometer. 
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The polymer films were cut into pieces with 1cm2 area. The cut samples 
were dipped in ethanol and placed in 24 well plates. After air-drying, the 
plates were sterilised using UV at 254nm for 30 minutes. After sterilisation, 
the cells were added to the samples at a density of 200,000 cells/ml. 
The hydrogel samples were cut into 1mm cubes and cells seeded as 
described as above.  
2.8.3. In vitro Direct Cell Viability Analysis 
Cell viability tests using BRIN BD11 cells were carried out on the PHA 
structures and alginate microbeads. The seeded scaffolds samples were then 
incubated with 1ml of complete RPMI media for 3-7 days at 37°C in a 5% 
CO2 atmosphere. Samples were fixed on day 1, day 3, day 5 and day 7 to 
analyse the cell viability. This was done using the MTT assay which 
determines the metabolic activity of the cells (Mosmann, 1983; Gerlier and 
Thomasset, 1986). The yellow tetrazolium MTT is reduced to purple 
formazan within metabolically active cells. The experiment was carried out 
in triplicate for each test. The assay was carried out using standard tissue 
culture plates with RPMI-1640 medium as the positive control and dimethyl 
sulfoxide (DMSO) as the negative control. The results of the MTT assay are 
represented as percentage of viability in comparison to the positive control.  
2.8.4. Indirect Cell Viability Analysis 
Indirect cell viability tests were carried out on 3D printed alginate 
hydrogels. Alginate hydrogels were equilibrated overnight in RPMI 1640 
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media. At the same time, BRIN BD11 cells were cultured in 24-well plates 
overnight at a density of 200,000cells/ml. After 24 hours, the media from 
the BRIN BD11 cells was replaced with the media obtained from 
surrounding of the alginate hydrogels  and cultured for 24 hours. After 24 
hours, cell viability studies were carried out using the MTT assay.  
2.9.BRIN BD11 FUNCTION TESTS 
2.9.1. Static Insulin Secretion Assay 
Acute insulin secretion assay was performed as described by McClenaghan 
et al. (McClenaghan, Barnett, Ah-Sing, et al., 1996). BRIN BD11 cells were 
attached to PHA and alginate structures overnight in RPMI-1640 media as 
described earlier. After overnight attachment of cells, culture medium was 
discarded and replenished with 1 ml of Krebs Ringer Bicarbonate (KRB) 
buffer containing 115 mM NaCl, 4.7 mM KCl, 1.28 mM CaCl2, 1.2 mM 
MgSO4, 1.2 mM KH2PO4, 25 mM HEPES, 8.4% (w/v) NaHCO3, 1% bovine 
serum albumin (BSA) and 1.1 mM glucose (pH 7.4). The structures seeded 
with cells were then incubated in KRB buffer for 40 min at 37oC, 5% CO2 
and 95% air. Following pre-incubation KRB buffer was removed and 
replaced with KRB solution containing 5.6 mM glucose. This was then 
incubated at 37oC, 5% CO2 and 95% air for 20 min. The supernatant (900 
µL) was subsequently removed and stored at -20oC. Immediately after, the 
supernatant removed was replaced with KRB solution containing 16.7mM 
glucose and incubated for 20 minutes. Supernatants from both tests were 
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stored at -20oC prior to measurement of insulin by immunoassay using the 
mouse insulin ELISA kit (Flatt and Bailey, 1981).  
2.10. IN VITRO SWELLING AND DEGRADATION TESTS 
in vitro swelling and degradation tests were carried out on the hydrogel and 
polymer films made to monitor the changes in weight over time.  
2.10.1. %Water Uptake and %Weight Loss in PHA Samples 
To evaluate the %water uptake and %weight loss of PHA samples over time, 
PHAs were cut into samples with area of 1cm2. The samples were then 
incubated in PBS and RPMI-1640. These media were selected because PBS 
is isotonic and can be used to stimulate body conditions. RPMI-1640 is the 
optimum medium for BRIN BD11 cell growth. Table 1.6 is a summary of 
the nutrient compositions of both media. Samples were incubated in either 
solution at 37oC at 5% CO2. Samples were weighed before incubation, after 
retrieval and after drying post-retrieval.  
Table 2.7: Nutrient composition of PBS and RPMI-1640 
Constituents PBS (g/L) RPMI-1640 (g/L) 
NaCl 8 6 
KCl 0.2 0.4 
Na2HPO4 1.42 1.512 
KH2PO4 0.24 - 
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NaHCO3 - 2 
MgSO4 - 0.1 
Ca(NO3)2 - 0.1 
 
The %water uptake and weight loss were then measured as: 
%Water Uptake =
 
𝑊𝑒𝑡 𝑤𝑒𝑖𝑔ℎ𝑡 𝑎𝑓𝑡𝑒𝑟 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 (𝑀𝑤)−𝑊𝑒𝑖𝑔ℎ𝑡 𝑎𝑓𝑡𝑒𝑟 𝑑𝑟𝑦𝑖𝑛𝑔 (𝑀𝑡)
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑀𝑑)
× 100 
% Weight Loss=
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑀𝑑)−𝑊𝑒𝑖𝑔ℎ𝑡 𝑎𝑓𝑡𝑒𝑟 𝑑𝑟𝑦𝑖𝑛𝑔 (𝑀𝑡)
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑀𝑑)
× 100 
Where Md= initial dry weight of samples 
Mw= wet weight of samples after incubation over time 
Mt= final dry weight after incubation. 
2.10.2. Swelling and Degradation of Hydrogel Samples 
For the hydrogel samples, swelling and degradation were calculated as % 
dry weight. To evaluate these, the hydrogel was cut into 1X1X1mm3 cubes 
and placed in PBS. After this, samples were incubated at 37oC at 5% CO2 
humidity. At appropriate time points, the samples were taken out, patted dry 
with lab roll and weighed. Samples were weighed before incubation and 
after retrieval.  
The %swelling and degradation were then measured as: 
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% Swelling =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑎𝑓𝑡𝑒𝑟 𝑠𝑤𝑒𝑙𝑙𝑖𝑛𝑔 (𝑀𝑠)−𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑀𝑖)
𝐼𝑛𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑀𝑖)
× 100 
% Degradation =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑎𝑓𝑡𝑒𝑟 𝑑𝑒𝑔𝑟𝑎𝑑𝑎𝑡𝑖𝑜𝑛 (𝑀𝑑)−𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑀𝑖)
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑀𝑖)
× 100 
Where Ms= weight after swelling 
Mi= initial weight 
Md= weight after degradation 
2.11. STATISTICAL ANALYSIS 
All data was expressed as mean ± standard error measurement (SEM). 
Where required, data was compared using one-way, two-way or three-way 
analysis of variance (ANOVA) tests. The tests were carried our using 
GraphPad Prism 7 (GraphPad Software Incorporated). Differences were 
considered significant when *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p 
≤ 0.0001. Where p>0.05, differences were considered non-significant.  
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3. POLYMER PRODUCTION AND 
CHARACTERISATION 
3.1.INTRODUCTION 
The ideal material for bioartificial pancreas should be biocompatible, inert, 
porous- allowing for exchange of oxygen, nutrients, glucose and insulin but 
also protective of the islet cells, protecting them from response molecules 
of the immune system (Lim and Sun, 1980; Weir, 2013; Kepsutlu et al., 
2014). These biomaterials also need to promote host integration and 
restoration of ECM-like interactions (Gibly et al., 2011; Tsuchiya et al., 
2015; Llacua et al., 2016; Perez-Basterrechea et al., 2018). 
A wide range of polymers have been explored for their use in islet 
transplantation, these include PLLA, PEG, PVA and collagen. All these 
polymers possess individual advantages and disadvantages. PLLA 
undergoes bulk degradation which ultimately leads to uncontrolled 
degradation in the final stages. It also degrades into lactic acid which is 
highly acidic and can lead to inflammatory responses. PEG is known to 
reduce the viability and function of islet cells. PVA has been shown to 
contain impurities due to its manufacturing process. Collagen hydrogels are 
crosslinked with toxic materials (Gough, Scotchford and Downes, 2002; 
Beck et al., 2007; Gajra et al., 2012; Krishnan et al., 2014). There is 
therefore a need for alternative polymers that can fulfil the requirements for 
scaffolds involved in islet transplantation. In addition, there is a need for 
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‘intelligent’ scaffolds that not only promote cell adhesion and 
differentiation, but can also be modified to improve biocompatibility 
(Malafaya, Silva and Reis, 2007; Khademhosseini and Langer, 2016). It is 
also important, when engineering a scaffold, to consider the mechanical, 
chemical, and physical properties of the native tissue and select materials 
able to mimic these.  
PHAs have been shown to be excellent candidates for Tissue Engineering 
scaffolds (P. Basnett et al., 2013; Lizarraga-Valderrama et al., 2015; 
Nigmatullin et al., 2015; Bagdadi et al., 2018; Lukasiewicz et al., 2018). In 
addition, they are also easily modifiable by attaching factors like VEGF 
(Nigmatullin et al., 2015) or blending with other polymers to improve 
mechanical, chemical and biocompatibility properties (Misra et al., 2006; 
Valappil et al., 2008).  
Of the bacteria that demonstrate ability to produce PHAs, Pseudomonas 
spp. and Bacillus spp. have been reported more frequently in literature. 
Examples of each include P. mendocina, P. oleovorans, B. subtilis and B. 
cereus. They produce mcl-PHAs and scl-PHAs respectively. The pathways 
for production of PHAs depend largely on the carbon source used- simple 
sugars, alkanes, lipids and alkanoic acids (Anderson and Dawes, 1990). 
When glucose is used as the carbon source, in scl-PHAs it undergoes the 
TCA cycle to produce the 2-acetyl-CoA molecules needed for PHA 
synthesis. Mcl-PHAs precursors can be produced through de novo fatty acid 
synthesis and other processes. (Philip, Keshavarz and Roy, 2007).   
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To ensure homogeneity and repeatability of the microbial production 
process, the fermentation conditions must be strictly monitored and 
controlled throughout the fermentation process. These factors include pH, 
temperature, airflow rate and agitator speed. As the fermentation proceeds, 
additional factors must be monitored to ensure the fermentation is 
progressing as expected. These factors include optical density (OD), 
biomass, dissolved oxygen tension (DOT), usage of nutrients. Fermentation 
products most also be thoroughly characterised to ensure purity and 
potential for use as medical grade matrials.  
This Chapter describes the production of two kinds of PHAs, P(3HB) and 
P(3HO-co-3HD), using optimal conditions in order to encourage the highest 
yield. The production process was monitoring and controlled throughout the 
fermentation. The polymers produced were thoroughly characterised. 
3.2.RESULTS 
3.2.1. P(3HB) Production by Bacillus subtilis OK2 using glucose as the 
carbon source 
Temporal profiling of P(3HB) production using B. subtilis OK2 (Figure 3.1) 
showed increasing optical density and polymer yield with time. From the 
beginning of the fermentation, there was an exponential rise in optical 
density (OD). At time zero, the OD observed was 0.875. The values from 
12-18 hours represented a brief lag phase with the OD values continuing to 
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rise later, until the end of the fermentation. 
 
Figure 3.1 Temporal profiling of the production of P(3HB) from B. subtilis 
OK2 showing variation in OD at 450nm, pH, DOT (%), glucose (g/L) and 
polymer yield (%dcw). 
As the concentration of biomass present in the bioreactor increased, more 
oxygen was required to support this growth, hence a drastic decrease was 
observed in the dissolved oxygen tension (%) from 100% to 2.95% after 3 
hours. On the other hand, the pH value gradually decreased from 6.80, to 
4.89. Glucose values reduced from 35g/L, at the beginning of fermentation, 
to about 17g/L at the end. This indicated that the glucose was not completely 
used. The highest OD value was measured at 48 hours and the 
corresponding polymer yield (% dcw) was found to be about 49% of  the 
dry cell weight at this time point. The yields observed at the 12, 24 and 36 
hours were 10, 12.5 and 17.34% dcw respectively. The highest yield 
observed was 49% dcw at 48 hours, indicating that 48 hours is the best time 
to harvest the culture and stop the fermentation.   
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3.2.2. Production of P(3HO-co-3HD) by Pseudomonas mendocina CH50 
using glucose as the carbon source. 
The mcl-PHA, P(3HO-co-3HD) was produced using the method described 
in section 2.2.2. The production was run in batch mode.  
 
 
Figure 3.2: Temporal Profiling of P(3HO-co-3HD) production from P. 
mendocina CH50 
Figure 3.2. shows the temporal profile for the production of P(3HO-co-
3HD) from Pseudomonas mendocina CH50, showing changes in O.D, pH, 
biomass, nitrogen concentration, glucose concentration and polymer yield. 
The culture showed an initial lag phase between 0 and 15 hours where the 
OD value was 1.07. After this, O.D values increased exponentially until 45 
hours (5.82) when foaming interfered with the O.D. readings. After 
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antifoam was added at 57 hours, the readings stabilised at 6.11, indicating a 
stationary phase. The biomass increased throughout the fermentation from 
0.13g/L to 4.17g/L. The pH of the fermentation was not controlled and was 
seen to drop from 6.98 at the 3rd hour of fermentation to 5.82 at the end of 
the fermentation. The nitrogen concentration dropped exponentially from 
the beginning of the fermentation until 39 hours, where it dropped to 0.05 
g/L, after which it gradually dropped even further, till the end of the 
fermentation. The glucose concentration reduced from 20g/L at the 
beginning of the fermentation to about 3g/L at the end of the fermentation, 
indicating that the glucose was not used up completely at the end of the 
fermentation. The yields observed for the production of P(3HO-co-3HD) 
were 12.3% dcw at 24 hours, 24.9% dcw at 36 hours, 42.1% dcw at 48 
hours, 27.8% dcw at 64 hours and 25.6% dcw at 72 hours. The yield at 48 
hours was the highest yield observed, indicating that 48 hours is the best 
time to stop the fermentation and extract the polymer.   
3.3. POLYMER CHARACTERISATION 
3.3.1. Fourier Transform- Infrared Spectroscopy (FT-IR) 
The FT-IR spectrum of P(3HB) obtained from B. subtilis OK2 using 
rapeseed oil as the carbon source is shown in Figure 3.3. The spectrum 
shows peaks at 1721cm-1, 1278cm-1 which are representative of the carbonyl 
and acyl groups present in P(3HB). The peaks between 400 and 1000cm-1 
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are indicative of the methyl carbons present in the molecule. These peaks 
are consistent with peaks expected from P(3HB) (Misra et al., 2010). 
 
Figure 3.3: The FT-IR Spectrum for P(3HB) derived from B. subtilis OK2  
The FT-IR spectrum for P(3HO-co-3HD) derived from Pseudomonas 
mendocina CH50 using glucose as the carbon source is shown in Figure 3.4. 
The spectrum shows peaks at 1726cm-1 and 1161cm-1 which are 
characteristic of the carbonyl and acyl groups present in mcl-PHAs. It also 
contains a peak at 2924cm-1, indicating a methylene group indicative of mcl-
PHAs (R. Rai et al., 2011). 
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Figure 3.4: FT-IR Spectrum for P(3HO-co-3HD) derived from P. 
mendocina CH50. 
 
3.3.2. Gas Chromatography Mass Spectroscopy 
Figure 3.5 shows the GC spectrum observed for methanolysed P(3HB) from 
B.subtilis OK2. The peak with a retention time (tR) of 6.4 min was identified 
to be methyl benzoate, which was the internal standard. The peak observed 
at tR of 4.01 min matched that of methyl-3-hydroxybutyrate upon 
comparison with the NIST spectral library. 
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Figure 3.5: Gas chromatogram of P(3HB) produced by B. subtilis OK2 
showing the spectrum observed and the relative abundance of the 3-
hydroxy methyl ester of butanoic acid  
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Figure 3.6 is the GC spectrum observed for P(3HO-co-3HD) produced by 
P. mendocina CH50. The peak with a retention time (tR) of 6.5 min was 
identified to be methyl benzoate, which was the internal standard. The mass 
spectra observed at tR of 7.78 min and 9.40 min were found to match those 
of methyl-3-hydroxyoctanoate and methyl-3-hydroxydecanoate upon 
comparison with the NIST spectral library.  
 
Figure 3.6: Gas chromatogram of P(3HO-co-3HD) produced by P. 
mendocina CH50 showing the spectrum observed and the relative 
abundance of the 3-hydroxy methyl esters of octanoic acid and decanoic 
acid.  
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The ratio of the monomers present in the co-polymer can be calculated by 
calculating the area under each peak. The area can be calculated using this 
formula: 
Area of peak = 𝑤𝑖𝑑𝑡ℎ 𝑜𝑓 𝑝𝑒𝑎𝑘 𝑎𝑡
1
2
 ℎ𝑒𝑖𝑔ℎ𝑡 × ℎ𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑒𝑎𝑘 
For methyl-3-hydroxyoctanoate, the width= 0.5mm, height= 5mm 
So, area= 2.5mm2 
For methyl-3-hydroxydecanoate, the width= 0.5, height= 18mm 
So, area= 9mm2 
Based on this, the ratio of methyl-3-hydroxyoctanoate to methyl-3-
hydroxydecanoate= 22%:78%. From this data, it can be confirmed that the 
mcl-PHA produced was P(3HO-co-3HD). 
 
3.3.3. Nuclear Magnetic Resonance 
The 13C NMR spectrum from P(3HB) derived from B. subtilis OK2 is shown 
in Figure 3.7. The spectrum shows four peaks corresponding to four 
different carbon environments in the molecule. The chemical shifts are at 
169 ppm, 67 ppm, 38 ppm and 19 ppm representative of the carbons in the 
C=O, CHO, CH2CO and RCH3 group of the P(3HB) molecule. 
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Figure 3.7:  13C NMR Spectrum of P(3HB) derived from B. subtilis OK2 
The 1H NMR spectrum of P(3HB) (Figure 3.8) shows four different peaks 
representing the four different hydrogen environments in the polymer. The 
first peak at 1.37ppm corresponds to the protons in the (-CH3-) group. The 
multiplex peak at 2.4-2.6ppm represents the protons in the (-CH2-) group. 
The peak at 5.3ppm represents the protons in the (-CH-) group.  
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Figure 3.8: 1H NMR Spectrum for P(3HB) derived from B. subtilis OK2  
In the 13C NMR of P(3HO-co-3HD) (Figure 3.9), eleven different peaks 
were observed consistent with different environments for the carbons in the 
molecule. The chemical shift at 169.40 ppm falls in the range of that 
expected from C=O group at C1. The peak at 70.82 ppm represents that of -
CHO- group (C3), 39.20 ppm of -CH2CO group (C2), 23-34 ppm of -CH2- 
group (C4, C5, C6, C7, C9), and 13.95 ppm of the -CH3 group (C8 C10). These 
chemical shifts obtained were found to be consistent with the spectrum 
expected from (3HO) and (3HD) monomers. 
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Figure 3.9: 13C NMR Spectrum of P(3HO-co-3HD) derived from P. 
mendocina CH50 
The 1H NMR spectrum (Figure 3.10) shows five different environments for 
the hydrogen in the polymer. The first peak is shown by the protons bound 
to C3 (-CHO-group) that gives a peak at 5.2 ppm. The peaks indicative of 
protons bound to C2 (-CH2CO- group) and C4 (-CH2- group) show peaks at 
2.5 ppm and 1.6 ppm. The peak at 1.2 ppm is indicative of (-CH2- group) in 
C5, C6, C7 of 3-hydroxyoctanoate (3HO) & C5, C6, C7, C8 and C9 of 3-
hydroxydecanoate (3HD). Finally, the fifth peak at 0.8 ppm belongs to 
protons found in the (-CH3) group of C8 in 3HO and C10 (-CH3) group of 
3HD. 
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Figure 3.10: 1H NMR spectra of P(3HO-co-3HD) derived from P. 
mendocina CH50  
3.3.4. Differential Scanning Calorimetry 
DSC was carried out to determine the thermal properties of the polymers in 
a bid to further characterise them.  
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Figure 3.11: DSC Thermogram of P(3HB) derived from B.subtilis OK2 
The DSC thermogram of P(3HB) is shown in Figure 3.11. From the graph, 
glass transition temperature (Tg), melting temperature (Tm) and enthalpy of 
fusion (∆Hf) were found to be -67.9oC, 174.1oC, 66.14J/g respectively. 
Crystallisation could also be observed.  
 
Figure 3.32: DSC Thermogram of P(3HO-co-3HD) derived from P. 
mendocina CH50 
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The DSC thermogram of P(3HO-co-3HD) is shown in Figure 1.12. From 
the graph, glass transition temperature (Tg), melting temperature (Tm) and 
enthalpy of fusion (∆Hf) were found to be -42.1°C, 55.6°C and 19.86 J/g 
respectively. Cold crystallisation was not observed with mcl PHA. Hence, 
the second heating-cooling-heating cycle did not show a complex peak for 
the melting transition of the crystalline phase of the polymer.  
The thermal properties of both polymers are summarised in Table 3.1.  
Table 3.1: Thermal properties of P(3HB) and P(3HO-co-3HD) produced 
 Melting 
Temperature 
(Tm) oC 
Glass Transition 
Temperature (Tg) oC 
Enthalpy of 
Fusion (ΔHf) 
J/g 
P(3HB) 174.1±1.838 -67.9±0.353 60.14 
P(3HO-
co-3HD) 
55.6±3.252 -42.10±0.919 19.86 
 
3.3.5. Tensile Testing 
Tensile testing was carried out to measure the mechanical properties of the 
polymers produced. The slope of the linear region of stress-strain curve 
obtained was recorded as the Young’s modulus (E) and the sharp bend 
indicated the tensile strength and elongation at break of the polymer.  
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Figure 3.43: Stress-strain curve obtained from P(3HB 
Figure 3.13 shows the stress-strain curve obtained from the P(3HB) 
produced. From the graph, elongation at break was calculated as 22.73%, 
Tensile Strength as 23.6MPa and the slope is calculated as Young’s 
Modulus of 747.22MPa.  
 
Figure 3.54: Stress-strain curve obtained from P(3HO-co-3HD) 
Figure 3.14 shows the stress-strain curve obtained from the P(3HO-co-
3HD) produced in the fermentation. From the graph, elongation at break 
was calculated as 478%, Tensile Strength as 9.78MPa and the slope is 
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calculated as Young’s Modulus of 5.62MPa. These values indicate that 
P(3HO-co-3HD) is more elastic than P(3HB) but also less stiff and strong 
than P(3HB). 
The mechanical properties of both polymers are summarised in Table 3.2. 
Table 3.2: Mechanical properties of polymers produced 
Polymer Elongation at 
break (%) 
Tensile Stress 
(MPa) 
Young’s 
Modulus (MPa) 
P(3HB) 27.94±0.021 23.6±0.275 747.22±1.08 
P(3HO-
co-3HD) 
1415±19.16 1.08±0.06 1.39±0.054 
3.4. DISCUSSION 
In this chapter, the production of two kinds of PHAs- P(3HB) and P(3HO-
co-3HD) was carried out. These two PHAs belong to two different classes 
of PHAs- the stronger, more brittle scl-PHAs and the more elastic, flexible 
mcl-PHAs. After production, these polymers were then extensively 
characterised.  
Bacillus sp. is the most common species of bacteria used in (P3HB) 
production. Different carbon sources have been used ranging from purified 
sugars like fructose, sucrose and glucose to impure sugars like sugarcane 
molasses and date molasses (Kulpreecha et al., 2009). In this production, 
glucose was used as the carbon source. Reports of yields of P(3HB) 
production vary based on the carbon source used. Other factors affecting 
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yield include the carbon/nitrogen ratio (C/N), the nutrient being limited and 
the mode of fermentation being used (Khanna and Srivastava, 2005; 
Verlinden et al., 2007b). Bacillus spp. favour the consumption of glucose 
over other carbon sources in the production of P(3HB) (Silva et al., 2004). 
The yield of P(3HB) observed in this study was 49% (0.911g/L) in a batch 
mode. This is similar to the yield of 50% observed when a fermentation was 
run using glucose as the carbon source with B. cereus CFR06 (Halami, 
2008b). It is however higher than 34% values observed when B. megaterium 
was run with glucose as the carbon source (Wu et al., 2001). It was also 
higher than the 24% dcw reported using Bacillus cereus SPV, under the 
same conditions (Valappil et al., 2008).  
Pseudomonas mendocina CH50 was used in the production of P(3HO-co-
3HD).In mcl-PHA production, the yields can vary depending on the carbon 
source and the C/N ratio. The yield reported here was 43% dcw at 48 hours 
during a batch fermentation. The yield is This yield is higher than the 21% 
observed by Diniz and colleagues using P. putida IPT 046. It is however 
lower than some other yields that have been reported for Pseudomonas spp. 
These values include 52% from P. stutzeri 1317. The difference here is that 
a different carbon/ nitrogen ratio (20) was used in their study in comparison 
to the 40 that was used in this study.  
Complete characterisation was carried out to confirm the polymers 
produced. The results were as expected confirming the chemical structure 
intended. FTIR confirmed the presence of PHAs in both polymers as 
expected. From literature, peaks for PHAs can be observed at  1700-
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1760cm-1 for the C=O bonds, 1220-1310cm-1 for the C-O-C (Wu et al., 
2001). P(3HB) has also been reported to have peaks at 400-100cm-1 
corresponding to the methyl groups (Valappil et al., 2008). Mcl-PHAs have 
been reported to have a peak around 2924cm-1 (Randriamahefa et al., 2003). 
GC-MS was used to calculate the monomer ratio in the P(3HO-co-3HD) 
copolymer. The ratio calculated was 22%: 78% for the methyl-3-
hydroxyoctanoate and methyl-3-hydroxydecanoate respectively. This 
finding was supported as literature as other studies using Pseudomonas spp. 
With glucose as the carbon source have found similar monomer content and 
ratio. A ratio of 74.3:6.9 for 3HD:3HO was observed when P. putida 
KT2442 was grown with glucose as the carbon source (Huijberts et al., 
1992). He et al. observed a ratio of 63:21 for 3HD:3HO (He et al., 1998). It 
was also observed that when P. guezennei was grown with glucose as the 
carbon source, a ratio of 62.8:22 for 3HD:3HO (Simon-Colin et al., 2008) 
One factor to be noted is that in the other studies, there were a lot of 
contaminating polymers and peaks. Those were not existent in our study, 
indicating that our polymer was pure.  
As expected, the thermal and mechanical properties of P(3HB) and P(3HO-
co-3HD) were different. Reported mechanical properties for P(3HB) are: 
Tensile Strength: 18-50MPa, Young’s Modulus: 1700-3800MPa & 
Elongation at Break: 1-5% (Avella, Martuscelli and Raimo, 2000; El-Hadi 
et al., 2002; Godbole et al., 2003; Valappil et al., 2008). For mcl-PHAs, the 
values are: Tensile Strength: 5-22MPa, Young’s Modulus: 4-15MPa and 
Elongation at break: 250-500% (Sudesh, Abe and Doi, 2000; R. Rai et al., 
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2011). For thermal properties, in literature values for P(3HB) have ranged 
from 165-175oC for the Tm. For mcl-PHAs, Tm of 42-75
oC have been 
observed. Simon-Colin et al. reported that for P(3HO-co-3HD) polymer, Tm 
of 49oC, Tg of -44
oC and ΔHf of 19J/g (Simon-Colin et al., 2008). 
In conclusion, both P(3HB) and P(3HO-co-3HD) have been produced at 
yields comparable to those reported in literature. Their production has been 
closely monitored to ensure that the processes were executed as expected. 
Finally, the polymers produced from each fermentation batch have been 
characterised thoroughly in order to confirm their identity and define their 
properties for use in the production of scaffolds.   
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4. 2D-POROUS AND NON-POROUS P(3HB) AND 
P(3HO-co-3HD) SCAFFOLDS 
4.1.INTRODUCTION 
One of the most important things to consider in scaffold design is the 
porosity of the scaffold. This refers to two factors: the concentration of void 
space (porosity) and pore size. The presence of pores in a material affects 
the mechanical properties, cell growth, adhesion and proliferation 
(Karageorgiou and Kaplan, 2005; Loh and Choong, 2013). Porosity is 
important in Tissue Engineering for the mediation of the exchange of 
nutrients, products and waste between cells; it also contributes to the 
formation of barriers, providing protection from immune cells and 
microorganisms (Stendahl, Kaufman and Stupp, 2009).  
Porosity is of interest because it is a factor that can be manipulated to control 
certain properties that could make the scaffold easily customisable. Since 
the porosity affects the mechanical properties, depending on the target 
organ, the pores can be manipulated to create scaffolds similar to those of 
the target organ. Porosity has also been shown to increase both the surface 
area and surface roughness of a material which in turn increase the protein 
adsorption and cell adhesion to the surfaces (Karageorgiou and Kaplan, 
2005; Daoud et al., 2011). 
One of the major challenges in creating porous scaffolds is finding the right 
balance of factors. The pore size must be small enough to let nutrients, waste 
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and products be exchanged but not large enough to prevent aggregation 
where needed. The degree of porosity must also be just right to allow both 
cell attachment and aggregation (Loh and Choong, 2013).  
The native pancreatic tissue is soft and viscoelastic, with a Young’s 
modulus of 1.4 ± 2.1 kPa (Sugimoto et al., 2014). To achieve values similar 
to this, porous structures have been used in islet transplantation. Porous 
structures have also been used since islet survival requires high oxygen 
demand, access to vascularisation and protection from the body’s immunity. 
Porous structures are highly valued in islet transplantation because they 
provide structural support and can maintain structural integrity the islets 
need to function and survive. Due to the roughness that porous scaffolds 
have, cell attachment is increased. The roughness also encourages the 
aggregation of β-cells into islet-like clusters. Porous structures have also 
been shown to trap islets within the interconnected pores, making it more 
difficult to lose islets and reducing the number of islets needed for 
transplantation in the long-term. Examples of porous polymer scaffolds that 
have been used for islet transplantation include: poly-L-lactic acid (PLLA), 
poly-glycolic acid (PGA), poly(-lactic-co-glycolic acid) PLGA, alginate 
and polydimethylsiloxane (PDMS) (Elçin et al., 2003; Blomeier et al., 
2006; Kawazoe et al., 2009; Pedraza et al., 2013). 
Different techniques for fabrication of 2D scaffolds exist. In salt leaching, 
porogen (sugar, salt) particles of specific sizes are poured in a mould 
followed by the polymer solution. After drying, the scaffold is thoroughly 
washed to leach out the porogen leaving pores behind. This technique is 
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applicable when there are small quantities of polymer and are very easy to 
make. In gas foaming, gas is used as the porogen and polymer discs are 
formed by compression moulding. Since high temperature and pressure is 
required in this technique, it is mainly applicable to polymers with low 
melting temperatures. (Hutmacher, 2000; Ma, 2004; Li, Thouas and Chen, 
2012; Janik and Marzec, 2015). 
This chapter aims to evaluate the effect of porosity of 2D PHA scaffolds on 
the viability and growth of BRIN BD11 cells seeded in them. To achieve 
this, both porous and non-porous structures were made and characterised. 
Varying types, concentrations and sizes of porogens were used to determine 
which scaffolds produced using these conditions is the most viable for islet 
transplantation.  
4.2.RESULTS 
4.2.1.  Polymers Produced  
Two types of PHAs were produced as described in section 2.2 (Figure 4.1). 
Figure 4.1a shows P(3HO-co-3HD) in its unprocessed form. The polymer 
itself is translucent in appearance. To the touch, it is flexible and elastic. 
Since it is elastic and sticky, during precipitation, the polymer sticks to itself 
and becomes a lump after the solvent is evaporated. Figure 4.1b is the 
P(3HB) produced in its unprocessed form. It is white in appearance and can 
be broken or torn apart very easily. It precipitates in clumps and hardens as 
it dries.  
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Figure 4.1: Polymers produced a. P(3HO-co-3HD) produced using 
fermentation of P. mendocina CH50 and glucose as the carbon source b. 
P(3HB) produced using  B. subtilis OK2 
2D non-porous scaffolds were made using P(3HB) and P(3HO-co-3HD) 
(Figure 4.2). These scaffolds were made using the solvent casting method 
as described in section 2.6.2. After solvent evaporation, P(3HB) scaffolds 
were easily taken off the glass petri dish diameter 52.4mm. The P(3HB) 
scaffolds appeared as white, hard and brittle (Figure 4.2a). In contrast, 
P(3HO-co-3HD) scaffolds appeared completely transparent, elastic and 
sticky Figure 4.2b. After solvent evaporation, the scaffolds were peeled 
back from the petri dish Figure 4.2c. Physically, the PLLA scaffolds are 
transparent and very brittle. The solvent evaporated very rapidly from the 
surface of the PLLA scaffolds.  
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Figure 4.2: 2D Non-porous scaffolds made by the solvent casting method. 
a. P(3HB) b. P(3HO-co-3HD) after solvent evaporation c. P(3HO-co-
3HD) after peeling from petri dish 
4.2.2. Comparison of the properties of PHA 2D scaffolds in comparison to 
PLLA 2D scaffolds 
4.2.2.1. Mechanical and Thermal Properties of Polymers 
Mechanical and thermal characterisation was carried out on P(3HB) and 
P(3HO-co-3HD). The results were then compared with those of PLLA, a 
polymer that has been widely explored commercially for Tissue 
Engineering applications (Hart et al., 2015). Table 4.1 shows the thermal 
and mechanical properties of the 3 polymers characterised. 
Of the polymers, PLLA was found to be the stiffest and most brittle with 
Tensile Strength and Young’s Modulus up to 50 and 2,500 times greater 
than that of P(3HO-co-3HD) respectively. P(3HO-co-3HD) was the most 
elastic of the three with elongation at break approximately 600 times greater 
than that of PLLA. P(3HB) had mechanical properties more similar to 
PLLA than P(3HO-co-3HD), although it was found to be less brittle than 
PLLA.  
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Thermally, P(3HO-co-3HD) had the lowest melting temperature of the 
three. P(3HB) had much higher melting temperatures. For glass transition 
temperature, both PHAs had similar values different to PLLA.  
Table 4.1: Mechanical and thermal properties of P(3HB), P(3HO-HD) 
and PLLA. Values are expressed as mean ± SEM for groups of 6. 
 Tensile 
Strength 
(MPa) 
Elongation 
at break 
(%) 
Young’s 
Modulus 
(MPa) 
Melting 
temperature 
(Tm/oC) 
Glass 
transition 
temperature 
(Tg/oC) 
P(3HB) 23.6±0.275 7.94±0.021 747.22±1.08 172.8±1.838 -67.15±0.35 
P(3HO-
co-
3HD) 
1.08±0.06 1415±19.16 1.39±0.054 54.7±3.252 -66.95±0.92 
 PLLA   53.5±3.5 2.4±0.06 3425±12.25 177.3±1.75 -61.73±3.36 
4.2.2.2.Direct Cell Viability Tests on P(3HB), P(3HO-co-3HD) and PLLA 
Cell viability tests were carried out on three polymers P(3HB), P(3HO-co-
3HD) and PLLA using murine BRIN BD11 cells. PLLA was selected 
because it is an FDA approved biopolymer and has been explored in Tissue 
Engineering (Hart et al., 2015). The results are shown in Figure 4.3. 
Compared to the positive control, the polymer that showed the highest 
BRIN BD11 cell viability was P(3HO-co-3HD), showing viabilities of 
84.94%, 97.19% and 98.06% on days 1, 3 and 7 respectively. P(3HB) was 
the next highest with 66.57%, 84.1% and 88.21%. Cells seeded on PLLA 
had viabilities of 38.91%, 70.16% and 71.5% on days 1, 3 and 7 
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respectively. In comparison with the positive control (Tissue Culture 
Plastic, TCP), by day 3,  the cell viability on P(3HO-co-3HD) showed no 
significant difference. In the case of P(3HB), the difference became less 
significant with the number of days indicating an increase in cell viability 
with increase in time. PLLA showed a highly significant difference on all 
days in comparison to the positive control.  
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Figure 4.3: Direct cell viabilities of BRIN BD11 cells seeded on 2D 
P(3HB) and P(3HO-co-3HD) and PLLA scaffolds. Values are expressed 
as % positive control (tissue culture plate) mean ± SEM for numbers of 6. 
p *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001 when compared with positive 
control (tissue culture plastic). 
4.2.2.3.Static Insulin Secretion Tests on P(3HB), P(3HO-co-3HD) and PLLA 
The average insulin released from BRIN BD11 cells seeded on  
P(3HO-co-3HD), P(3HB) and PLLA scaffolds are shown in Figures 4.4 and 
4.5. Upon addition of 5.6mM glucose (normoglycaemia), the average 
insulin released for the positive control (tissue culture plastic) was 0.984 
ng/106 cells/20 min; for P(3HO-co-3HD), 3.742 ng/106 cells/20 min; 
P(3HB), 2.211 ng/106 cells/20 min and PLLA, 1.529 ng/106 cells/20 min. 
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Cells seeded on both PHAs had significantly greater insulin release than the 
positive control with those on P(3HO-co-3HD) released the highest amount 
of insulin in response to glucose stimulus.  
When 16.7mM glucose (hyperglycaemia) was added, the average insulin 
released for the positive control (tissue culture plastic) was 1.481 ng/106 
cells/20 min; for P(3HO-co-3HD), 3.967 ng/106 cells/20 min; P(3HB), 
2.506 ng/106 cells/20 min and PLLA, 1.379 ng/106 cells/20 min. Again, 
cells seeded on both PHAs had significantly greater insulin release than the 
positive control with those on P(3HO-co-3HD) released the highest amount 
of insulin in response to glucose stimulus. 
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Figure 4.4: Insulin secretion at normoglycaemia (5.6mM glucose) from 
BRIN BD11 cells seeded in P(3HO-co-3HD), P(3HB), PLLA scaffolds and 
positive control (tissue culture plastic) in ng of insulin/106 cells/20 
minutes. Values are expressed as mean ± SEM for groups of 6. ***p ≤ 
0.001, ****p ≤ 0.0001 when compared with insulin release from positive 
control.  
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Figure 4.5: Insulin secretion at hyperglycaemia (16.7mM glucose) from 
BRIN BD11 cells seeded in P(3HO-co-3HD), P(3HB) PLLA scaffolds and 
positive control (tissue culture plastic) in ng of insulin/106 cells/20 
minutes. Values are expressed as mean ± SEM for groups of 6. **p ≤ 0.01, 
****p ≤ 0.0001 when compared with insulin released from positive 
control. 
4.2.3. Fabrication of 2D Porous (P3HO-co-3HD) Scaffolds Using NaCl 
Porogen 
4.2.3.1. Physical Properties of Porous P(3HO-co-3HD) Scaffolds 
The scaffolds made appeared white with NaCl particles interspersed before 
leaching (Figure 4.6). After leaching, the scaffolds appeared white with 
open pores. The scaffolds were physically less elastic and had to be handled 
carefully. The higher the concentration of porogen used, the more brittle the 
scaffolds. Similarly, the same thing was observed as the size of the porogen 
increased. 
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Figure 4.6: Porous P(3HO-co-3HD) scaffolds made before washing. 
 
Figure 4.7 shows SEM images of the porous scaffolds showing their internal 
structures. When A and B are compared, there is an obvious increase in 
pores due to the increased concentration of porogen. The diameter of the 
pores also increases with the size of porogen as expected. This trend is also 
observed when C and D are compared. The SEM images also show that the 
salt particles have been completely leached out as there were no salt crystals 
observed.  
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Figure 4.7: Scanning electron microscopy (SEM) images of porous 
P(3HO-co-3HD) scaffolds made with varying porogen sizes and 
concentrations of NaCl and sucrose. 
 
4.2.3.2.Mechanical Properties of P(3HO-co-3HD) Porous Scaffolds  
The mechanical properties observed are recorded in Table 4.2. The highest 
value for the Young’s modulus (E), a measure of material stiffness, was 
measured in scaffold A- 3.32±0.78MPa. After A, there is a continuous 
reduction in the E values as both porosity and pore size increase. The lowest 
E value was for scaffold D at 2.30±1.47 MPa.  
Similarly, tensile strength trend seems to reveal that the higher the porosity 
and the pore size, the lower the tensile strength, as scaffold A had 3.19 MPa, 
in comparison to scaffold D which had 0.25 ± 0.17 MPa.  
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Elongation at break also followed the same trend, indicating that the 
elasticity reduces gradually from 277.7±29.85% in scaffold A to 
49.5±18.2% for scaffold D. Table 4.3 shows a summary of the mechanical 
properties of the P(3HO-co-3HD) porous scaffolds that were made. 
Table 4.2: Summary of mechanical properties of of P(3HO-co-3HD) 
porous scaffolds produced. Samples are expressed as value±SEM for 
groups of 6. 
Structures Young 
Modulus 
(MPa) 
Tensile Strength 
(MPa) 
Elongation 
break (%) 
A 3.32±0.78 3.19±0.84 277.7±29.85 
B       3.19±0.86 1.81± 0.47 192.2±27.77 
C       2.90 ± 0.97 0.80 ± 0.26 71.6 ± 6.12 
D       2.30 ± 0.47 0.25 ± 0.17 49.5 ± 18.2 
 
4.2.3.3. Water Contact Angle (ɵ) of P(3HO-co-3HD) Porous Scaffolds   
The static water contact angle is a measure of hydrophobicity or 
hydrophilicity of a material. Table 4.3 shows the ɵ values for the four 
different P(3HO-co-3HD) porous scaffolds made. A material is considered 
hydrophobic if its ɵ >70. Increase in both porosity and pore size led to a 
decrease in the water contact angle observed. The highest water contact 
angle was for the neat P(3HO-co-3HD) scaffold while the lowest was for 
scaffold D. 
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4.2.3.3.Protein Absorption of P(3HO-co-3HD) Porous Scaffolds  
Protein adsorption refers to the attachment of proteins to the surface of a 
material. It is an indication of the possible cell adhesion and proliferation 
on a material, the higher the better. Table 4.3 shows the protein adsorption 
in (µg/cm2) of the four different P(3HO-co-3HD) porous scaffolds. These 
values show that as both porosity and pore size increase, the protein 
adsorption increases. The highest protein adsorption was for the neat 
scaffold and the lowest was on scaffold A. 
Table 4.3: Water Contact Angle (ɵ) and Protein Adsorption (µg/cm2) for 
the P(3HO-co-3HD) scaffolds.  
Structures Water Contact Angle 
(ɵ) 
Protein Adsorption 
(µg/cm2) 
P(3HO-co-3HD)  104.58±8.63 353.69±19.85 
A 120.34±14.79 95.72±11.14 
B       104.13±9.65 250.447±17.38 
C       116.62±11.59 125.17±7.90 
D       94.64±5.69 235.33±25.48 
 
4.2.3.4.Water Uptake (%) of P(3HO-co-3HD) Porous Scaffolds   
Water uptake is a measure that is used to measure any potential changes in 
weight and degradation of a structure in vivo. It was measured in samples 
incubated in both phosphate buffered saline (PBS) and Roswell Park 
Memorial Institute (RPMI) media, the media for culturing BRIN BD11 cells 
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at 37oC. The average water absorption value was calculated as a % of the 
initial weight of the structure. The results are summarised in Figure 4.8. All 
four structures showed a statisitically significant increase in water absorbed 
by 30th day in comparison with the P(3HO-co-3HD) neat scaffold. This was 
observed in samples incubated in both PBS and RPMI.  
4.2.3.5.Weight Loss (%) of P(3HO-co-3HD) Porous Scaffolds   
Weight loss is another factor that enables the monitoring and calculation of 
degradation of polymer structures. Figure 4.8 shows that all four scaffolds 
lost weight after incubation for 30 days. In PBS, all scaffolds had 
statistically different (increased) weight loss except scaffold A in 
comparison to the neat P(3HO-co-3HD) scaffold. In RPMI, all four 
scaffolds had statistically significant (increased) weight loss.  
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Figure 4.8: %Water absorption and %weight loss values for porous 
P(3HO-co-3HD) scaffolds made. Samples are expressed as % of initial 
weight ± SEM for groups of 6. ****p ≤ 0.0001 when compared with neat 
P(3HO-co-3HD) scaffolds. 
4.2.4. Comparison of 2D P(3HO-co-3HD) Porous Structures Made Using 
NaCl and Sucrose as Porogens  
Since porosity was found to be a crucial factor in earlier made scaffolds, an 
indepth study using two different porogens- sodium chloride (NaCl) and 
sucrose was carried out.  
4.2.4.1. Porogen, Porogen Size and Concentration for P(3HO-co-3HD) Porous 
Scaffolds with NaCl and Sucrose as Porogens 
Table 4.4 is a summary of the porous P(3HO-co-3HD) 2D scaffolds made 
with both porogens. Both porogens were used at two different particle sizes 
(100 & 300µm) and two concentrations (5 and 15%). 
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Table 4.4: Porogen type, concentration and sizes for the production of 
P(3HO-co-3HD) 2D porous scaffolds. 
Porogen Porogen 
Concentration 
(%w/v) 
Porogen Size 
(µm) 
Identity of 
the 
P(3HO-
co-3HD) 
scaffold 
NaCl 5 100 A 
NaCl 15 100 B 
NaCl 5 300 C 
NaCl 15 300 D 
C6H12O6 5 100 E 
C6H12O6 15 100 F 
C6H12O6 5 300 G 
C6H12O6 15 300 H 
4.2.4.2. Properties of P(3HO-co-3HD) Porous Scaffolds Made with NaCl and 
Sucrose 
Table 4.5 gives a summary of the mechanical properties of the porous 
P(3HO-co-3HD) scaffolds made with NaCl and sucrose. From the results 
obtained, the stiffest of the porous scaffolds is A with the highest Young’s 
modulus. As the porosity increases, the Young’s Modulus decreases 
indicating a reduction in stiffness. Also, as the pore size increases, there is 
a reduction in the Young’s Modulus. The porous scaffolds made with NaCl 
are stiffer than those made with sucrose.  
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For tensile strength, the same trend was observed. Although the 2D scaffold 
C had the highest tensile strength, the general trend observed was that an 
increase in both porosity and pore size lead to a reduction in the tensile 
strength of the scaffolds. Also, 2D porous scaffolds made using glucose as 
the porogen had a reduced value of tensile strength as compared to the ones 
made using NaCl. The value of elongation at break also followed the same 
trend with the 2D scaffold A having the highest elongation at break.   
Table 4.5: Summary of the mechanical and thermal properties of P(3HO-
co-3HD) porous scaffolds produced using NaCl and sucrose. Samples are 
expressed as value ± SEM for groups of 6. 
Scaffolds Young’s 
Modulus (MPa) 
Tensile Strength 
(MPa) 
Elongation at 
break (%) 
A 89.84±14.33 4.20±0.34 83.39±12.56 
B 17.60±2.78 1.11±0.052 42.92±9.25 
C 57.06±12.27 4.42±0.067 61.12±8.63 
D 13.21±1.82 2.84±0.18 29.74±8.93 
E 35.63±9.79 3.49±0.071 59.40±4.78 
F 8.40±0.123 1.09±0.083 35.10±3.47 
G 10.97±0.97 2.45±0.62 36.53±4.41 
H 2.75±0.059 1.35±0.071 27.60±5.36 
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4.2.4.3.Water Contact Angle (ɵ) and Protein Adsorption of P(3HO-co-3HD) 
Porous Scaffolds Made with NaCl and Sucrose  
Water contact angle and protein adsorption tests were carried out to evaluate 
the effect of porogen on the hydrophobicity and cell adhesion characterisitcs 
of porous scaffolds.  
Table 4.6 is a summary of the water contact angle and protein adsorption 
values of the 8 porous scaffolds made with two different porogens. Among 
the scaffolds, the most hydrophobic was A with a water contact angle of 
120.34±14.79. For protein adsorption, scaffold D had the greatest 
adsorption with 253.33±25.48 µg/cm2. 
Table 4.6: Summary of static water contact angle and protein adsorption 
values of porous P(3HO-co-3HD) scaffolds with different porogens. 
Samples are expressed ± SEM for groups of 6. 
Structures Water Contact Angle 
(ɵ) 
Protein Adsorption 
(µg/cm2) 
A 120.34±14.79 95.72±11.14 
B       104.13±9.65 250.45±17.38 
C       116.62±11.59 125.17±7.30 
D       94.64±7.23 253.33±25.48 
E 107.93±11.96 85.21±15.48 
F 106.49±7.44 205.34±27.58 
G 123.72±13.56 130.76±32.91 
H 95.61±4.21 114.62±20.54 
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4.2.4.4. Direct Cell Viability Tests using BRIN BD11 Cells Seeded on P(3HO-co-
3HD) Porous Scaffolds with different porogens 
Direct cell viability tests were carried out to measure the cytocompatibility 
of the eight porous scaffolds. Figure 4.12 shows the cell viabilities of BRIN 
BD11 cells seeded in the 8 different porous scaffolds produced using NaCl 
and sucrose as porogens. By day 7, cells in all eight samples had viabilities 
>80%. 2D Porous scaffold B had the highest cell viability of 99.93±7.5. 
Increase in porosity led to an increase in cell viability, while increase in pore 
size led to decreased cell viability. 2D Porous Scaffolds A and B had cell 
viabilities not significantly different p >0.05 to the neat P(3HO-co-3HD) 
scaffold.  
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Figure 4.9: Direct cell viability of BRIN BD11 seeded in P(3HO-co-3HD) porous scaffolds with NaCl and sucrose as porogens. 
Samples are expressed as % of positive control (tissue culture plastic) ± SEM for groups of 6. *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001 
when compared with neat P(3HO-co-3HD) scaffolds
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4.2.4.5. Static Insulin Secretion from BRIN BD11 Cells Seeded on P(3HO-co-3HD) 
Porous Scaffolds Using NaCl and Sucrose as Porogens 
Insulin release analyses were carried out to evaluate the effect of the 
porogen on the insulin released from BRIN BD11 cells seeded on the 
scaffolds, after glucose stimulus, at both normoglycaemia (5.6mM glucose) 
and hyperglycaemia (16.7mM). 
At normoglycaemia- 5.6mM glucose (Figure 4.13), increases in both 
porosity and pore size led to a decrease in insulin release. At 
hyperglycaemia- 16.7mM (Figure 4.14), a similar trend was observed. 
Increasing porosity and pore size led to decreased insulin release. Cells 
seeded on scaffolds A exhibited insulin release significantly higher than the 
neat P(3HO-co-3HD) scaffolds. 
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Figure 4.10: Insulin secretion at normoglycaemia (5.6mM glucose) from BRIN BD11 cells seeded in 2D porous scaffolds made 
using NaCl and sucrose in ng of insulin/106 cells/20 minutes. Values are expressed as mean ± SEM for groups of 6. **p ≤ 0.01, 
***p ≤ 0.001, when compared with insulin release from P(3HO-co-3HD) scaffold. ****p ≤ 0.0001 for all other porous 
scaffolds.  
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Figure 4.11: Insulin secretion at hyperglycaemia (16.7mM glucose) from BRIN BD11 cells seeded in 2D porous scaffolds made 
using NaCl and sucrose in ng of insulin/106 cells/20 minutes. Values are expressed as mean ± SEM for groups of 6. **p ≤ 0.01, 
***p ≤ 0.001, ****p ≤ 0.0001 when compared with insulin release from P(3HO-co-3HD) scaffold.  
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4.3.DISCUSSION 
In this chapter, several features were evaluated. First, non-porous 2D scaffolds 
of P(3HB), P(3HO-co-3HD) and PLLA were evaluated for their thermal and 
mechanical properties. They were also tested for their effect on the viability of 
BRIN BD11 cells seeded on them. Next, the effect of porosity and pore size on 
the properties of porous P(3HO-co-3HD) scaffolds were measured. These 
properties included mechanical properties, water contact angle, protein 
adsorption, weight loss and water absorption. BRIN BD11 cells were also 
seeded in these structures and their viabilities and insulin response was 
measured.  
The mechanical and thermal properties observed for P(3HB), P(3HO-co-3HD) 
and PLLA all fell within those reported in literature. Previously reported Tm 
and Tg values for PLLA have been observed to be between -59
 oC & -61oC for 
Tg and 178-181
oC for Tm (Miyata and Masuko, 1998). These values are in line 
with those observed in this study (Tm: 177.3
oC, Tg: -61.73
oC) confirming 
PLLA. According to literature, the tensile strength values for PLLA are 55-
59MPa, Young’s Modulus 3,400-3,700MPa and elongation at break of 2-3% 
(Perego, Cella and Bastioli, 1996; Miyata and Masuko, 1998; Renouf-Glauser 
et al., 2005).  These are also similar to the values reported in this work (Tensile 
Strength: 53.5MPa, Young’s Modulus: 3,425MPa and elongation at break: 
2.4%), further confirming PLLA. 
Mechanical and thermal properties for P(3HB) have been widely reported in 
literature and the values measured in this work fall within the range observed 
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in literature. These values are Tensile Strength: 18-50MPa, Young’s Modulus: 
1700-3800MPa & Elongation at Break: 1-5% (Avella, Martuscelli and Raimo, 
2000; El-Hadi et al., 2002; Godbole et al., 2003; Valappil et al., 2008) In this 
work, the Tensile strength observed was 23.6MPa, Young’s Modulus: 
747.22MPa and elongation at break: 7.94%. Tensile strength observed was 
within the range reported in literature. However, Young’s Modulus and 
elongation at break are not within the range reported. This could be due to the 
fact that a different organism was used. Bacillus subtilis OK2. was used in this 
study. In the previously reported studies, B.cereus, A. eutrophus and 
commercially derived P(3HB) were used.  
Actual values for P(3HO-co-3HD) have not been reported in literature. This is 
because this polymer with its monomer content (22% hydroxyoctanoate, 78% 
hydroxydecanoate) is a novel polymer under patent being reported for the first 
time. Values for other mcl-PHA monomers have been reported. For 
hydroxyoctanoate (HO): Tm: 53.7 to 61
oC, Tg: -35 to -42.9
oC (Gross et al., 
1989; Liu et al., 2011; Wang, Chung and Chen, 2017). For hydroxydecanoate 
(HD), Tm: 45.2 to 77.6
 oC, Tg: -37.2 to -48.1
oC (Gross et al., 1989; Wang, 
Chung and Chen, 2017). The values observed for Tm and Tg of P(3HO-co-3HD) 
in this study were 54.7 and -66.95oC respectively. These values fit into the 
ranges expected. For Tensile Strength: 1.8-10.1MPa, Young’s Modulus: 1.3-
11.6MPa and elongation at break of 198-511.3% for hydroxyoctanoate (Marois 
et al., 1999; Dufresne and Vincendon, 2000; Lee and McCarthy, 2009; Ranjana 
Rai et al., 2011). For hydroxydecanoate, Tensile Strength: 19.86MPa, Young’s 
Modulus: 11.96MPa and elongation at break: 312.86% (Liu et al., 2011). The 
values derived in this study for P(3HO-co-3HD) deviate from those reported in 
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literature. This could be attributed to the mole composition of the polymer. The 
values reported are for the monomer compositions, so they do not give an 
accurate picture.   
Comparison of the viabilities of BRIN BD11 cells seeded on the P(3HB), 
P(3HO-co-3HD) and PLLA scaffolds, revealed significant differences between 
cells seeded in them and the positive control on day 1. By day 7 of cell culture, 
cells on P(3HO-co-3HD) scaffold had no statistically different cell viabilities 
to the positive control (tissue culture plastic). This confirms the results from a 
study conducted by Yang and his colleagues. The study compared two different 
PHAs- a scl-PHA poly(3-hydroxybutyrate-co-4-butyrate P(3HB-co-4HB) and 
mcl-PHA poly(3-hydroxybutyrate-co-hexanoate) P(3HB-co-HHX) with PLLA 
in terms of islet cell growth and function. The results from that study also 
showed that the islets exhibited higher viability on the mcl-PHA. This could be 
attributed to surface properties of the polymer. In Yang’s study, PLLA and 
P(3HB) were shown to have very flat, smooth surfaces and hence, the islets 
were not able to adhere to them. P(3HO-co-3HD) surfaces were not as flat as 
the others and hence were able to facilitate cell adhesion (Yang et al., 2009). 
Another factor that could have contributed to the increased cell viability in 
P(3HO-co-3HD) is the mechanical properties. Of the two polymers 
investigated, P(3HO-co-3HD) had mechanical properties similar to the native 
properties of the pancreas; thereby providing similar structure for adhesion and 
proliferation. 
The same pattern was observed in the insulin release studies with cells seeded 
on P(3HO-co-3HD) scaffolds having higher insulin release on stimuli at both 
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normoglycaemia (5.6mM) and hyperglycaemia (16.7mM). This was also 
observed in Yang’s study in which NIT-1 pancreatic cell lines seeded in the 
mcl-PHA had a higher insulin release. Insulin release is exponentially linked 
to cell growth; hence, increased cell growth will lead to an increase in insulin 
sensitivity and release. Yang and colleagues found that insulin expression 
increases where aggregation is present i.e. the mcl-PHA. It is then to be 
expected that BRIN BD11 cells form more aggregates on the surface of P(3HO-
co-3HD) leading to increased insulin expression and release (Sorenson and 
Brelje, 1997; Yang et al., 2009).  
Creation of porous structures for Tissue Engineering has a potential amount of 
benefits. These include the ability to weaken stiffer materials to produce 
mechanical properties similar to those of native tissue. Addition of pores would 
also improve the permeability of the material to allow exchange of nutrients 
and waste materials (Hollister, 2005). One of the challenges of designing 
porous scaffolds is achieving just the right balance of strength and stiffness in 
a porous material to enable it to bear the load while also maintaining structural 
integrity. The presence of pores in a material increases the interconnectivity 
but reduces the integrity of the structure and hence the more porous a material 
is, the lower its load bearing capacity. Pore size is also an important factor as 
bigger pore sizes leave bigger voids in the structure, thus weakening it even 
further. As porosity increases, tensile strength, stiffness and elongation at break 
decrease (Nam and Park, 1999; Chen, Ushida and Tateishi, 2001; Hollister, 
2005). This was observed in this study as tensile strength, Young’s Modulus 
and elongation at break decreased as the porogen and pore size increased. The 
same trend was observed when both NaCl and sucrose were used as porogens.  
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It was also observed that in comparison to porous scaffolds made with NaCl, 
porous scaffolds made with sucrose had decreased tensile strength, Young’s 
Modulus and elongation at break. This is corroborated by Dorati’s study in 
which NaCl and sucrose were used to make porous PLGA structures and 
compared. Their study found that the mechanical properties of sucrose-based 
structures were lower than those of NaCl based structures. This is due to the 
fact that NaCl and sucrose provide different polymer matrices when they are 
used as porogens (Dorati et al., 2010). These differences could also be 
attributed to the solubilities of NaCl and sucrose.  
Both water contact angle and protein adsorption are connected closely with 
surface roughness. In porous surfaces, roughness depends on the surface 
microstructure and the size and shape of the pores. The rougher a surface, the 
higher its wettability and hence, higher the protein adsorption to the surface. 
As a result, cell adhesion is directly linked to porosity (Boyan et al., 1996; Wei 
and Ma, 2004; Arima and Iwata, 2007; Förch, Schönherr and Jenkins, 2009). 
This was observed in this study, where as water contact angle increased, protein 
adsorption decreased. As the concentration of porogen increased, the cell 
viability increased. However, as the size of porogen increased, the cell viability 
decreased. The average islet cell is 80-100µm in size, suggesting that pore sizes 
~100µm will be ideal for islet transplantation (Ionescu-Tirgoviste et al., 2015). 
This validates the data from this study that shows the 2D scaffolds A (pore size 
100µm/ porogen concentration 5%) and B (pore size 100µm/ porogen 
concentration 15%) have the best combination of properties making them ideal 
porous materials. 
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Degradation is another important factor to be considered in the design of 
scaffolds with biomaterials. It is defined by factors like water uptake/ 
absorption and weight loss (Lu et al., 2000; Wei and Ma, 2004). The % water 
uptake and % weight loss observed in this study confirm a steady rate of 
degradation typical of PHAs. Although degradation rates have been shown to 
affect cell growth negatively, the degradation products of PHAs are not toxic. 
PHAs are degraded into their water-soluble monomers and oligomers (Numata, 
Abe and Iwata, 2009; Ong, Chee and Sudesh, 2017). On the other hand, PLLA 
degrades into lactic acid (Leenslag et al., 1987).  
In conclusion, in comparison to PLLA (FDA approved polymer for Tissue 
Engineering), P(3HB) was found to have similar properties while P(3HO-co-
3HD) exhibited mechanical properties similar to soft tissue. In terms of islet 
viability, cells seeded on P(3HO-co-3HD) scaffolds had the highest viabilities. 
The mechanical properties of P(3HO-co-3HD) were finetuned to be more 
similar to those of the pancreas through the integration of pores. The question 
of optimum pore size and porosity for porous structures in Tissue Engineering 
has been researched for decades. It is widely accepted that it depends on the 
cell type and its particular needs. In this work, it was confirmed that the 
optimum pore size for pancreatic islets is 100µm. Water contact angle, protein 
adsorption and cell adhesion were shown to be dependent on the porosity of 
the materials. It was also observed that scaffolds that had NaCl as the porogen 
exhibited better cell viability results for BRIN BD11 cells. In light of all the 
findings, scaffolds A&B were selected as the best options for scaffolds.   
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5. P(3HB) & P(3HO-co-3HD) 2D/3D STRUCTURES 
5.1.INTRODUCTION 
In the early stages of Tissue Engineering, the scaffolds used were 2D 
constructs used mainly as support for cells. As understanding has matured, 
the need for these structures to be improved to have appropriate mechanical, 
physical and biological properties to mimic the in vivo environment of the 
cells in vitro became apparent (Santos et al., 2012). This has shifted research 
to 3D structures to better understand the interactions between cells, 
scaffolds, molecules and component of the extracellular matrix (Coronel 
and Stabler, 2013). In islet transplantation, especially, these interactions are 
important for islet cell growth, proliferation and function (Goh et al., 2013). 
There are a wide range of methods to create 3D scaffolds for Tissue 
Engineering. They range from the classic porogen leaching, gas foaming, 
phase separation to the newer techniques like fibre making and 3D printing 
(Chen, Ushida and Tateishi, 2002).  
In islet transplantation, 3D structures have been widely investigated. 
Ethisorb (a scaffold made of a composite of polygalactin, poly-p-
dioxanone) has been used to transplant islets in large animal models. One 
of the dogs that received the scaffold containing the highest number of islets 
achieved normoglycaemia up to 5 months post-transplantation. Those dogs 
that received an average number of islets, maintained normoglycaemia up 
to 2 months post-transplantation (Kin et al., 2008). Ethisorb has also been 
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used for islet transplantation in monkeys, with similar results (Berman et 
al., 2009). 
When PLGA-collagen hybrid meshes were used to culture rat RIN-5F 
insulin producing cells, the results were positive. The meshes promoted 
insulin production while also supporting adhesion, proliferation and 
differentiation of RIN-5F cells (Kawazoe et al., 2009). Different PLGA 3D 
structures have been used in islet transplantation. Islets transplanted in this 
structure survived longer while also maintaining their native shape and 
function in comparison to the control group. PLGA discs were also used to 
transplant islets into BALB/C mice. Mice that received these seeded discs 
took 45% less time to attain normoglycaemia than the control group (Dufour 
et al., 2005). 
Islets encapsulated in silk 3D hydrogels remained viable and retained their 
insulin secretion up to 7 days post-transplantation. In combination with 
mesenchymal stem cells and ECM proteins, by day 7 the insulin release has 
increased 3.2 fold than the control group (Davis et al., 2012). Islets cultured 
in agarose cryogels exhibited 15 fold higher insulin release at 3mM glucose 
than the control (Bloch et al., 2005).  
In 3D printing, a 3D printing device controlled by a computer deposits cells, 
molecules, and biomaterials into exact structures that mimic native tissue 
structures. 3D printing biological scaffolds can create replacements for 
damaged tissues and organs and can also create small models for research 
purposes quickly and reproducibly (Skardal and Atala, 2015). The major 
challenge of 3D printing is finding the balance between maintaining the 
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architecture of the scaffold and the functionality of the scaffolds. The 
biomaterials for 3D printing can be used in two ways: as curable inks either 
by melting or solvent dissolution with the cells seeded after formation of the 
scaffold or as cell supporting hydrogels with the cells printed within the 
hydrogels (Skardal and Atala, 2015).  
Two predominant techniques in 3D printing exist. Inkjet printing involves 
the use of a cartridge filled with biomaterial ink that is dropped into XYZ 
plotting devices. The cells and biomaterials can be loaded into multi 
cartridges and printed at the same or at different times. This technique 
requires ‘bioink’ that is quick to polymerise, so each drop stabilises before 
the next drop. A modification of this technique called thermojet printing can 
also be used for biomaterials that require melting (Murphy and Atala, 2014; 
Skardal and Atala, 2015). 
In extrusion printing, pneumatic pressure is used to drive an extrudable 
material out of a syringe in a fixed manner. Materials to be printed using 
this technique must exhibit fluid-like properties and must hold their shape 
post-extrusion. Viscosity and pressure are really important factors in this 
method and can be altered to determine the structure(s) printed (Griffith and 
Naughton, 2002; Ventola, 2014; Skardal and Atala, 2015).  
Since the Edmonton protocol, the field of Islet Transplantation has 
researched ways to provide the minimum number of islets necessary in a 
manner that requires the least immunosuppression. This has led to the 
development of the bioartificial pancreas.  
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“A bioartificial pancreas is a 3D biomimetic device that substitutes for the 
endocrine portion of the pancreas while also avoiding the need for 
immunosuppression.” - (Kizilel, Garfinkel and Opara, 2005) 
The bioartificial pancreas contains cells or cell clusters in a membrane 
separating foreign tissues from the immune system (Silva et al., 2006). 
Valdes-Gonzalez and his colleagues designed a bioartificial pancreas 
containing surgical grade stainless steel and polytetrafluoroethylene (PTFE) 
rods. This device was transplanted into 12 humans and in half of the group, 
there was a significant reduction in the exogenous insulin required (Valdés-
González et al., 2005). Maki and his colleagues made a device containing 
islets in a semi-permeable tube-like membrane connected to the vascular 
system. Of the 13 dogs that received this device, 8 dogs required a reduced 
amount of insulin supplementation and 4 dogs required no supplementation 
up to 3 weeks post-transplantation (Maki et al., 1991; Monaco et al., 1991). 
Ludwig and her colleagues at Beta-O2 designed a device containing a PTFE 
membrane with alginate encapsulated islets. The device normalised blood 
glucose levels in diabetic rodents up to 3 months post-transplantation. It also 
reduced the number of islets required for transplantation and no delay in 
insulin response to glucose stimulus was observed (Ludwig et al., 2012). 
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5.2.RESULTS 
5.2.1. PHA blend based 2D & 3D Scaffolds  
2D and 3D scaffolds were fabricated using P(3HB) and P(3HO-co-3HD) to 
determine the effect of surface area, geometry, porosity and surface 
roughness on viability of murine BRIN DB11 cells seeded on them.  
 
Figure 5.1: P(3HO-co-3HD) fabricated structures. (a.) 2D- Non-Porous 
Film (b.) 2D-Porous Film (c.) 3D Structure, bars: 10mm. 
Figure 5.1 shows the three different P(3HO-co-3HD) structures that were 
made. 5.1a is a solvent cast P(3HO-co-3HD) film. The film appears 
transparent and elastomeric fitting with the structural characteristics of mcl-
PHAs. 5.1b is a P(3HO-co-3HD) porous film that was solvent cast using 
NaCl as porogen. The film appears flat, with macroscopic pores. Both neat 
and porous films have diameters of about 35-45mm. 5.1c is a P(3HO-co-
3HD) 3D porous structure made by solvent casting technique with NaCl as 
a porogen. The 3D structures were cast in Teflon moulds. The final 3D 
structure created had dimensions of 35 x 10 x 0.5mm.  
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5.2.2. Mechanical Properties of 2D & 3D Structures 
As shown in Table 5.1, for P(3HB) 2D and 3D scaffolds, the 3D scaffold 
has a higher (p ≤ 0.0001) Young’s Modulus value of 850.24±45.19MPa than 
747.59±58.08MPa for the P(3HB) 2D structure. This is an indication that 
the P(3HB) 3D structure is stiffer than the P(3HB) 2D structure. Tensile 
Strength for the P(3HB) 3D structure was 37.5±2.28MPa as compared to 
that of the P(3HB) 2D structure (23.6±0.28MPa).  On the other hand, the 
elongation at break of the P(3HB) 2D structure was measured to be 
7.94±0.21% while that of the 3D structure was 6.8±0.79%. No significant 
difference (p > 0.05) was observed between the Tensile Strength, Young’s 
Modulus and elongation at break of both the P(3HB) 2D and 3D structures. 
Table 5.1: Summary of mechanical properties of P(3HB) and P(3HO-co-
3HD) 3D and 2D structures.  Values are expressed as ± SEM for groups 
of 6. 
Structures Young Modulus 
(MPa) 
Tensile Strength 
(MPa) 
Elongation break 
(%) 
P(3HB)-2D 747.59±58.08 23.6±0.28 7.94±0.21 
P(3HB)-3D 850.24±45.19 37.5±2.28 6.8±0.79 
P(3HO-co-3HD)-
2D 
1.37±0.054 1.19±0.06 1415±19.16 
P(3HO-co-3HD)-
3D 
2.20±0.75 2.15±0.93 946.59±30.547 
P(3HO-co-3HD)-
2D Porous 
1.05±0.032 1.08±0.08 192.2±27.77 
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P(3HO-co-3HD)-
3D Porous 
1.17±0.37 1.17±0.03 236.23±22.47 
 
Between the P(3HO-co-3HD) 2D and 3D structures, no significant 
difference (p > 0.05) was observed between the two structures for both 
Tensile Strength and Young’s Modulus. For the elongation at break, there 
was a significant (p ≤ 0.05) difference between both structures; elongation 
at break of the P(3HO-co-3HD) 2D structure 1415±19.16% for the 2D and 
946.59±30.547% for the 3D structure. This is an indication that the P(3HO-
co-3HD) 2D structure is more elastic than the P(3HO-co-3HD) 3D structure.  
Comparing both P(3HO-co-3HD) porous 2D and 3D structures, no 
significant difference (p > 0.05) was observed between the Tensile Strength 
for the P(3HO-co-3HD) porous 2D (1.08±0.08 MPa) and P(3HO-co-3HD) 
porous 3D (1.17±0.03 MPa) structure. The same trend was observed for the 
Young’s Modulus values of the P(3HO-co-3HD) porous 2D and P(3HO-co-
3HD) porous 3D of 1.05±0.032MPa and 1.17±0.37MPa respectively. 
Similarly, no significant difference was observed between the elongation at 
break of 192.20±27.77% and 236.23±22.47% for the P(3HO-co-3HD) 
porous 2D and P(3HO-co-3HD) porous 3D structures. 
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Figure 5.2: Mechanical properties of P(3HB) and P(3HO-co-3HD) 2D 
and 3D structures a) Tensile Strength (MPa) b) Young’s Modulus (MPa) 
c) Elongation at break (%). Values are expressed as mean ± SEM for 
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groups of 6. *p ≤ 0.05, ****p ≤ 0.0001 when 2D and 3D structures were 
compared.  
 
5.2.3. Water Contact Angles of 2D & 3D Structures 
The water contact angles for all the structures made are shown in Figure 5.3. 
The water contact angles for the P(3HB) 2D and 3D structures were 
72.12o±8.67 and 74.37o±5.92. No significant difference (p > 0.05) was 
observed between both values.  
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Figure 5.3: Static water contact angle (ɵ) of P(3HB) and P(3HO-co-3HD) 2D and 3D structures. Values are expressed as mean 
± SEM for groups of 6. No significant difference (p > 0.05) was observed when 2D structures were compared with 3D 
structures.  
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For the P(3HO-co-3HD) 2D and 3D structures, the water contact angles 
were 107.580o±10.63 and 107.78o±8.39 respectively with no significant 
difference (p > 0.05).  
For both P(3HO-co-3HD) 2D and 3D porous structures, the water contact 
angles were 104.13o±9.65 and 108.92o±7.67. Similarly, no significant 
difference (p > 0.05) was observed between the two types of structures.  
5.2.4. Protein Adsorption of 2D & 3D Structures 
The protein adsorption for the P(3HB) and P(3HO-co-3HD) 2D and 3D 
structures are shown in both Figure 5.4. For the 2D and 3D P(3HB) 
scaffolds, the protein adsorption values were 204.19±11.91µg/cm2 and 
247.68±14.76µg/cm2 respectively. The protein adsorption value for the 
P(3HB) 3D structure was significantly higher (p ≤ 0.001) than that of the 
P(3HB) 2D scaffold.  
 140 
 
P
(3
H
B
)-
2
D
P
(3
H
B
)-
3
D
P
(3
H
O
-c
o
-H
D
)-
 2
D
P
(3
H
O
-c
o
-H
D
)-
 3
D
 
P
(3
H
O
-c
o
-H
D
)-
 2
D
 P
o
ro
u
s
P
(3
H
O
-c
o
-H
D
)-
 3
D
 p
o
ro
u
s
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
P
ro
te
in
 A
d
s
o
rp
ti
o
n
 (

g
/c
m
2
)
P (3 H B )-2 D
P (3 H B )-3 D
P (3 H O -c o -H D )-  2 D
P (3 H O -c o -H D )-  3 D
P (3 H O -c o -H D )-  2 D  P o ro u s
P (3 H O -c o -H D )-  3 D  p o ro u s
* * *
* * * *
* * * *
 
Figure 5.4: Protein adsorption of P(3HB) and P(3HO-co-3HD) 2D and 
3D structures. Values are expressed as mean ± SEM for groups of 6. ***p 
≤ 0.001, ****p ≤ 0.0001 when 2D structures were compared with 3D 
structures. 
 
For the P(3HO-co-3HD) 2D and 3D structures, the protein adsorption values 
were 353.65±7.61µg/cm2 and 398.72±12.55µg/cm2 respectively. The value 
observed for the P(3HO-co-3HD) 3D structure was higher (p ≤ 0.0001) than 
that of the P(3HO-co-3HD) 2D structure. Finally, the protein adsorption 
values of both P(3HO-co-3HD) 2D and 3D porous structures were 
253.45±17.3861µg/cm2 and 427.50±18.79µg/cm2 respectively. The values 
for the P(3HO-co-3HD) porous 3D structure was higher (p ≤ 0.0001) than 
the P(3HO-co-3HD) porous 2D structure.  
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5.2.5. Cell Viability Tests on BRIN BD11 Cells in 2D & 3D Structures 
Figure 5.5 shows the cell viability tests carried out to evaluate the effects of 
the scaffolds on BRIN BD11. For BRIN BD11 cells seeded in P(3HB) 2D 
and 3D structures, the indirect cell viabilities were 94.59±5.52% and 
95.61±6.57% respectively. No significant difference (p>0.05) was observed 
between the cell viability of the two types of structures.  
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Figure 5.5: Cell viability of BRIN BD11 cells seeded in P(3HB) and 
P(3HO-co-3HD) 2D and 3D structures. Values are expressed as % of 
positive control (tissue culture plastic) ± SEM for groups of 6. P > 0.05 
when 2D structures were compared with corresponding 3D structures. 
Comparing the P(3HO-co-3HD) 2D and 3D structures, the viabilities of the 
cells seeded in them were 91.78±8.33 and 95.13±7.51 respectively. There 
was no significant difference (p>0.05) observed between both structures. 
No significant difference (p>0.05) was observed between the 2D 
(95.39±11.19) and 3D (98.55±9.38) porous P(3HO-co-3HD) structures.  
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5.2.6. Static Insulin Secretion from BRIN BD11 Cells in 2D & 3D Structures 
Insulin release tests were carried out in BRIN BD11 cells seeded in media 
incubated with the P(3HB) and P(3HO-co-3HD) 2D and 3D structures. The 
results are shown in Figure 5.6. The tests were carried out at two different 
concentrations of glucose.  
At 5.6mM (normoglycaemia), the insulin release values for P(3HB) 2D and 
3D structures were 2.978±0.093ng/106cells/20 minutes and 3.026±0.159 
ng/106cells/20 minutes respectively. No significant difference (p > 0.05) 
was observed between the two structures. For the P(3HO-co-3HD) 2D and 
3D structures, the insulin release values were 3.373±0.155ng/106cells/20 
minutes and 3.565±0.079ng/106cells/20 minutes. Again, no significant 
difference (p > 0.05) was observed. Finally, comparing the porous  
P(3HO-co-3HD) porous 2D and 3D structures, the insulin release was  
3.923±0.064 ng/106cells/20 minutes and 4.278±0.358 ng/106cells/20 
minutes respectively. In this case, no significant difference (p > 0.05) was 
also observed.  
At 16.7mM glucose (hyperglycaemia), the insulin release values for P(3HB) 
2D and 3D structures were 3.279±0.095ng/106cells/20 minutes and 
3.682±0.078 ng/106cells/20 minutes respectively. No significant difference 
(p > 0.05) was observed between both. For the P(3HO-co-3HD) 2D and 3D 
structures, the insulin release values were 4.292±0.106ng/106cells/20 
minutes and 4.340±0.254ng/106cells/20 minutes. Again, no significant 
difference (p > 0.05) was observed between the 2D and 3D structures. 
Finally, comparing the porous P(3HO-co-3HD) 2D and 3D structures, the 
 143 
 
insulin release was 4.995±0.23ng/106cells/20 minutes and 
5.106±0.32ng/106cells/20 minutes respectively. In this case too, no 
significant difference (p > 0.05) was also observed.  
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Figure 5.6: Insulin secretion from BRIN BD11 cells seeded in media from 
P(3HB) and P(3HO-co-3HD) 2D and 3D structures at a.) 
normoglycaemia (5.6mM glucose) and b.) hyperglycaemia (16.7mM 
glucose) in ng/106cells/20 minutes. Samples are expressed as % of positive 
control (tissue culture plastic) ± SEM for groups of 6. *p ≤ 0.05, p > 0.05 
when 2D structures were compared with 3D structures. 
5.3.DISCUSSION 
In this chapter, P(3HB) and P(3HO-co-3HD) 2D and 3D structures were 
made and characterised with respect to mechanical properties, water contact 
angle and protein adsorption. Indirect cell viability and insulin release tests 
were also carried out on BRIN BD11 cells seeded on them. The same 
processes were applied to the porous P(3HO-co-3HD) porous 2D and 3D 
structures. These properties were then compared to evaluate the differences 
between 2D and 3D structures. 
Measuring mechanical properties showed no significant difference between 
the 2D and 3D structures. This could be attributed to the fact that mechanical 
properties of 2D and 3D structures are not exactly comparable. 3D 
structures may not lend themselves to direct comparison with those of 2D 
structures. In addition, the mechanical properties were all measured in dry 
conditions so a whole picture could not be drawn (Huang et al., 2005; Hess 
et al., 2017).  
For the water contact angle measurement, no significant difference was 
observed when the P(3HB) and P(3HO-co-3HD) 2D and 3D porous and 
non-porous structures were compared. This is because static water contact 
angle is a surface measurement and will only be affected by surface 
roughness, not surface area (Cassie and Baxter, 1944). 
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For protein adsorption, in every 2D/3D pairing, there were significant 
differences in protein adsorption observed. Increases between 1.2-1.8-fold 
were observed on the 3D structure as compared to the 2D structure. Protein 
adsorption is dependent on surface area and the increased surface area in 3D 
structures provides more room for the protein to be adsorbed (Du, 
Chandaroy and Hui, 1997; Roach, Farrar and Perry, 2006; Wei and Ma, 
2009). 
Native β-cells exist in aggregates with α, δ and Pancreatic Polypeptide 
producing (PP) cells in clusters called islets of Langerhans (Wills, Thomas 
and Gillham, 2006). These islets contain multiple cells and have an average 
size of 100µm. When these cells are grown on porous surfaces, the pores 
must be big enough that multiple aggregates could fit through them.  
In this work, murine BRIN BD11 cells were selected. BRIN BD11 cells are 
created from electrofusion of RINm5f cells with rat pancreatic islets hence 
they combine the insulin release function of their parent cells with 
immortality (McClenaghan, Barnett, Ah-Sing, et al., 1996). In comparison 
with other existing pancreatic cell lines like INS-1, MIN6 and NIT-1, BRIN 
BD11 cells are relatively more responsive to increasing glucose 
concentrations (Skelin, Rupnik and Cencič, 2010). BRIN BD11 cells also 
exhibited pronounced responses to a range of amino acids including leucine, 
arginine and alanine (McClenaghan, Barnett, O’Harte, et al., 1996; Skelin, 
Rupnik and Cencič, 2010). BRIN BD11 cells also show a pattern 
comparable to rat islets when secretory responses were measured (Hamid et 
al., 2002). BRIN BD11 cells have been studied extensively in terms of 
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insulin inhibition, amino acid consumption and gene expression 
(McClenaghan and Flatt, 1999; Ahmad et al., 2000; Dixon et al., 2003). 
No significant differences were observed between cell viabilities of the 2D 
and 3D P(3HB) and P(3HO-co-3HD) structures. On the other hand, there 
was also no significant difference observed between the cell viabilities of 
BRIN BD11 cells in 2D and 3D porous P(3HO-co-3HD) structures. Islets 
have a higher tendency to cluster, rather  than migrate (Aloysious and Nair, 
2014). This could be because the pores in the 3D scaffold may have already 
been occupied by these clusters. It is also possible that the cells perceive the 
3D structure as a 2D surface with ridges (Biomater et al., 2009). Insulin 
release is a direct consequence of cell viability, so no significant difference 
was also observed in that case.  
Another factor that could have led to this is the number of cells seeded on 
the surface. Islet density has been shown to have a direct effect on the 
viability and survival of islets post-transplant (McCall and Shapiro, 2012). 
Porous structures and 3D structures have an increased surface area so using 
the same number of cells for both structures would not give an accurate 
comparison.   
Incidentally, it was also discovered in this study that upon stimulation at 
both normoglycaemia and hyperglycaemia glucose, cells seeded in both 
PHA structures release up to 10-fold more insulin than cells seeded in the 
positive control (tissue culture plastic). This confirms work from Chapter 4 
and can be explained by the aggregation that the PHA surfaces and porosity 
provide.  
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In conclusion, comparison of the mechanical properties of 2D and 3D 
porous/non-porous structures revealed no significant difference. The water 
contact angle measured also showed no significant difference between the 
2D and 3D structures. Protein adsorption measurements on the other hand, 
demonstrated significant differences between 2D and 3D structures owing 
to the differences in available surface area. Even though differences were 
observed in protein adsorption, no significant differences were observed in 
cell viability and insulin release values. Further investigation is needed in 
order to evaluate the correlation between the surface area and cell density in 
both 2D and 3D scaffolds.   
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CHAPTER SIX: 
P(3HO-co-
3HD)/P(3HB) 
BLENDS 
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6. P(3HO-co-3HD)/P(3HB) BLEND SCAFFOLDS 
6.1. INTRODUCTION 
One of the most important factors in scaffold design is the choice of scaffold 
materials. The Scaffold material should ideally have similar mechanical and 
thermal properties as the targeted tissue.  
Having shown PHAs to be excellent materials for use in islet 
transplantation, it is important to select the specific PHA fit for this role. 
Two classes of PHAs have been discussed in Chapters 3 and 4. Even though 
P(3HB) is the stronger of both PHAs, it is very brittle and lacks the 
flexibility required from materials for soft tissue engineering. Mcl-PHAs, 
on the other hand, are more suited to soft tissue engineering due to their 
flexibility but lack strength and hence are difficult to handle.  
Blending of both classes of PHAs is a process of that can lead to the 
production of new polymers with properties different to their parent 
polymers. In blending, one has the capability of tuning the physical and 
mechanical properties of the final polymer by adjusting the amounts of each 
polymer type present. Blending P(3HB) with mcl-PHAs have been shown 
to reduce its brittleness and increase its biocompatibility (Li, Yang and Loh, 
2016).  
When chondrocytes were grown on two different PHA scaffolds: P(3HB), 
P(3HB)/P(3HHx), almost two-fold cell proliferation was observed on the 
P(3HB)/P(3HHx) blend scaffold in comparison with the neat P(3HB) 
scaffold (Deng et al., 2002). Neuronal cells cultured on (P3HO), P(3HB) 
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and P(3HO)/P(3HB) blend films showed increased viabilities on the blends 
in comparison to the neat (P3HO) and P(3HB) films (Lizarraga-Valderrama 
et al., 2015). HMEC-1 cells seeded in P(3HO)/P(3HB) blend films had 
better viabilities than those of  (P3HO) and P(3HB) films (Basnett et al., 
2013). 
In this chapter, P(3HO-co-HD) dominated P(3HO-co-HD)/ P(3HB) blend 
scaffolds were made in three different concentrations: 95:5, 90:10 and 
80:20. These different scaffolds were then characterised and evaluated for 
cell viability and insulin release. After this evaluation, the most promising 
blend concentration was then fabricated into three different structures: non-
porous 2D, porous 2D and porous 3D scaffolds. These structures were also 
characterised and evaluated for cell viability and influence on insulin release 
of the insulin producing BRIN BD11 cell line.  
 
6.2.RESULTS 
6.2.1. DSC Analysis of P(3HO-co-3HD)/P(3HB) Blends 
DSC analysis was carried out on the P(3HB), P(3HO-co-HD) and P(3HO-
co-3HD)/P(3HB) blends to determine the effects of blending on their 
thermal behaviour. The results observed are recorded in table 6.1. 
During the 1st DSC cycle, the initial peak indicated the melting temperature 
of the P(3HO-co-HD) in the blend. The second peak corresponded to the 
melting temperature of the P(3HB) present. After the second heating cycle 
in the DSC run, only a peak for P(3HB) could be observed. For each blend, 
 151 
 
two melting temperatures were recorded. An initial, lower one belonging to 
the P(3HO-co-HD) component and the second higher one to P(3HB) 
component. 
For the lower melting temperatures observed, as the concentration of 
P(3HO-co-HD) in the blends decreased, the melting temperature decreased 
from about 54.7oC for pure P(3HO-co-HD) to 51.2oC for the 80:20 P(3HO-
co-3HD)/P(3HB) blend. For the higher melting temperatures, as the P(3HB) 
concentration increased, the melting temperature increased from 164.5oC 
for the 95:5 P(3HO-co-3HD)/P(3HB) blend to 172.8oC for P(3HB).  
Considering glass transition temperatures observed, there was a marked 
difference observed in the glass transition temperatures of the 90:10 and 
80:20 P(3HO-co-3HD)/P(3HB) blends. Tg of -48.05
oC and -44oC were 
observed in comparison to the -65 to -67oC observed for all the other 
polymers and blends.  
 
Table 6.1: Thermal properties of P(3HB), P(3HO-co-HD) and P(3HO-co-
3HD)/P(3HB) blends. 
Polymer Melting Point, Tm 
(°C) 
Glass transition, 
Tg (°C) 
P(3HB) 172.8 ± 1.83 -67.15 ± 0.35 
80:20 a. 51.2 ± 0.07 
b. 170.4 ± 0.78 
-44.0 ± 0.64 
90:10 a. 51.7 ± 0.71  
b. 170.15 ± 1.77 
-48.05 ± 1.20 
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95:5 a. 54.55 ± 2.33 
b. 164.5 
-65.9 ± 0.85 
P(3HO-co-
HD) 
54.7 ± 3.25 -66.95 ± 0.92 
 
6.2.2. Mechanical Analysis of P(3HO-co-3HD)/P(3HB) Blends 
Mechanical analysis was carried out on the P(3HB), P(3HO-co-HD) and 
P(3HO-co-3HD)/P(3HB) blends to evaluate the effect of blending on their 
strength, stiffness and flexibility. The results observed are recorded in table 
6.2. 
For elongation at break, it was observed that as the P(3HB) component was 
increased in the P(3HO-co-3HD)/P(3HB) blends, the elongation at break 
decreased, indicating a decrease in flexibility. Tensile strength, on the other 
hand, increased as the P(3HB) component was increased in the P(3HO-co-
3HD)/P(3HB) blend. A similar pattern was observed with the Young’s 
Modulus which also increased as the P(3HB) component was increased in 
the P(3HO-co-3HD)/P(3HB) blend. 
So as the P(3HB) component was increased in the P(3HO-co-3HD)/P(3HB) 
blends, the strength and stiffness increased while the flexibility redces.  
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Table 6.2: Mechanical properties of P(3HB), P(3HO-co-HD) and P(3HO-
co-3HD)/P(3HB) blends. 
 
6.2.3. Cell Viability Studies on P(3HO-co-3HD)/P(3HB) Blends  
Cell viability studies were carried out on the P(3HB), P(3HO-co-HD) and 
P(3HO-co-3HD)/P(3HB) blends to determine their suitability as scaffolds 
for bioartificial pancreas. These studies were carried out using the murine 
BRIN BD11 islet cell line. The cell viabilities observed were expressed as 
% of the positive control (tissue culture plastic) as shown in Figure 5-3.  
In all the polymers and blends, the viabilities of BRIN BD11 cells seeded 
in them increased from day 1 to day 7. In comparison to the P(3HO-co-HD) 
polymer, on all days both the 95:5 and 90:10 P(3HO-co-3HD)/P(3HB) 
Polymer Elongation at 
break (%) 
Tensile strength 
(MPa) 
Young’s 
Modulus, E 
(MPa) 
P(3HB) 7.94 ± 0.02 
  
23.6± 0.28 747.22 ± 1.08 
80:20  621.7 ± 0.54 6.81 ± 0.98 1.77 ± 0.04 
90:10 818.8 ± 0.14 5.57 ± 2.67 1.66 ± 0.39 
95:5 1318.7 ± 0.02 2.11 ± 0.06 
  
1.64 ± 0.37 
P(3HO-co-
HD) 
 1415.1± 0.02 1.08 ± 0.06 1.39 ± 0.05 
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blends showed no significant difference in viabilities. By day 7, cells seeded 
on both blends and P(3HO-co-HD) showed no significant difference when 
compared to the positive control.  
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Figure 6.1: Cell viability of BRIN BD11 cells seeded on P(3HB), P(3HO-
co-HD) and P(3HO-co-3HD)/P(3HB) blends. Values are represented as 
%positive control (tissue culture plastic) mean ± SEM for groups of 6. 
***p ≤ 0.001, ****p ≤ 0.0001 when compared with P(3HO-co-HD).  
6.2.4. Static Insulin Secretion on P(3HO-co-3HD)/P(3HB) Blends 
Insulin release studies were carried out to evaluate the functionality of the 
BRIN BD11 cell line seeded on the P(3HB), P(3HO-co-HD) and P(3HO-
co-3HD)/P(3HB) blends. The analyses were run at normoglycaemia 
(5.6mM glucose) and hyperglycaemia (16.7mM glucose). 
At normoglycaemia (5.6mM glucose), all cells seeded in all the PHA 
samples exhibited insulin release. From day 1, cells on all scaffolds 
responded to the glucose stimulus but as the number of days of incubation 
increased, the insulin release was stronger as shown in Figure 6.4. in 
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comparison with the insulin released from cells seeded in the P(3HO-co-
HD), insulin released from 95:5 P(3HO-co-3HD)/P(3HB) blend showed no 
significant difference on all days. By days 3&7, cells seeded on the 90:10 
P(3HO-co-3HD)/P(3HB) blend also showed no significant difference in 
insulin release. Insulin released from cells seeded in the 80:20 blend was 
significantly lower than the P(3HO-co-HD).  
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Figure 6.2: Insulin secretion at normoglycaemia (5.6mM glucose) from 
BRIN BD11 cells seeded P(3HB), P(3HO-co-HD) and P(3HO-co-
3HD)/P(3HB) blends in ng of insulin/106 cells/20 minutes. Values are 
expressed as mean ± SEM for groups of 6. **p ≤ 0.01, ***p ≤ 0.001, 
****p ≤ 0.0001 when compared with insulin release from cells seeded in 
P(3HO-co-HD).  
 
At hyperglycaemia (16.7mM), a similar pattern was observed where 
in comparison to the cells seeded in the P(3HO-co-HD), the insulin released 
from 95:5 P(3HO-co-3HD)/P(3HB) blend showed no significant difference 
on all days. On the other hand, by day 7, insulin released from cells seeded 
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in both 90:10 and 80:20 P(3HO-co-3HD)/P(3HB) blends were significantly 
lower.  
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Figure 6.3: Insulin secretion at hyperglycaemia (16.7mM glucose) from 
BRIN BD11 cells seeded P(3HB), P(3HO-co-HD) and P(3HO-co-
3HD)/P(3HB) blends in ng of insulin/106 cells/20 minutes. Values are 
expressed as mean ± SEM for groups of 6. ***p ≤ 0.001, ****p ≤ 0.0001 
when compared with insulin release from cells seeded in P(3HO-co-HD). 
6.2.5. Processing 95:5 P(3HO-co-3HD)/P(3HB) Blend into Scaffolds 
Since the 95:5 blend showed the best cell viability and insulin release data, 
this blend was selected to be processed into porous 2D and 3D scaffolds. 
6.2.6. Cell Viability Studies on Cells seeded in 95:5 P(3HO-co-3HD)/P(3HB) 
Blend Scaffolds 
Direct cell viability studies were carried out on the P(3HO-co-HD) and 95:5 
P(3HO-co-HD)/P(3HB) blend scaffolds to determine their suitability as 
scaffolds for bioartificial pancreas. These studies were carried out using the 
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murine BRIN BD11 islet cell lines. The cell viabilities observed were 
expressed as % positive control (tissue culture plastic) and shown in Figure 
6.4. When all 95:5 P(3HO-co-3HD)/P(3HB) blend scaffolds were compared 
to their corresponding P(3HO-co-HD) scaffolds, no significant difference 
was observed except in the 3D structures on day 1. By day 7, when all 
structures were compared to both positive control and their corresponding 
P(3HO-co-HD) scaffolds, no significant difference was observed.  
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Figure 6.4: Cell viability of BRIN BD11 cells seeded on 2D and 3D 
P(3HO-co-HD) and 95:5 P(3HO-co-3HD)/P(3HB) blend scaffolds. Values 
are represented as %positive control (tissue culture plastic) mean ± SEM 
for groups of 6. *p ≤ 0.05, when 95:5 P(3HO-co-3HD)/P(3HB) 3D 
scaffold was compared with P(3HO-co-HD) 3D scaffold.  
6.2.7. Static Insulin Secretion from 95:5 P(3HO-co-3HD)/P(3HB) Blend 
Scaffolds 
Insulin release studies were carried out to compare the functionality of the 
BRIN BD11 cell line seeded on the P(3HO-co-HD) and 95:5 P(3HO-co-
HD)/P(3HB) blend scaffolds. Figure 6.5 shows insulin release from cells 
seeded in different P(3HO-co-HD) and 95:5 P(3HO-co-HD)/P(3HB) blend 
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scaffolds at hyperglycaemia (16.7mM glucose). In comparison with their 
corresponding P(3HO-co-HD) scaffolds, no significant difference was 
observed in the insulin release from cells seeded in 95:5 P(3HO-co-
HD)/P(3HB) blend scaffolds. It was also observed that the insulin release 
from the cells seeded in 3D structures was highest. 
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Figure 6.5: Insulin secretion at hyperglycaemia (16.7mM glucose) from 
BRIN BD11 cells seeded on 2D and 3D P(3HO-co-HD) and 95:5 P(3HO-
co-3HD)/P(3HB) blend scaffolds in ng of insulin/106 cells/20 minutes. 
Values are expressed as mean ± SEM for groups of 6. P > 0.05 (not 
significant) when compared with corresponding with P(3HO-co-HD) 
scaffold. 
6.2.8. Scanning Electron Microscopy of P(3HO-co-3HD) & 95:5 P(3HO-co-
3HD)/P(3HB) Blend Scaffolds 
Scanning electron microscopy was carried out on BRIN BD11 cells seeded 
on 2D P(3HO-co-3HD) & 95:5 P(3HO-co-3HD)/P(3HB) blend scaffolds to 
evaluate their surface topography and morphology of growth of the BRIN 
BD11 cells.  
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It was observed that the surfaces were entirely covered by the BRIN BD11 
cells growing in clusters as expected for BRIN BD11 cells. 
 
Figure 6.6: Scanning electron microscopy of 1a) P(3HO-co-HD) 2D 
scaffold (500X), 1b) 95:5 P(3HO-co-3HD)/P(3HB) blend 2D scaffolds 
(500X), 2a) P(3HO-co-HD) 2D scaffold (1500X) and 2b) 95:5 P(3HO-co-
3HD)/P(3HB) blend 2D scaffolds (1500X). 
 
6.3.DISCUSSION 
In this chapter, three different P(3HO-co-HD) dominated P(3HO-co-
3HD)/P(3HB) blends were made: 95:5, 90:10 and 80:20. These blends were 
then characterised mechanically and thermally to evaluate the miscibility of 
the P(3HO-co-3HD)/P(3HB) blends. They were also evaluated for the 
viability of BRIN BD11 cells seeded in them and for the insulin release upon 
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glucose stimulus from cells seeded in them. Finally, the most suitable blend 
was picked, fabricated into 2D & 3D scaffolds and compared to P(3HO-co-
HD) based on the viability and insulin release of BRIN BD11 cells seeded 
in them. 
In the thermal analysis of the polymers, the melting and glass transition 
temperatures observed in this study were within range of those observed in 
other studies of mcl-PHA/scl-PHA blends (Basnett et al., 2013; Lizarraga-
Valderrama et al., 2015). The appearance of two melting events in each 
blend thermogram is an indication of the incompatibility and immiscibility 
of the blends; since each component is crystallising separately (Olabisi, 
1981; Zhu et al., 1999; Bhatia et al., 2007). Addition of P(3HB) into the 
P(3HO-co-HD) introduces another independent melting event because the 
polymers are in different states (Bhatia et al., 2007). Introduction of the 
crystalline P(3HB) into amorphous P(3HO-co-HD) reduces the mobility of 
the amorphous region (Basnett et al., 2013).  
At the same time, only one glass transition temperature was observed for 
each blend. This glass transition temperature increased as the amount of 
P(3HB) in the blend increased, largely owing to the inclusion of crystalline 
P(3HB) into the amorphous P(3HO-co-HD) (Bhatia et al., 2007). This 
corresponds with the results observed when Basnett and colleagues 
incorporated P(3HB) into P(3HO) (Basnett et al., 2013). 
Although the values for Young’s Modulus (E), Tensile Strength and 
Elongation at break have never been reported for these novel blends, the 
patterns observed were similar to those reported in literature for other mcl-
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PHA/scl-PHA blends. The addition of P(3HB) into the mcl-PHAs led to an 
increase in the Young’s Modulus and Tensile Strength of the blends. This 
could be attributed to the increase in crystallinity with addition of P(3HB) 
which is related to increased stiffness and strength. These trends have been 
observed in P(3HO)/P(3HB) blends as well as blends of mcl-PHAs with 
other crystalline polymers like PLA (Qiu et al., 2005; Martelli et al., 2012; 
Basnett et al., 2013; Lizarraga-Valderrama et al., 2015). 
The primary aim of creating these blend structures is to assess their 
suitability for use as scaffolds for bioartificial pancreas. Hence, it is 
important to evaluate their biocompatibility with BRIN BD11 murine islet 
cells. In this study, all P(3HO-co-3HD)/P(3HB) blends made exhibited 
>80% cell viability with BRIN BD11 cells with the 95:5 P(3HO-co-
HD)/P(3HB) blend exhibiting the highest viability of 98.54%. This further 
confirmed the results obtained in Chapter 4. The P(3HO-co-3HD) and the 
related blends showed greater cell viability than P(3HB). This could be 
attributed to their relative mechanical properties. The elasticity and strength 
of mcl-PHAs are similar to the those of the native pancreas and so they are 
able to better mimic the natural environment for the cells. In comparison, 
P(3HB) is not able to provide that and exhibits lower cell viability. In the 
cases of the blends, with the addition of P(3HB), the mechanical properties 
were altered favourably, leading to slight increases in strength and stiffness. 
This resulted in samples better suited for scaffold architecture. This could 
explain why the 95:5 blend performed better than the neat P(3HO-co-3HD) 
samples.  
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These results were confirmed by the insulin release data, which showed that 
creating the blends not only improved the mechanical properties of these 
samples, it also increased the viability and functionality of BRIN BD11 cells 
grown on them.  
In the second part of the study, the P(3HO-co-HD) and 95:5 blend samples 
were fabricated into three different structures: non-porous 2D, porous 2D 
and porous 3D scaffolds. They were then seeded with cells for viability and 
insulin release tests. No significant differences were observed, confirming 
the points already discussed in chapter 5.  
In conclusion, in this chapter, three P(3HO-co-HD)/P(3HB) blend 
compositions were made- 95:5, 90:10 & 80:20. These blends were 
characterised mechanically and thermally; showing the effect of the addition 
of P(3HB) to the P(3HO-co-HD). All the trends observed followed those 
predicted and observed in other studies. Cell viability and insulin release 
studies were carried out to determine which of the blends better supported 
BRIN BD11 cell viability and the insulin release function. The P(3HO-co-
3HD)/P(3HB) 95:5 blend showed the most promising results.  Hence this 
blend, along with the neat mcl-PHA as a control was processed into three 
scaffold structures. Of the three scaffold structures, 2D, 2D porous and 3D 
structures, the 95:5 3D structure showed the best combination of 
mechanical, thermal, cell viability and insulin release data to make it the 
best blend composition for a scaffold for the development of bioartificial 
pancreas.   
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7. ALGINATE HYDROGELS 
7.1.INTRODUCTION 
Hydrogels refer to a group of hydrophilic polymers that possess linkages 
that enable them to absorb large volumes of water from 10% of their dry 
weight up to hundred/ thousand times of their dry weight. Due to their ability 
to form stable, porous, 3D structures and their ability to mimic the ECM, 
they have been widely accepted as model materials for Tissue Engineering 
(Hoffman, 2012; Sivashanmugam et al., 2015). They have found 
applications in a wide range of fields from drug delivery (Hoare and 
Kohane, 2008), cell culture (Caliari and Burdick, 2016), wound dressings 
(Murphy and Evans, 2012), ocular lenses (Lloyd, Faragher and Denyer, 
2001), muscle tissue engineering (Christman et al., 2004), bone tissue 
engineering (Lee and Mooney, 2001) and islet transplantation (Vos et al., 
1997). 
Hydrogels can be classified in many ways. Based on the materials, they can 
be classified into natural and synthetic hydrogels. Natural polymers include 
alginate, agarose, collagen, gelatin and chitosan. Synthetic polymers include 
poly(acrylic acid), poly(ethylene oxide) and polyvinyl alcohol (Mooney and 
Drury, 2003; Lee and Mooney, 2012). 
Another method of classifying hydrogels is by the manner of synthesis. 
Based on this, there are gels where the crosslinking is via non-covalent 
interactions including hydrophobic links, hydrogen and ionic bonds. Due to 
their reversible nature, they are not widely accepted in Tissue Engineering 
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(Ullah et al., 2015). Chemical gels with covalent linakges are more useful 
in Tissue Engineering because of their stability and desirable mechanical 
properties (Akhtar, Hanif and Ranjha, 2016). 
Alginate is a class of natural anionic polysaccharide derived from brown 
algae and fermentation of Pseudomonas. They are made of D-mannuronic 
acid and L-glucuronic acid. It is widely used in Tissue Engineering due to 
the ease of cross-linking, its ability to mimic the ECM and the low cost of 
production and processing (Vlierberghe, Dubruel and Schacht, 2011; Lee 
and Mooney, 2012). It is biocompatible and non-immunogenic (Bidarra, 
Barrias and Granja, 2014). It has also been shown to have cell protective 
qualities; a factor particularly important for islets (Bidarra, Barrias and 
Granja, 2014). It can be used in the form of microspheres, microcapsules 
for cell encapsulation and as block hydrogels (Vlierberghe, Dubruel and 
Schacht, 2011). 
Alginate hydrogels have been applied as microspheres, microcapsules and 
block hydrogels in drug, cell and protein delivery (Lee and Mooney, 2012; 
Bidarra, Barrias and Granja, 2014),  wet and dry patches in wound 
dressings, 3D model systems in cell culture (Lee and Mooney, 2012), bone 
marrow and delivery of growth factors in bone tissue engineering 
(Vlierberghe, Dubruel and Schacht, 2011), macroporous gels for cartilage 
tissue engineering (Bedian et al., 2017), muscle (Rowley, Madlambayan 
and Mooney, 1999), liver (Bedian et al., 2017) and islet tissue engineering 
(Vos et al., 1997; Ludwig et al., 2012). 
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Diabetic AO-rats that received islet encapsulated in alginate microcapsules 
became normoglycemic from 5 days up to 20 weeks post-transplantation 
(Vos et al., 1997). The same trend was observed in Balb/c mice that received 
alginate islets, (Schneider et al., 2005). Diabetic male nude mice who also 
received alginate encapsulated islets retained normoglycaemia up to 134 
days post-transplantation (Qi et al., 2008). In primate studies, 8 cynomolgus 
that received porcine neonatal islets experienced a 36% decrease in 
supplementary insulin dose requirement, which increased up to 43% at 24 
weeks. By 36 weeks, one of the monkeys was weaned off supplementary 
insulin (Elliott et al., 2005).  
Not a lot of research exists in the application of 3D printing of alginate 
hydrogel and islets (Marchioli et al., 2015). 3D printing has been used to 
print murine alginate-gelatin structures with INS1E insulin producing cells 
embedded within (Marchioli et al., 2015). 3D printing has also been used to 
print macroporous alginate structures with pluripotent stem cells that 
differentiated into β-cells (Song and Millman, 2016). 
This chapter aimed to evaluate the difference between alginate microbeads 
and 3D printed block alginate hydrogel structures with respect to the cell 
viability and insulin release using encapsulated/incorporated BRIN BD11 
cells. Thus, two kinds of alginate hydrogel systems- BRIN BD11 
encapsulated alginate microbeads and 3D printed block hydrogel structures 
with BRIN BD11 cells were produced. They were characterised with respect 
to their swelling and degradation behaviour. BRIN BD11 cells in them were 
then tested for cell viability and insulin release. Finally, both hydrogel 
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systems were compared with respect to cell viability and insulin release of 
the BRIN BD11 cells seeded within them.  
7.2.RESULTS 
7.2.1. Alginate Microbeads 
The alginate microbeads produced in this work are shown in Figure 7.1 is 
an image of the dry microbeads made, Figure 7.2 is light microscopy images 
of wet alginate microbeads made. The dry alginate microbeads appeared as 
heterogenous white beads with average diameters of 0.87±0.13mm. Light 
microscopy of wet beads showed spherical beads filled with water. Wet 
spheres measured 1.26±0.59mm in diameter.  
 
Figure 7.1: Dry alginate microbeads. Beads measure 0.87±0.13μm, bars: 
1 μm. 
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Figure 7.2: Light microscopy of wet alginate microbeads. Magnification 
100X, Bars: 500μm. 
7.2.2.  3D Printed Alginate Block Hydrogel 
The 3D printed alginate block hydrogel was a white cube with a 
length/width/height of 13.5mm (Figure 7.3). For the cell culture studies, 
cubes of 1x1x1mm were made.  
 
Figure 7.3: 3D Printed Alginate Hydrogel Cube measuring 
13.5x13.5x13.5mm, bars:10mm. 
7.2.3. Cell Viability of BRIN BD11 Cells in Alginate Microbeads 
Cell viability assays were carried out to evaluate the effect of cell density 
on the viability of cells and to determine the optimum cell density for 
encapsulation.   
Figure 7.4 shows the cell viabilities observed. In comparison with the 
positive control (tissue culture plastic), microbeads with the lower cell 
density (1x105cells/ml) exhibited significantly lower cell viabilities (p ≤ 
0.001). On the other hand, microbeads with the higher cell density 
(5X105cells/ml) showed no significant difference (p > 0.05) in comparison 
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to the positive control. The viability for microbeads with cell density 
5X105cells/ml was higher (p ≤ 0.05) than the beads with cell density 
1X105cells/ml, indicating an increase in cell viability with increase in cell 
density.  
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Figure 7.4: Cell viabilities of BRIN BD11 encapsulated at densities of 
1x105 cells/ml and 5x105cells/ml in alginate microbeads. Values are 
expressed as % of positive control (tissue culture plastic) ± SEM for 
groups of 6. *p ≤ 0.05 in comparison with 5x105cells/ml, ***p ≤ 0.001 
when compared with the positive control (tissue culture plastic).  
7.2.4. Static Insulin Secretion from BRIN BD11 Cells Encapsulated in 
Alginate Microbeads 
Insulin release analyses were carried out to evaluate the effect of cell 
densities on the insulin release from alginate microbeads. The results are 
shown in Figure 7.5. 
At normoglycaemia (5.6mM glucose), the insulin released in response from 
microbeads with both low and high cell densities were significantly higher  
(p ≤ 0.0001) than that of the positive control (Figure 7.5A). In addition, the 
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insulin released from microbeads with higher cell density (5X105cells/ml) 
was significantly higher (p ≤ 0.0001) than that with low cell density (1X105 
cells/ml). These results indicate that increasing cell density increases insulin 
released at a rate higher than cell viability.  
A similar result was obtained at hyperglycaemia (16.7mM glucose), shown 
in Figure 7.5B. Insulin released from microbeads at both cell densities was 
significantly higher (p ≤ 0.0001) than that of the positive control (tissue 
culture plastic). Insulin released from microbeads with higher cell density 
(5x105cells/ml) was significantly higher (p ≤ 0.001) than that with low cell 
density (1x105 cells/ml).
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Figure 7.5: Insulin release from BRIN BD11 cells encapsulated in 
alginate microbeads at densities of 1x105 cells/ml and 5x105cells/ml at A. 
normoglycaemia (5.6mM glucose) and B. Hyperglycaemia (16.7mM 
glucose) in ng/106cells/20 minutes. Samples are expressed as values± SEM 
for groups of 6. ***p ≤ 0.001 when compared with microbeads with cell 
density 5x105cells/ml and ****p ≤ 0.0001 when compared with both the 
positive control. 
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7.2.5. The swelling behaviour of the Alginate Block Hydrogels 
The swelling behaviour of the alginate block hydrogel was evaluated at 
varying w/v% concentrations of alginate (2%, 4%, 5%) to monitor the 
behaviour of the hydrogel in a buffer (PBS) over 300 minutes and to test the 
influence of the alginate concentration on the swelling behaviour (Figure 
7.6). For all concentrations, there was a steady increase in weight gain (% 
dry weight) until about 60minutes; after which there was a steady phase 
until the weight gain started to decrease very slowly. Of the 3 
concentrations, 5% w/v absorbed the maximum amount of water.  
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Figure 7.6: Swelling (% dry weight) of 2%, 4% & 5% w/v alginate block 
hydrogels. Values are expressed ±SEM for groups of 3 over 300 minutes. 
7.2.6. Cell Viability of BRIN BD11 Cells in the 3D Alginate Block Hydrogel 
Cell viability assays were carried out to evaluate the effect of alginate 
concentration on the viability of BRIN BD11 cells in hydrogels and to 
determine the optimum alginate concentration for the hydrogel.   
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Figure 7.7 shows the cell viabilities observed for BRIN BD11 cells seeded 
in the hydrogels made using 2%, 4% and 5% alginate concentrations. In 
comparison with the positive control, only cells seeded in 2% alginate 
hydrogel showed significantly lower (p ≤ 0.01) cell viability. No significant 
difference (p > 0.05) was observed between the viabilities observed for all 
three concentrations indicating that increasing alginate concentrations does 
not affect cell viabilities.  
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Figure 7.7: Cell viability of BRIN BD11 cells in 2, 4 & 5% w/v alginate 
block hydrogels. Values are expressed as % of positive control (tissue 
culture plastic) ± SEM for groups of 6. **p ≤ 0.01 in comparison with the 
positive control, p > 0.05 when all other 4% and 5% were compared to the 
positive control. 
7.2.7. Static Insulin Secretion from BRIN BD11 Cells Seeded in 3D Printed 
Alginate Hydrogel  
Insulin release analyses were carried out to evaluate the effect of alginate 
concentration on the insulin release from BRIN BD11 cells in the alginate 
hydrogel. The results are shown in Figure 7.8. 
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At normoglycaemia (5.6mM glucose), insulin release from all three 
concentrations of hydrogel were significantly higher (p ≤ 0.0001) than the 
positive control. A steady increase in insulin release was observed as the 
concentration of alginate increased. In comparison with 2% and 4% alginate 
hydrogels, the insulin release from the 5% alginate hydrogel was 
significantly higher (p ≤ 0.0001 & p ≤ 0.001 respectively).  
At hyperglycaemia (16.7mM glucose), a similar pattern was observed. 
Insulin release increased as alginate concentration increased. In comparison 
with 2% and 4% alginate hydrogels, the insulin release from the 5% alginate 
hydrogel was significantly higher (p ≤ 0.001 & p ≤ 0.01 respectively).   
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Figure 7.8: Insulin release from BRIN BD11 cells in 2, 4 & 5% w/v 
alginate hydrogels at A. Normoglycaemia (5.6mM glucose) and B. 
Hyperglycaemia (16.7mM glucose) in ng/106cells/20 minutes. The insulin 
release values are expressed as values± SEM for groups of 6. **p ≤ 0.01, 
***p ≤ 0.001, ****p ≤ 0.0001 in comparison with the 5% alginate 
hydrogel and positive control. 
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7.2.8. Comparison of Alginate Microbeads & 3D Alginate Block Hydrogels 
A comparison of the cell viability and insulin release from BRIN BD11 cells 
encapsulated in alginate microbeads at a density of 5x105cells/ml and 
seeded in 3D alginate block hydrogel at a density of 5x105cells/ml was 
carried out to evaluate the effect of the structure of the alginate hydrogel on 
the cells. 
7.2.8.1.Cell Viability of BRIN BD11 in Alginate Microbeads and 3D Alginate 
Block Hydrogel  
The cell viabilities of BRIN BD11 encapsulated in alginate microbeads and 
seeded in 3D alginate hydrogel are shown in Figure 7.9. The cell viabilities 
observed were 79.49±5.54% for the microbeads and 92.27±8.39% for the 
block hydrogel. There was a significant difference (p ≤ 0.01) observed 
between the cell viabilities indicating that block hydrogel is a more suitable 
environment for the BRIN BD11 cells.   
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Figure 7.9: Cell viabilities of BRIN BD11 cells in alginate microbeads and 
3D printed block alginate hydrogels. Values are expressed as % of 
positive control (tissue culture plastic) ± SEM for groups of 6. *p ≤ 0.05 
when microbeads and the 3D printed block hydrogel are compared, ***p 
≤ 0.001 when compared to the positive control. P > 0.05 when block 
hydrogel was compared to the positive control.  
7.2.8.2. Static Insulin Secretion from BRIN BD11 Cells in Alginate Microbeads 
and 3D Block Alginate Hydrogel 
The insulin released from BRIN BD11 cells in both alginate microbeads and 
3D alginate hydrogel are shown in 7.10. At both normoglycaemia and 
hyperglycaemia (5.6mM & 16.7mM glucose respectively), insulin released 
from the microbeads and 3D hydrogel were significantly higher (p ≤ 0.0001) 
than the positive control. When the microbeads and 3D block hydrogel were 
compared, insulin released from cells in 3D block hydrogels at both 
normoglycaemia and hyperglycaemia were significantly higher (p ≤ 0.0001) 
than that from the microbeads.  
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Figure 7.10: Insulin release from BRIN BD11 cells in alginate microbeads 
and 3D printed alginate hydrogel at normoglycaemia (5.6mM glucose) 
and hyoerglycaemia (16.7mM glucose) in ng/106cells/20 minutes. Samples 
are expressed as values± SEM for groups of 3. ****p ≤ 0.0001 when 
compared with both block hydrogel and postive control (tissue culture 
plastic). 
7.3.DISCUSSION 
Based on results from this chapter, cell viability increases with increase in 
cell density in both the cells encapsulated in the alginate hydrogel and in the 
3D printed block. This is in accordance with literature; although after a 
certain threshold, loading the hydrogel with more cells is detrimental to the 
functioning of all the cells as increasing cell load beyond a certain threshold 
value leads to loss in stability of the beads (Lin and Anseth, 2011). This 
phenomenon has not been observed in this study which could be due to the 
fact that perhaps that critical threshold had not been reached.  
Cell morphology affects the functionality of the cells, so for the insulin 
release function of cells, it is important for the cells to remain as true to 
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nature as possible. The natural conformation of β-cells is to aggregate into 
islets. Aggregation is very important in the insulin release process in islets. 
This is because the cells work through cell-to-cell interactions. Islets will 
always revert to the aggregation morphology (Lucas-Clerc et al., 1993). At 
low cell densities, aggregation is limited so cells are not able to respond as 
well to glucose stimulation (Dvir-Ginzberg et al., 2003). At high densities, 
more aggregates are found leading to the presence of more insulin positive 
cells (Segev et al., 2004). β-cells in aggregates are able to release up to 3-
fold more insulin in response to glucose than cells in unaggregated islets 
(Hopcroft, Mason and Scott, 1985). This is also observed in this study as 
the cells at higher densities have higher insulin release values than those at 
lower densities. 
Swelling behaviour is important to measure as it predicts the behaviour of 
the hydrogel in vivo. It is a result of the hydration of the hydrogel, leading 
to water entry into the polymer chains of the beads to create swelling (Dai 
et al., 2008). When swelling occurs in PBS, there is an exchange of Ca2+ 
and Na+ ions that encourages swelling (Pasparakis and Bouropoulos, 2006). 
The initial rapid increase in weight gain is due to the rapid exchange of ions 
that occurs immediately after introduction into PBS (Bajpai and Sharma, 
2004). The difference in %weight gain of the 3 different concentrations is 
due to binding between alginate and CaCl2 and the ease of ion exchange 
between the hydrogel and PBS. A similar pattern was observed with 
degradation where the initial rapid weight loss could be attributed to the 
quicker release of Ca2+ than in swelling. Long term studies have shown 
alginate block hydrogels to be stable for up to 90 days with constant 
 180 
 
hydration (Shapiro and Cohen, 1997). In this work, the 5% hydrogel 
exhibited the least %weight loss of the three concentrations; possibly due to 
the fact that with higher alginate concentration, the Ca2+ ions were more 
tightly bound. A similar pattern was observed in Bajpai and Sharma’s study. 
When 2%, 3% & 4% w/v alginate solutions were used to make microbeads, 
the 4% w/v beads were the most stable during swelling (Bajpai and Sharma, 
2004). 
The concentration of alginate affects many factors that influence the 
viability of cells in the hydrogels. These include the viscosity of the 
hydrogel solutions, strength of the block hydrogels and shear force of the 
hydrogel. In this study, the 5% hydrogel had the highest cell viability. Kong 
and colleagues found when they evaluated the cell viabilities of three 
different concentrations of alginate- 2, 3.5 & 5% w/v, that 3.5% w/v had the 
highest cell viability (Kong, Smith and Mooney, 2003). This could be due 
to the difference in molecular weight of the alginate used. In their study, 
they used low molecular weight alginate (~100g/mol), while the alginate 
used in this study had molecular weight of 216.12g/mol. As a result, the 
alginate used in this study had higher viscosity than theirs. Cells are better 
able to form aggregates in solutions of high viscosity (Bohari, Hukins and 
Grover, 2011). This then has a trickledown effect on the insulin release. 
Since insulin release is a function of cellular aggregation, it follows that as 
increase in concentration leads to an increase in cellular aggregation, which 
then leads to an increase in insulin release.  
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Of  both structures, the 3D block alginate hydrogel proved better for cells 
with respect to cell viability and insulin release. This is due to many factors, 
the average diameter of the microbeads was 0.87±0.13mm, with a surface 
area of 2.32±0.345mm2 and volume of 0.33±0.061mm3. The hydrogel on 
the other hand, had a length of 1mm and surface area of 6mm2 and volume 
of 1mm3. The microbeads have a smaller capacity for cells due to their size; 
an average islet measures 100μm and even though the microbeads provide 
the shape, the number of islets are not as adequate. The other factor is the 
difference in surface area. The hydrogel blocks also provide an open space 
for cell-cell contact.  
In conclusion, in this chapter, it has been shown that 5x105cells/ml of BRIN 
BD11 cells was an optimal cell density for use in microbeads with average 
diameter 0.8±0.13mm and 3D printed block hydrogels of 1mm sides. It was 
also shown that the 3D-printed block alginate hydrogels behaved the same 
way as previously reported for alginate hydrogels with respect to swelling. 
Finally, upon comparison of 2, 4 and 5 w/v% concentrations of alginate, 5% 
w/v was the best concentration for optimum cell viability and insulin release 
using the 3D printed block alginate hydrogels.  
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8. CONCLUSIONS AND FUTURE WORK 
8.1. CONCLUSIONS 
Type 1 Diabetes mellitus remains one of the major chronic diseases 
plaguing individuals in the UK and around the world (Diabetes UK, 2017). 
Amongst the variety of treatment options available, islet transplantation has 
emerged as the gold-star of treatment. One of the major challenges of islet 
transplantation is the rapid loss of islets after transplantation (Shapiro et al., 
2006; McCall and Shapiro, 2012). This work was planned to investigate a 
potential solution to this issue. In this project, a multilayer approach was 
investigated. This involved an outer PHA scaffold surrounding an inner 
alginate hydrogel environment including cells.  
Initially, two different PHAs were produced- a short chain length PHA, 
P(3HB) and a novel medium chain length PHA, P(3HO-co-HD). P(3HB) 
was made using fermentation of Bacillus subtilis OK2, using glucose as the 
carbon source. The yield reported for P(3HB) was 49% dcw. This value 
matches the highest reported values for P(3HB) production in literature.  A 
novel medium chain length polymer P(3HO-co-HD) was produced using 
Pseudomonas mendocina CH50, also using glucose as the carbon source. 
The yield obtained was 43% dcw, which is again promising as it is among 
the higher reported yields in literature. Both polymers were characterised 
and identified using FTIR, GCMS and NMR. The novel polymer produced 
from Pseudomonas mendocina CH50 fermentation was identified as a 
medium chain length PHA with HO and HD monomers in the ratio 22:78. 
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It was named P(3HO-co-HD). One requirement of tissue engineering is the 
ability of potential biomaterials to mimic native tissue. In order to determine 
the properties of these materials, mechanical and thermal characterisation 
was undertaken. Values observed indicated the differences in both 
polymers- P(3HB) a stiff, brittle polymer with high melting temperature and 
P(3HO-co-HD), an elastomeric polymer with low melting temperature. 
Based on these characteristics, it was postulated that P(3HO-co-HD) was 
more suited to soft tissue engineering, especially islet transplantation. 
To confirm this hypothesis and evaluate the suitability of these PHAs for 
islet transplantation, their mechanical and thermal properties were 
compared to PLLA, a FDA approved polymer that has been investigated 
extensively in tissue engineering and specifically in islet transplantation. 
BRIN BD11 murine islet cells were seeded on P(3HB), P(3HO-co-HD) and 
PLLA and evaluated for cell viability. Of the three polymers, cells seeded 
on P(3HO-co-HD) had the highest cell viabilities with no significant 
difference observed in comparison with the positive control (tissue culture 
plastic). The same pattern was identified when the insulin release function 
of these cells was measured at both normoglycaemia (5.6mM) and 
hyperglycaemia (16.7mM) blood. At both levels, cells seeded on P(3HB) 
and P(3HO-co-HD) released higher insulin than cells seeded in both PLLA 
and the positive control. Cells seeded in P(3HO-co-HD) released 4 and 3-
fold more insulin than those seeded on the positive control at 
normoglycaemia and hyperglycaemia respectively. This indicated that both 
PHAs were non-toxic and allowed insulin release from BRIN BD11 cells 
seeded on them.  
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Even though the Young’s modulus of P(3HO-co-HD) is the most similar to 
soft tissue, it is still higher than that of the native pancreas. The observed 
Young’s modulus of P(3HO-co-HD) from this study was 5.62±0.054MPa 
while that of the native pancreas is 2.1x10-3MPa. One way to reduce the 
mechanical properties of a scaffold is the introduction of pores.  Porosity 
also allows for the exchange of nutrients and waste in the scaffold. In order 
to determine the optimum porosity, 2D porous P(3HO-co-HD) scaffolds 
were fabricated. Two different concentrations of porogen (5% and 15%) and 
porogen sizes (100µm and 300µm) were used in making the scaffolds. 
Mechanical characterisation of these scaffolds confirmed that the addition 
of pores reduced the Young’s modulus by 5-fold with an increase in porogen 
concentration and size leading to a decrease in Young’s modulus to 
1.11±0.052MPa. Additionally, upon examination of their water contact 
angles, the scaffolds became less hydrophobic as the porogen concentration 
and size increased. These scaffolds were then examined to determine the 
effect of pore size and concentration on the viability and insulin release of 
BRIN BD11 cells seeded in them. Even though porosity decreased Young’s 
modulus and tensile strength, it did not lead to an improvement in the 
viabilities and insulin release of the BRIN BD11 cells seeded in them. 
Further, comparing NaCl and sucrose as porogens, it was found that NaCl 
was a better porogen because the cell viabilities and insulin release of BRIN 
BD11 cells seeded in them were higher than those in sucrose made 
scaffolds. The porous scaffold that was the best performing one was the one 
with 100µm NaCl at a concentration of 15%. This scaffold was used for 
further investigation. 
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To better understand the interactions between cells, scaffolds, molecules 
and components of the extracellular matrix in an in vivo context, research in 
tissue engineering has shifted from 2D to 3D scaffolds (Coronel and Stabler, 
2013). To investigate the effect of these interactions on the islets, P(3HB) 
and P(3HO-co-HD) 3D structures were fabricated. These 3D structures 
were then compared to 2D structures. No significant differences were 
recorded when mechanical properties were compared between 2D and 3D 
structures. Similarly, no significant difference was observed when the 
viabilities and insulin release of BRIN BD11 cells seeded in them were 
compared. These results require further investigation as the number of cells 
seeded per unit surface area of the structures need to be considered.  
One of the drawbacks of introducing porosity in 3D structures is that they 
become difficult to handle. Blending is a technique that has been employed 
to tune the physical and mechanical properties of a material. In order to 
improve the handling of the P(3HO-co-HD) 3D structures, blending with 
P(3HB) was carried out. Three different P(3HO-co-HD) dominated P(3HO-
co-HD)/P(3HB) blends were made: 95:5, 90:10 and 80:20. Upon blending 
of both polymers, another melting peak in the range of the Tm for P(3HB) 
was observed in the DSC thermogram, indicating the presence of an 
immiscible phase of P(3HB). Incorporation of P(3HB) into the blend led to 
an increase in both the tensile strength and Young’s modulus, while also 
decreasing their flexibility. Cells seeded in 95:5 P(3HO-co-HD)/P(3HB) 
blend were the best performing of all the blends with respect to cell viability 
and insulin release studies. Further, in comparison to neat P(3HO-co-HD), 
cells seeded in 95:5 P(3HO-co-HD)/P(3HB) blend showed no significant 
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difference in viabilities and insulin release. This was positive because an 
increase in the stiffness did not affect the viabilities of the cells. Based on 
this data, the 95:5 P(3HO-co-HD)/P(3HB) blend was fabricated into porous 
2D and 3D structures. These were then compared with their corresponding 
P(3HO-co-HD) structures. No significant difference was observed in cell 
viabilities and insulin release of BRIN BD11 cells seeded in them when they 
were compared; indicating that the 95:5 P(3HO-co-HD)/P(3HB) blend is 
the best candidate for the scaffold of a bioartificial pancreas with a 
handleable structure and good biological performance.  
Finally, alginate hydrogels were made and evaluated for their use in islet 
transplantation. Two kinds of hydrogel structures were made- microbeads 
and 3D printed block hydrogels containing BRIN BD11 cells. First, two 
different cell densities (1x105 & 5x105 cells/ml) were investigated to 
evaluate the optimum density for making the microbeads. The cell viability 
and insulin release of BRIN BD11 cells at higher densities were 
significantly higher than lower densities. Hence, 5x105 cells/ml cell 
concentration was chosen for further investigation. Next, alginate hydrogel 
cube blocks were 3D printed using three different concentrations of alginate 
solution (2,4 & 5 w/v%). These hydrogels were then evaluated for their 
swelling behaviour where it was observed that the 5 w/v% hydrogel was the 
most stable. Evaluating them for cell viability and insulin release indicated 
that the 5 w/v% hydrogel had the highest cell viability and insulin release. 
Finally, the alginate microbeads were compared with the 3D printed block 
hydrogels in terms of viability and insulin release of BRIN BD11 cells. In 
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this case, the 3D printed hydrogel also had significantly higher viability and 
insulin release than the microbeads.  
In summary, based on this work, the 95:5 P(3HO-co-HD)/P(3HB) blend 
was selected as the scaffold material while the 3D printed alginate hydrogel 
containing 5x105 cells/ml was selected for the inner hydrogel environment 
within the bioartificial pancreas.  
8.2. FUTURE WORK 
This work represents a preliminary step in the use of PHAs alongside 
alginate in the creation of the bioartificial pancreas. In order to further 
expand understanding of this work, the following areas should be 
investigated. 
The yields of PHAs produced in this study are not representative of the 
current data in literature. Optimum yields can be achieved using techniques 
like low carbon feeding (Mohd Fadzil et al., 2018). In addition, since the 
P(3HO-co-HD) produced in this study is a novel polymer, further studies 
into the fermentation process would be interesting. Optimisation studies 
with mathematical modelling tools like MATLAB should be used to fine 
tune the mix of conditions necessary for the optimal production of the 
PHAs.  
One of the challenges faced in this work was the accurate measurement of 
porosity and the consistency of pores. Finetuning of the process of creation 
of pores should be carried out to ensure better understanding and 
consistency.  There should also be characterisation and evaluation of surface 
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properties and porosity of both porous and non-porous scaffolds made 
would be helpful in better understanding the interactions. According to the 
American Society for Testing and Materials (ASTM), porous structures 
should be characterised in terms of pore size, pore volume and mechanical 
properties. In the future, complete porosimetry would be helpful in 
maintaining the consistency of the scaffolds and adherence to ASTM 
guidelines.   
Following the complete characterisation of porous structures, a standardised 
method for the comparison of 2D and 3D structures should be established. 
Both structures behave differently in terms of mechanical properties and 
their measurements and viability of cells. The design of a standardised way 
to compare the viabilities of cells seeded in both 2D and 3D structures while 
accounting for differences in surface area and volume should be considered. 
This will lead to more accurate assessments. 
In evaluating the suitability of a material for biological purposes, 
measurement of the behaviour of the cells in relation to the scaffolds is 
important. Complete evaluation of the biocompatibility, toxicity and 
biodegradability of the scaffolds is paramount. In this work, basic tests like 
cell viability and short-term insulin secretion have been carried out. Further 
tests need to be carried out. Extended insulin release tests should be carried 
out to show long-term insulin secretion. Insulin staining using dithizone 
should also be carried out to show intracellular insulin. Further, the 
investigation of insulin release upon the addition of insulinotropic agents 
like GLP, GIP and amino acids. Eventually, molecular analysis should be 
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carried out. The hepatocyte nuclear factor-4α (HNF-4α) is of particular 
interest (Gupta et al., 2005).  
After thorough characterisation of the scaffolds with respect to viability of 
cells, functionalisation of the scaffolds should be carried out to improve the 
viability of the cells. Since islet cells have been shown to have highly 
specific demands, the addition of factors and active molecules will better 
improve the survival of islets post-transplantation.  
These factors include VEGF to stimulate vascularisation, oxygen producing 
molecules and ECM proteins like collagen. Studying these would lead to 
the production of more robust scaffolds. 
Due to time constraints, the final assembly of the bioartificial pancreas was 
not achieved. Different methods of assembly should be investigated 
including printing of both layers, layer-by-layer printing, surface coating 
and surface spraying. After the final printing method is selected, complete 
characterisation as described above should be carried out as the interactions 
may differ from final assembly.  
Since this is a bioartificial pancreas intended to be used clinically, actual 
murine and porcine islets should be used in the evaluation of the 
biocompatibility of these devices.  
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